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Abstract 
Harlequin Ichthyosis (HI) is the most severe disorder in the family of autosomal 
recessive congenital ichthyosis (ARCI). Recessive mutations in the ABC transporter 
ABCA12 were found to be causative in HI. Loss of ABCA12 leads to defective transport 
of ceramides, impaired transportation of proteases, premature terminal differentiation, 
transepidermal water loss (TEWL) and the retention of squames, which leads to the 
characteristic clinical phenotype of thickened hyperkeratotic plates overlying the skin. 
This thesis focuses on the genetic and functional role of ABCA12 in the skin and how 
loss of ABCA12 leads to the HI epidermis.  
Several molecular genetic techniques were utilised to ascertain and evaluate possible 
causative mutations for HI in the gene ABCA12. The identification of novel and known, 
point and complex mutations give molecular diagnostics a greater reservoir to help 
identify possible causative mutations in future cases. The spectrum of ABCA12 
mutations, which have been attributed to different diseases within ARCI, was discussed. 
A HI immortalised cell line was derived from a patient with a compound heterozygote 
mutation in ABCA12, with a nonsense p.Glu2264X and c.5382-2a/g, a complex splice 
site mutation of the putative acceptor site (AG) preceding exon 35. Further 
investigations assessed the use of low affinity acceptor sites by the spliceosome. 
Immunohistochemistry of the patient biopsy showed an absence of ABCA12 and a 
reduction of ABCA1 proteins. Knockdown of ABCA12 in control K17 immortalised 
keratinocytes decreased expression levels of ABCA1 and LXRβ proteins. Functional 
studies of the HI patient derived cell line validated a HI cellular phenotype in 
monolayer. 
The expression levels of involucrin, TGM1 and K10 proteins showed how the patient 
derived HI cell line under calcium shift initiated premature terminal differentiation in 
vitro, compared to controls. The activation of nuclear hormone receptors PPARβ/δ and 
LXRβ by the application of their agonists on the HI cell line increased the transcript and 
protein levels of the reduced ABCA1. The same agonists reduced specific markers of 
differentiation, which were activated prematurely in the HI cell line under calcium shift, 
suggesting a potential therapeutic strategy to explore.  
  4 
Table of Contents 
Abstract ................................................................................................................ 3	
List of Figures and Tables .................................................................................. 8	
Abbreviations ..................................................................................................... 10	
Publications, presentations, and awards arising from this work .................. 14	
Acknowledgements ............................................................................................ 16	
1	 Chapter 1: Introduction ......................................................................................... 17	
1.1. The Skin ........................................................................................................................... 18	
1.1.1. The Epidermis ........................................................................................................... 18	
1.1.2. The Dermis ................................................................................................................ 27	
1.2. Keratinocyte Differentiation .......................................................................................... 27	
1.2.1. Calcium Gradient ...................................................................................................... 27	
1.2.2. Desquamation ............................................................................................................ 29	
1.3. Lamellar Granules .......................................................................................................... 30	
1.3.1. Ultrastructural organisation ....................................................................................... 31	
1.3.2. Molecular composition and cargo ............................................................................. 32	
1.4. Epidermal Lipids and the Permeability Barrier ......................................................... 34	
1.4.1. Composition and Structure ........................................................................................ 38	
1.5. The Nuclear Hormone Receptors .................................................................................. 38	
1.5.1. Nuclear Hormone Receptors and their Ligands ........................................................ 39	
1.5.2. Nuclear Hormone Receptors and Terminal Differentiation ...................................... 40	
1.6. The Ichthyoses ................................................................................................................. 44	
1.7. Harlequin Ichthyosis ...................................................................................................... 44	
1.7.1 Clinical Features ......................................................................................................... 44	
1.7.2. Ultrastructural Features of Harlequin Ichthyosis ...................................................... 46	
1.7.3. Genetics of Harlequin Ichthyosis .............................................................................. 46	
1.8. ABCA12 ............................................................................................................................ 47	
1.8.1. The Role of ABCA12 in the Epidermis ..................................................................... 48	
1.8.2. The Role of ABCA1 in the Epidermis ....................................................................... 51	
1.8.3 ABCA12 and Disease .................................................................................................. 52	
1.9. ABC Transporters .......................................................................................................... 52	
1.9.1. The ABCA Subfamily ............................................................................................... 53	
1.10. ARCI .............................................................................................................................. 54	
1.11. Hypothesis and Aims .................................................................................................... 55	
2	 Chapter 2: Materials and Methods ....................................................................... 56	
  5 
2.1.1.	 Nucleic Acid Methods ........................................................................................... 57	
2.1.2.	 DNA and RNA extraction ...................................................................................... 57	
2.1.3.	 DNA and RNA quantification ............................................................................... 58	
2.1.4.	 Primer design ......................................................................................................... 58	
2.1.5.	 DNA amplification by polymerase chain reaction (PCR) ..................................... 58	
2.1.6.	 Agarose gel electrophoresis ................................................................................... 59	
2.1.7.	 Gel purification ...................................................................................................... 60	
2.1.8.	 Sanger sequencing ................................................................................................. 60	
2.1.9.	 Reverse-Transcriptase PCR (RT-PCR) .................................................................. 61	
2.1.10.	 Real Time PCR (qPCR) ....................................................................................... 61	
2.2.	 Molecular biology ........................................................................................................ 62	
2.2.1.	 TOPO cloning ........................................................................................................ 62	
2.2.2.	 Restriction enzyme digest ...................................................................................... 63	
2.2.3.	 Transformation of competent cells ........................................................................ 63	
2.3.	 Cell Culture .................................................................................................................. 63	
2.3.1.	 Cell lines and Conditions ....................................................................................... 63	
2.3.2.	 Cryopreservation .................................................................................................... 64	
2.3.3.	 Fugene and PEI Transfections ............................................................................... 65	
2.3.4.	 Transient siRNA-mediated ABCA12 knock down ................................................ 65	
2.3.5.	 Calcium Shift in monolayer ................................................................................... 66	
2.3.6.	 Agonist Application in monolayer ......................................................................... 66	
2.3.7.	 Testing for Mycoplasma ........................................................................................ 67	
2.3.8. Immortalisation of patient derived HI keratinocyte cell line .................................... 67	
2.4. Antibody dilutions .......................................................................................................... 68	
2.5. Immunostaining .............................................................................................................. 69	
2.5.1. Embedding and Sectioning of frozen tissue .............................................................. 69	
2.5.2. Immunocytochemistry ............................................................................................... 69	
2.5.3. Immunohistochemistry .............................................................................................. 70	
2.5.4. FACS analysis ........................................................................................................... 70	
2.6.	 Western Blotting .......................................................................................................... 71	
2.6.1.	 Preparation of protein lysates from cells ............................................................... 71	
2.6.2.	 Gel Electrophoresis (SDS-PAGE, pre-cast TRIS-Acetate or pre-cast Bis-TRIS) . 71	
2.6.3.	 Transfer to nitrocellulose membrane ..................................................................... 72	
2.6.4.	 Protein visualisation by Ponceau Red .................................................................... 72	
2.6.5.	 Blocking ................................................................................................................. 73	
2.6.6.	 Primary antibody incubation .................................................................................. 73	
2.6.7.	 Secondary antibody incubation and detection ....................................................... 73	
  6 
2.6.8.	 Stripping membranes for antibody re-probing ....................................................... 74	
2.7. General methods ............................................................................................................. 74	
2.7.1. Chemicals and consumables ...................................................................................... 74	
2.7.2. Ethical procedure ....................................................................................................... 74	
2.7.3. Next generation sequence data analysis .................................................................... 74	
2.7.4. Statistical analysis ..................................................................................................... 75	
3	 Chapter 3: Mutation Analysis of ABCA12 in Harlequin Ichthyosis ................... 76	
3.1. Introduction .................................................................................................................... 77	
3.1.1. Genetic screening of ABCA12 in patients clinically diagnosed with HI ................... 77	
3.1.1. Results ........................................................................................................................... 78	
3.1.2. Case 1 ........................................................................................................................ 78	
3.1.3. Case 2 ........................................................................................................................ 81	
3.1.4. Case 3 ........................................................................................................................ 85	
3.1.5. Case 4 ........................................................................................................................ 99	
3.1.6. Case 5 ...................................................................................................................... 100	
3.1.7. Case 6 ...................................................................................................................... 102	
3.2. Discussion ...................................................................................................................... 108	
3.2.1. Genetic screening of ABCA12 in HI cases .............................................................. 108	
3.2.2. The genotype-phenotype correlation of ABCA12 and HI ....................................... 109	
3.3. Summary ....................................................................................................................... 112	
4	 Chapter 4: Characterisation of a Patient Derived Harlequin Ichthyosis Cell 
Line ............................................................................................................................... 113	
4.1. Introduction .................................................................................................................. 114	
4.2.	 Results ........................................................................................................................ 114	
4.2.1.	 Genetic analysis of patient of patient derived HI cell line ................................... 114	
4.2.2.	 Immunohistochemistry of ABCA12 and ABCA1 in the HI skin ........................ 124	
4.2.3.	 Analysis of transient siRNA mediated ABCA12 knockdown .............................. 126	
4.2.4.	 Functional analysis of cell line under calcium shift ............................................. 128	
4.2.5.	 FACS analysis of cell death and apoptosis during calcium shift ......................... 130	
4.3. Discussion ...................................................................................................................... 132	
4.4. Summary ....................................................................................................................... 136	
5	 Chapter 5: A Possible therapeutic strategy for Harlequin Ichthyosis utilising 
Nuclear Hormone Receptor Agonists ........................................................................ 137	
5.1. Introduction .................................................................................................................. 138	
5.2. Results ............................................................................................................................ 141	
  7 
5.2.1. Immunohistochemistry of terminal differentiation markers in the HI skin ............ 141	
5.2.2. Activation of PPARβ/δ and LXRβ increases ABCA1 mRNA and protein expression 
in the HI cell line ............................................................................................................... 143	
5.2.3. The modulation of terminal differentiation markers under calcium shift and the 
application of agonists ....................................................................................................... 146	
5.3. Discussion ...................................................................................................................... 160	
5.4. Summary ....................................................................................................................... 163	
6	 Chapter 6: Final Discussion and Future Work .................................................. 164	
6.1. Background ................................................................................................................... 165	
6.2. Mutation analysis of ABCA12 and the genotype – phenotype relationship ............ 165	
6.3. Treatment of HI ............................................................................................................ 166	
6.4. Future Work ................................................................................................................. 170	
7	 Chapter 7: Bibliography ....................................................................................... 172	
8	 Chapter 8: Appendices ......................................................................................... 192	
8.1. Appendix 1 ..................................................................................................................... 193	
8.2. Appendix 2 ..................................................................................................................... 197	
 
 
 
 
 
  
  8 
List of Figures and Tables 
Figure 1.1. Schematic of the epidermis. ....................................................................................... 20	
Figure 1.2. Lamellar granule transportation model. ..................................................................... 33	
Figure 1.3. The activation of nuclear hormone receptors in the epidermis. ................................ 43	
Figure 1.4. A typical presentation of HI at birth .......................................................................... 45	
Figure 3.1. Genetic screening of case 1. ...................................................................................... 80	
Figure 3.2. Sanger sequencing of the affected and paternal samples to evaluate pulled variants in 
case 2. .................................................................................................................................. 83	
Figure 3.3. Sanger sequencing of the affected and paternal samples to evaluate pulled variants in 
case 2. .................................................................................................................................. 84	
Figure 3.4. Clinical appareance of the affected in case 3. ........................................................... 85	
Figure 3.5. An example of the deletion analysis undertaken in case 3. ....................................... 88	
Figure 3.6. Sanger sequencing of the paternal sample to indentify allelic discrepancies in case 3.
 ............................................................................................................................................. 90	
Figure 3.7. Expression discrepancy and aberrant splicing analysis of the paternal sample in case 
3. .......................................................................................................................................... 92	
Figure 3.8. Paternal ABCA12 transcript analysis of case 3 using PCR and Sanger sequencing. . 94	
Figure 3.9. Sanger sequencing of candidate variants in case 3. ................................................... 98	
Figure 3.10. Splice site analysis of case 4 of the variants c.6286-17delTGT. ............................. 99	
Figure 3.11. Screening of case 5 using Sanger sequencing. ...................................................... 101	
Figure 3.12. Clinical and histopathological appearance of the affect female at the neonatal stage.
 ........................................................................................................................................... 103	
Figure 3.13. Genetic screening of case 6. .................................................................................. 105	
Figure 3.14. A schematic representation of the ABCA12 protein, denoting the location of 
known mutations and specific domains ............................................................................ 111	
Figure 4.1. In silico splice site prediction and agarose gel electrophoresis of 377 bp cDNA 
fragment ............................................................................................................................ 116	
Figure 4.2. Electropherograms of the Sanger sequencing of the 3 splice variants. ................... 118	
Figure 4.3. TA cloning of aberrant splicing ............................................................................... 120	
Figure 4.4. The MultAlin sequence alignment of the four TA cloning products. ..................... 121	
Figure 4.5. Electropherograms of Sanger sequecning for mutation analysis. ............................ 123	
Figure 4.6. Immunohistochemistry of HI patient and normal skin ............................................ 125	
Figure 4.7. Analysis of ABCA12 knock down in culture. .......................................................... 127	
Figure 4.8. qPCR data showing an increase of ABCA12 mRNA expression in culture under 
calcium shift. ..................................................................................................................... 129	
  9 
Figure 4.9. FACS analysis of cell death and apoptosis. ............................................................. 131	
Figure 5.1. Schematic diagram of the epidermis and localisation of markers of epidermal 
differentiation. ................................................................................................................... 140	
Figure 5.2. Immunohistochemistry of HI patient and normal skin. ........................................... 142	
Figure 5.3. PPAR and LXR activation increase ABCA1 mRNA and protein expression. ........ 145	
Figure 5.4. Western blot analysis of the modulation of involucrin protein expression under 
calcium shift and treatment. .............................................................................................. 149	
Figure 5.5. Western blot analysis of the modulation of TGM1 protein expression under calcium 
shift and treatment. ............................................................................................................ 151	
Figure 5.6. Western blot analysis of the modulation of loricrin protein expression under calcium 
shift and treatment. ............................................................................................................ 153	
Figure 5.7. Electrophoresis gel of loricrin size variants analysis in HI and K17 cell lines. ...... 154	
Figure 5.8. Western blot analysis of the modulation of K10 protein expression under calcium 
shift and treatment. ............................................................................................................ 157	
Figure 5.9. Western blot analysis of the modulation of K14 protein expression under calcium 
shift and treatment ............................................................................................................. 159	
Figure 6.1. Possible therapeutic strategies for HI. ..................................................................... 171	
Figure A1.1. Negative controls of the immunohistochemistry of HI and NS. .......................... 197	
Figure A1.2. A preliminary study of the modulation of the protein expression of ABCA1 in 
keratinocytes under PPARβ/δ and LXRβ activation. ........................................................ 198	
Table 2.1. Table of primary antibodies and their optimised dilutions for Western blot, ICC and 
IHC. ..................................................................................................................................... 68	
Table 3.1. Selected variants from the exome data of the affected in case 3. ............................... 86	
Table 3.2. Previously described deletions within  the gene ABCA12. ......................................... 87	
Table 3.3. Filtered variants from the exome data of the affected in case 3. ................................ 96	
Table 3.4. An example of the first screening in case 5. ............................................................. 100	
Table 3.5. Summary of cases in chapter 3…………………….……………………………….107 
Table A1.1. ABCA12 cDNA primers. ........................................................................................ 194	
Table A1.2. ABCA12 genomic primers. ..................................................................................... 195	
Table A1.3. Genomic primer pairs. ............................................................................................ 196	
Table A1.4. Primers used for qPCR (Rotorgene). ..................................................................... 196	
Table A1.5. Primer sequences used for the screening of loricrin allelic size variants in 5.2.3.. 197	
  10 
Abbreviations  
AT 
ABC 
ApoA1 
AP-1 
bp 
BMZ 
BSA 
Annealing temperature 
Adenosine triphosphate (ATP) binding cassette 
Apolipoprotein A1 
Activator protein-1 
Base pair 
Basement membrane zone 
Bovine serum albumin  
 
CaCl2 
CDC 
Calcium chloride 
Cell division cycle 
 
CDK Cyclin-dependent kinase  
cDNA Complementary DNA  
CIE 
CNV 
CTSD 
CTSC 
DAPI 
Congenital ichthyosiform erythroderma 
Copy number variation 
Cathepsin D 
Cathepsin C 
4',6-diamidino-2-phenylindole 
 
DNA Deoxyribose nucleic acid  
ddH20 Double distilled water  
DEB Dystrophic epidermolysis bullosa  
DDEB Dominant dystrophic epidermolysis bullosa  
DMEM Dulbecco’s modified Eagle’s medium  
DMSO Dimethyl sulfoxide  
DNA 
dNTP 
Deoxyribonucliec acid 
Deoxyribonucleotide triphosphate 
 
DSB Double strand breaks  
DTT 
EB 
Dithiothreitol 
Epidermolysis bullosa 
 
ECM Extracellular matrix  
EDTA Ethylenediaminetetraacetic acid   
EGF Epidermal growth factor  
EGFR Epidermal growth factor receptor  
EST Expressed sequence tag  
EtOH 
FACS 
Ethanol 
Fluorescence activated cell sorting 
 
FBS Fetal bovine serum   
FCS Fetal calf serum  
  11 
FGF Fibroblast growth factor 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase  
GFP Green fluorescent protein  
HCl Hydrochloric acid  
HKGS Human keratinocyte growth supplement  
HI 
HR 
Harlequin ichthyosis 
Homologous recombination 
 
IBS 
ICC 
IHC 
IF 
Ichthyosis bullosa of Siemans 
Immunocytochemistry 
Immunohistochemistry 
Immunofluorescence 
 
IFE Interfollicular epidermis  
IV 
K 
Ichthyosis vulgaris 
Keratin 
 
K1 Keratin 1  
K5 Keratin 5  
K10 Keratin 10  
K14 Keratin 14  
Kb 
kDa 
Kilobase 
Kilodalton 
 
KIFs 
KLK5 
KLK7 
LEKTI 
LG 
Keratin intermediate filaments  
Kalikrein 5 
Kalikrein 7 
Lympho-epithelial Kazal-type-related inhibitor 
Lamellar granule 
 
LXR Liver X receptor  
M 
mA 
mM 
miRNA 
Molar 
Milli amp 
Millimolar  
MicroRNA 
 
MgCl2 Magnesium chloride  
Mock Keratinocytes treated with transfection reagent only   
mRNA Messenger RNA  
NaCl Sodium chloride  
NaOH Sodium hydroxide  
NBCIE 
NBD 
ncRNA 
NEM 
Non-bullous congenital ichthyosiform erythroderma 
Nuclear binding domain 
Non-coding RNA 
N-ethylmalemide 
 
  12 
NGS 
nt 
NTP 
OTCC 
PAGE 
Next generation sequencing 
Nucleotide 
Nucleoside triphosphate 
Organotypic co-culture 
Polyacrylamide gel electrophoresis 
 
PBS Phosphate buffered saline  
PBST Phosphate buffered saline supplemented with 0.1% Triton X-100  
PCR 
PFA 
Pri-RNA 
Polymerase chain reaction 
Paraformaldehyde 
Primary RNA 
 
PPAR 
P/S 
Peroxisome proliferator-activated receptors 
Penicillin/streptomycin 
 
qPCR Quantitative polymerase chain reaction   
RISC RNA-induced silencing complex  
RDEB Recessive dystrophic epidermolysis bullosa  
ROS Reactive oxygen species   
RNA Ribonucleic acid  
RNAi RNA interference  
RNase Ribonuclease  
RT Room temperature  
RT-PCR 
RXR 
SAGE 
Reverse transcription PCR 
Retinoid X receptor 
Serial analysis of gene expression 
 
SDS Sodium dodecyl sulfate  
shRNA Small hairpin RNA  
siRNA Small interfering RNA  
SMOC Secreted modular calcium binding protein  
SNP 
SPR 
SPRR 
STS 
TBS 
Single nucleotide polymorphism 
Small proline-rich protein 
Small proline rich region 
Steroid sulfatase 
Tris-buffered saline 
 
TGF Transforming growth factor  
TGM 
TGN 
TMD 
TINCR 
UTR 
UVR 
Transglutaminase-1  
Trans-Golgi network 
Transmembrane domain 
Terminal differentiation-induced ncRNA 
Untranslated region 
Ultra violet radiation 
 
WB Western blot  
  13 
v/v 
v/w 
XLRI 
Volume per volume 
Volume per weight 
X-linked recessive ichthyosis 
 
  14 
Publications, presentations, and awards 
arising from this work 
Publications  
Manuscripts 
Bland, P. J., Chronnell, C., Plagnol, V., Kayserili, H., & Kelsell, D. P. (2014). A severe 
collodion phenotype in newborn period associated with a homozygous missense 
mutation in ALOX12B. British Journal of Dermatology, 173(1), 285–287. 
doi:10.1111/bjd.13627 
 
Aggarwal, S., Kar, A., Bland, P., Kelsell, D., & Dalal, A. (2014). Novel ABCA12 
mutations in harlequin ichthyosis: A journey from photo diagnosis to prenatal diagnosis. 
Gene, 556(2), 254–256. doi:10.1016/j.gene.2014.12.002 
 
Scott, C. a, Plagnol, V., Nitoiu, D., Bland, P. J., Blaydon, D. C., Chronnell, C. M., … 
Kelsell, D. P. (2013). Targeted sequence capture and high-throughput sequencing in the 
molecular diagnosis of ichthyosis and other skin diseases. The Journal of Investigative 
Dermatology, 133(2), 573–6. doi:10.1038/jid.2012.332 
 
Blaydon, D. C., Nitoiu, D., Eckl, K.-M., Cabral, R. M., Bland, P., Hausser, I., … 
Kelsell, D. P. (2011). Mutations in CSTA, encoding Cystatin A, underlie exfoliative 
ichthyosis and reveal a role for this protease inhibitor in cell-cell adhesion. American 
Journal of Human Genetics, 89(4), 564–71. doi:10.1016/j.ajhg.2011.09.001 
 
 
Abstracts 
P Bland, B Fell and D P Kelsell. “The up-regulation of ABCA1 by the activation of 
LXRβ and PPARδ/γ to renew archetypical differentiation in Harlequin Ichthyosis”, 
European Society for Dermatological Research (ESDR) Meeting Copenhagen, 
Denmark, 10-13 September 2014. 
 
  15 
P Bland and D P Kelsell. The functional mechanisms underlying Harlequin Ichthyosis. 
William Harvey Symposium, Barts and the London, London, 16 October 2013. 
 
 
Oral presentations  
Talk at the 44th Annual European Society for Dermatological Research (ESDR) 
Meeting, “The up-regulation of ABCA1 by the activation of LXRβ and PPARδ/γ to 
renew archetypical differentiation in Harlequin Ichthyosis”, Copenhagen, Denmark, 
10-13 September 2014.  
 
Talk at the Blizard Institute Graduate Studies Day, “The genetic and functional role of 
ABCA12 in Harlequin Ichthyosis”, London, UK, 22 April 2014.  
 
 
Awards 
Awarded £5,000 for a successful grant application from the Ichthyosis Support Group, 
“Recovery from the Harlequin Ichthyosis cellular phenotype through the over 
expression of ABCA1 by the activation of LXR and PPARs”, January 2012. 
 
 
 
  16 
Acknowledgements 
I would like to acknowledge and thank my supervisor, Professor David Kelsell, for the 
opportunity to undertake this PhD and for the constant guidance and supervision 
throughout. David has been ever present throughout this process and always willing to 
lend his expertise, which has been instrumental in the development of this work. I 
would also like to give thanks to my second supervisor Professor Edel O’Toole for 
continued support and advice through the entirety of this project. A large amount of 
thanks must also be given to the SHHiRT charity for funding this project, their first and 
hopefully not last studentship.   
 
I would like to thank all the members of the Kelsell group, past and present for sharing 
their knowledge and technical know-how, particularly Dr Diana Blaydon, who 
introduced me to research, the lab and was a constant source of technical support. A 
special thanks to Dr Vera Martins, Dr Supatra Marsh, Dr Thiviyani Maruthappu and 
Benjamin Fell, for unique friendships that helped me through the difficult times. Thanks 
to the Centre for Cutaneous Research for creating a friendly and professional 
environment. 
 
Finally a big thank you to my family and friends and to Sarah Griesler whose eunoia 
has been a constant source of inspiration and strength. 
  
  17 
1 Chapter 1: Introduction 
 
 
 
 
 
 
  18 
1.1. The Skin 
The skin is a complex organ that envelops the vast majority of the human body, its 
functions are numerous and critical to survival. The most discernible of which is the 
physical barrier the skin produces that shields the body from the immediate external 
environment. The skin helps to maintain homeostasis, the immune system and the 
physical form. Succinctly, the skin consists of three layers; the hypodermis, dermis and 
(outermost) epidermis.  
 
The subcutaneous layer or hypodermis contains; lymphatic vessels, blood vessels, 
adipose tissue and is connected through striated muscle to the body. The dermis is 
found directly above the hypodermis and forms from the embryonic development of the 
mesoderm. It also contains lymphatic and blood vessels, but differs from the 
hypodermis in composition greatly. It generates the skin’s elasticity, thermoregulation, 
strength and supplies the epidermis with nutrition. The matrix of this layer is 
predominately formed from proteoglycans and collagen, the former helps retain water 
when processed in the epidermis and the latter, with elastin, gives rise to the flexibility 
and suppleness of the skin. The principle cell type of the dermis is the fibroblasts, which 
secrete the constitutional components of the matrix. They are joined in the dermis by 
ephemeral immune cells, adipocytes and macrophages (Chu 2008).  
1.1.1. The Epidermis 
The epidermis adheres to the dermis through the dermoepidermal junction, a key 
structure in anchoring the epidermis through anchoring filaments and fibres that 
increase the skin’s tensile capability. Within the skin, the epidermis itself has several 
layers; the first or basal layer is where the keratinocytes proliferate before they undergo 
terminal differentiation in the subsequent suprabasal layers. The main role of the 
epidermis is to maintain the skin’s physical barrier against the environment; this barrier 
is maintained through the constant production and shedding of squamous keratinocytes. 
The rest of the cellular composition of the epidermis contains; Merkel cells, dendritic 
Langerhans’ cells and melanocytes that bequeath melanin to keratinocytes. The 
epidermis is also a key structure in the skin’s water retention, UV protection, vitamin D 
synthesis and immune function (Freinkel & Woodley 2001). 
  19 
The predominant cell type in the epidermis is the keratinocyte and it is the 
differentiation of this cell type that generates the stratified layers key to the structure 
and function of the epidermis. During the migration of these terminal differentiating 
cells, the four layers of the epidermis are created; the basal layer or stratum basal, 
spinous layer or stratum spinosum, granular layer or stratum granulosum and the 
stratum corneum, shown in Figure.1.1. (Chu 2008). 
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Figure 1.1. Schematic of the epidermis. The journey of a keratinocyte through the epidermis 
is unidirectional and designed by terminal differentiation. Keratinocytes become flattened and 
lose cellular content including the nucleus as they reach the upper layers. In the upper layers 
their morphology, protein content, organelle compliment and function changes, as they establish 
important skin barriers and undergo programmed cell death. BM, basement membrane; SB, 
stratum basale; SS, stratum spinosum; SG, stratum granulosum; SC, stratum corneum. 
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The stratum basale adheres to the basement membrane through hemidesmosomes, 
which sequester keratin and often integrate to the dermis through laminin-derived 
anchoring fibrils. The sequestered keratins of proliferating cells are different to that of 
differentiating cells; of note, keratin 5 and 14 (K5 and K14) are the main structural 
proteins expressed by the proliferating keratinocytes in the stratum basale, whereas 
keratin 1 and keratin10 (K1 and K10) are markers of a suprabasal differentiating 
keratinocyte. K5 and K14 form keratin intermediate filaments (KIF), which are 
heterodimers of one type I and one type II keratin, in the basal layer keratinocytes, the 
KIFs alongside microfilaments and microtubules are key structural components that 
travel to the nuclear lamina from desmosomes (Fuchs 1998).   
 
The epidermis regenerates by the propagation and differentiation of slow cycling 
epidermal stem cells, which are located in the stratum basale. Specific compartments of 
stem cells give rise to the individual lineages, compartments such as; basal region of the 
sebaceous glands, interfollicular bulge and interfollicular epidermis (Jiang et al. 2010). 
The delamination of stem cells from the stratum basale or direct differentiation of 
keratinocytes from stratum basale to the stratum spinosum can start the process of 
terminal differentiation, though mitotic spindle orientation is a crucial differentiation 
initiator (Lechler & Fuchs 2005). Symmetrical mitosis encourages the keratinocytes to 
migrate laterally across the stratum basale increasing surface area, whereas asymmetric 
mitosis orientates keratinocytes for stratification through terminal differentiation. 
Spindle trajectory is thought to coordinate migration, as spindles in parallel with the 
basement membrane will favor symmetrical division and vice versa. Spindle orientation 
involved in asymmetric cell division is driven by the localization of nuclear mitotic 
apparatus protein (NuMA), but not by the transcription regulator of stratification P63 
(Poulson & Lechler 2010).  
 
The stratum spinosum comprises of keratinocytes with polyhedral morphology, highly 
spherical nuclei lying adjacent to the stratum basale, as recent products of asymmetrical 
mitoses. At this point of epidermal differentiation keratinocytes cease the normal cell 
cycle and start to initiate further cell attachments through an increase in desmosomes 
and gap junctions. Protein production of K5 and K14 is terminated, though the proteins 
are retained and K1 and K10 expression is actuated, which producers a larger and flatter 
keratinocyte bordering the stratum granulosum (Simpson et al. 2011). The K1/K10 
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heterodimer replaces the K5/K14 heterodimer in the KIFs, which is crucial for nuclear 
and desmosomal stability during keratinocyte differentiation (Wallace et al. 2012).  
 
K10 and K1 are two of the most prevalent proteins in the suprabasal layers of the 
epidermis; synonymous with differentiation, K10 inhibits proliferation through cell 
cycle arrest when incorporated into the cytoskeleton via non-helical terminal domains. 
In turn this process can be inhibited in such hyperproliferative states as wound healing 
the expression and IF binding of keratin 16 (K16) reverses the K10-induced inhibition 
and renews proliferation (Paramio et al. 1999). The type I keratin K16 forms 
heterodimers with the type II keratin 6 (K6), together they aid keratinocyte migration 
and resistance from mechanical stress, though in an aged epidermis an increase in K16 
alone creates a defect in cell migration (Trost et al. 2010). In keratinocytes found in the 
uppermost regions of the stratum spinosum lamellar granules (LGs) are synthesized for 
the first time, an organelle crucial for the correct barrier formation (Chu 2008). The 
highest concentration of lamellar granules and their extruded contents are localised to 
stratum granulosum, with the permeability barrier formation occurring at the periphery 
with the stratum corneum, which will be discussed in more detail (1.3) (Vielhaber et al. 
2001). 
 
The stratum granulosum is the layer of the epidermis where keratinocytes manufacture 
the vast majority of the components needed to assemble the cornfield cell envelope. 
Keratinocytes that occupy this stratified layer possess keratohyalin granules containing 
predominately profilaggrin and lesser proportions of loricrin and keratin (Elias & 
Feingold 2005). Profilaggrin is a large phosphoprotein containing multiple repeating 
subunits of filaggrin, during terminal differentiation profilaggrin is dephosphorylated 
and cleaved (Presland et al. 1997). Profilaggrin contains two different linker sequences, 
which are cleaved by specific enzymes; following this calcium-dependent proteolytic 
cleavage by profilaggrin endoproteinase I and calpain I, filaggrin is produced (Resing et 
al. 1989). In the stratum corneum filaggrin aggregates with keratin to form 
macrofilaments that are degraded to simpler molecules with hydrating and UV-
protective properties.  
 
The basal layer keratinocytes are susceptible to malignant transformation by UVB 
irradiation and are thus protected by the reflection and absorption of UVB in the upper 
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layers of the skin. The aromatic amino acid residues of proteins, DNA and melanin of 
the upper layers of the epidermis are all chromophores of UVB and help to protect the 
proliferating basal layer keratinocytes (Young 1997). Processed filaggrin in the 
epidermis interacts with intermediate filaments that form the intracellular matrix of 
keratinocytes, then its proteolytic degradation forms components of moisturizing 
surfactants, all contributing to the primary role of filaggrin in the formation of cornified 
layer and the physical barrier of the skin (Pendaries et al. 2014). Filaggrin also plays a 
role in UVB protection, as a reduction in processed filaggrin in the skin has been shown 
to increase sensitivity to UVB and reduce the amount of urocanic acid (UCA) in late 
differentiation (Mildner et al. 2010). UCA has been shown to accumulate in the stratum 
corneum and is the product of the enzymatic activity of histidase on histidine. Ablation 
of the histidase enzyme causes a UVB-photosensitive phenotype in mice that 
accumulates more DNA damage under UVB irradiation than wild type (Barresi et al. 
2011). 
 
In the upper granular layer transglutaminase 3 (TGM3) initiates the first cross-linking in 
the formation of the cornified envelope, TGM3 acts as the catalyst forming the 
isopeptide bonds between loricrin and involucrin. This cross-linking is increased in the 
stratum corneum as other calcium-dependent transglutaminases, 1 and 5 (TGM1) 
(TGM5) join TGM3 in the creation of the insoluble and resistant cornified envelope 
(Lorand & Graham 2003). The calcium gradient within the epidermis is referred to in 
greater detail later in (1.2.1). Filaggrin aggregates with the KIFs forming tight bundles, 
which account for a great percentage of the mass of the epidermis and change the 
morphology of the keratinocytes, making them flatter with pronounced cellular 
projections. Keratinocytes of the stratum granulosum takes on a more differentiated 
morphology, they form tight junctions that help to promote a barrier against the external 
environment. By forming these knot type adhesions between neighboring cells the 
epidermis allows exclusively for the transition of ions and small molecules between 
keratinocytes. Desmosomes continue to play a role in differentiation, in the stratum 
granulosum/corneum boundary, they bind to the adjacent plasma membrane through 
loricrin, and involucrin via TGM1 activity, further defining the permeability barrier of 
the skin (Candi et al. 2005).  
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The stratum lucidum resides between the stratum granulosum and stratum corneum and 
is prevalent in palmar-plantar skin, the glabrous, non-hairy, skin of the soles of the feet 
and palms of the hands (Freinkel & Woodley 2001). This specialized additional layer 
was postulated through the characterization of palmar-plantar skin, in particular by the 
comparison of the keratin profiles of palmar-plantar and normal skin. It is rich in lipids 
and thiol groups secreted by the keratinocytes of the stratum granulosum that aid the 
structural integrity of the epidermis in these areas of high mechanical stress (Swensson 
et al. 1998). The type I intermediate filament keratin, keratin 9 (K9) is expressed 
uniquely in the suprabasal layers of the epidermis of palmar-plantar skin and is required 
for terminal differentiation and maintaining the mechanical integrity of the 
palmoplantar epidermis (Fu et al. 2014). 
 
The stratum corneum is the uppermost layer of the epidermis and holds keratinocytes in 
their final stage of terminal differentiation. The keratinocytes here are labelled as 
corneocytes as they have undergone apoptosis and exocytosed or degraded much of 
their intracellular content forming a layer of flat cell remnants creating a physical 
barrier of the skin. This physical barrier is the cornified envelope, which has a general 
structure containing a multitude of proteins cross linked together through the enzymatic 
work of several transglutaminases, creating a continuous insoluble boundary replacing 
the plasma membranes in the layer of corneocytes (Kalinin et al. 2001). The ~15 nm 
thick cornified envelope consists of a scaffold of KIFs and filaggrin upon which other 
structural proteins are added, including loricrin, involucrin and the small proline-rich 
(SPR) family of proteins (Hohl 1990). Corneocytes are affixed to one another through 
corneodesmosomes, embedded in a lipid complex of cholesterol, phospholipids, 
ceramides and free fatty acids (Candi et al. 2005). This lipid complex forms lipid 
bilayers, crucial for the skin barrier and the only continuous structure bridging the upper 
layers of the epidermis and tight bundle formation of K1 and K10 with filaggrin within 
the cytoskeleton of corneocytes resulting in a dramatic flattening of the cells of the 
cornified envelope (Manabe et al. 1991). 
 
The cornified envelope is a key structure in establishing the mechanical resilience and 
insolubility of the epidermis; these properties are shaped by its structure, which has 
many attributes.  One of which is the addition of TGM cross linked structural proteins, 
involucrin, loricrin and the S100 family of proteins. They S100 family is classified by 
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containing the calcium binding EF-Hand domains and binding calcium to rely cell 
regulatory signals. Found in the cornified envelope their expression is initiated in the 
stratum basale and spinosum, as keratinocyte differentiation takes place the localization 
of S100A7 and A11 moves from the nucleus, to the cytoplasm and finally the plasma 
membrane (Broome et al. 2003). S100 proteins regulate target protein activity through 
calcium-dependent binding and are themselves cross linked in the cornified envelope by 
calcium-dependent TGM1 and TGM2 a mechanism deemed to regulate the activity of 
the S100 family (Ruse et al. 2001). 
 
Loricrin is a central component of the cornified envelope and accounts for ~80% of the 
total protein mass of the cornified envelope (Steinert 1998). The expression of loricrin 
is initiated in keratinocytes of the stratum granulosum and once translated it is 
frequently cross linked by the addition of isopeptide bonds through the activity of 
TGM1, 3 and 5. Found cross linked to itself forming loricrin oligomers, attached to SPR 
proteins or both this heterogeneity promotes disorder in the cornified envelope that 
contributes to its elasticity (Yoneda & Steinert 1993). The loricrin protein is rich in 
glycine-serine-cysteine residue repeats, the number of which is not conserved, though 
the loops they form are flanked by either aromatic or aliphatic residue forming a 
common motif in the protein. The binding of which forms either inter or intramolecular 
disulfide and N-(γ-glutamyl)lysine isodipeptide bonds, which stabilise loricrin into a 
rosette like structure (Hohl et al. 1991). These glycine rich loops separated by 
hydrophobic interactions create flexible Ω-loop like structures that impart the elasticity 
characteristic on cornified envelope. 
 
Involucrin localises to the cytosol of keratinocytes in the stratum granulosum, 
eventually it is cross linked to other structural proteins of the plasma membrane in the 
stratum corneum, where the formation of the cornified envelope takes place. The 
involucrin gene comprises of one central exon containing a 30 nucleotide sequence 
repeated 39 times, high in glycine and aspartic acid residues, with intermittent 
rearrangements occurring through recent evolution (Eckert & Green 1986). Comparable 
with loricrin, involucrin forms cross links with N-(γ-glutamyl)lysine isodipeptide bonds 
through the enzymatic activity of TGM1. The structure of involucrin is predominately 
α-helical culminating in a flexible rod 3D structure that translocates and strengthens 
with Gln495 and Gln496 available for cross linking to loricrin and SPR proteins 
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(Envelope et al. 1992). The involucrin protein provides the cornified envelope with the 
physical cross links needed to produce the mechanical resilience found in the epidermis, 
it may also be pivotal in the attachment of extracellular lipids a constituent of the skin’s 
permeability barrier. A type of TGM1 can function located on the plasma membrane 
and forms ester bonds linking the available glutaminyl residues involucrin to ω-
hydroxyceramides (Nemes et al. 1999). 
 
The SPR family of proteins contains 13 proteins divided into three classes, SPR1-3, all 
of which are 6-18 kDa and rich in proline amine acid residues. Similar to the 
aforementioned loricrin protein, the size and structure of SPR make them ideal for cross 
linking to other constituents of the cornified enveloped. However, unlike loricrin, which 
is constitutively expressed in the stratum corneum of the epidermis, SPR proteins are 
facultatively expressed at varying levels depending on the physical requirements of the 
skin (Steinert et al. 1998). This natural variation to the ratio of loricrin to SPR proteins 
varies from less than 1:100 in skin with a relatively thin skin to around 1:10 in areas 
containing a thickened epidermis such as the palms and soles. Upon which it can be 
postulated that SPR proteins play a role in constructing or maintaining a thickened 
epidermis (Steinert 1998). 
 
These elements of the cornified envelope sit entrenched within the lipid envelope, a 
complex structure of lamellae originating from a highly organised myriad of lipids, 
which helps to negate transepidermal water loss (TEWL) from the skin. The lipid 
envelope and the lamellar granules (LG) that supply them are disseminated in 1.3. and 
1.4. respectively. The complementation of the cornified and lipid envelopes is 
fundamental in giving the epidermis its distinctive resilience and creating an 
environment for microbial defense. Antigen invasion through a physical disruption to 
the barrier causes an inflammatory response through the extension of dendrites from 
active Langerhans’ cells, when the microbial defense is breached (Simpson et al. 2011). 
The layers of fully differentiated corneocytes forming the stratum corneum produce an 
ideal cuticle against the external environment, but are continuously attenuated by 
proteases. Proteases from the LGs degrade the remaining corneodesmosomes and lipid 
complexes, shredding the non-viable corneocytes (Freinkel & Woodley 2001). 
  27 
1.1.2. The Dermis 
The main bulk of the skin is made up of the dermis, which provides much of the 
elasticity, structural integrity and flexibility that are characteristic of this organ. The 
dermal layers adhere to the epidermis through the dermoepidermal junction, a section of 
the skin comprising of anchoring filaments, type VII collagen containing 
hemidesmosomes, which connect the dermis to the basement membrane. The dermis 
contains many different cell types such as mast cells, immune cells, macrophages and 
predominately fibroblasts. All of which are located in a blend of cellular, fibrous, 
filamentous and diffuse connective tissue elements that house vascular and nerve 
networks aiding water retention, thermoregulation and holding the sensory receptacles. 
During repair after wounding and embryonic development the dermis is continuously 
interacting with the dermoepidermal junction and the epidermis for nourishment and 
maintenance (Chu 2005). 
1.2. Keratinocyte Differentiation  
The differentiation of keratinocytes is a highly specialised function that enables the 
separation of organism from the environment by the formation of the stratified 
epidermis. Markers of early keratinocyte differentiation, such as the aforementioned 
TGM1 and involucrin portray the initiation of this process in the stratum spinosum and 
through a complex gene regulatory network, this process ends with cornification in the 
stratum corneum. Differentiation of the epidermis is promoted by many factors 
including an increase in the concentration of calcium, hydrocortisone, Vitamin D, cell to 
cell contacts and the reduction of vitamin A (Hennings et al. 1980; Cline & Rice 1983; 
Bikle 2010; Dotto 1999; De Luca 1977). The expression of markers of terminal 
differentiation, cornified envelope formation and general epidermal stratification is 
reduced by the action of retinoids on the epidermis (Eckert & Rorket 1989).  
1.2.1. Calcium Gradient 
Calcium is the main factor in promoting keratinocyte differentiation within the 
epidermis. The path of differentiation mirrors the change in the concentration of 
calcium in the skin, with the proliferating, undifferentiated keratinocytes of the stratum 
basale present at a relatively low calcium concentration that increases as the progression 
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is made through the subsequent layers of the epidermis to the stratum corneum. This 
calcium gradient coincides with increased cytosolic free calcium and calcium contained 
within organelles of keratinocytes of the upper epidermal layers (Pillai et al. 1993). As 
the keratinocytes start to differentiate they migrate through the stratified layers of the 
epidermis, their morphology changes driven by the increase in calcium, which affects 
the cell in many ways before terminating as anucleate squames. The constituents of the 
IF change, keratinocytes become flattened, start to express proteins of the cornified 
envelope and have a greater permeability to calcium and other ions (Eckert & Rorket 
1989). Keratinocytes exit the cell cycle when migrating from the proliferating stratum 
basale. In monolayer culture when calcium shifted, keratinocytes show increased 
intercellular connections, including desmosomes within hours, minor stratification and 
termination of DNA synthesis by 2 days, and between 3-4 days transcription and 
translation are reduced by half, preceding the end of terminal differentiation (Hennings 
et al. 1980). 
 
The maintenance of intracellular calcium levels in proliferating keratinocytes and those 
undergoing calcium switch into differentiation is managed by two elements of the store-
operated calcium entry (SOCE) pathway. These are the endoplasmic reticulum (ER)-
located calcium sensor STIM1 and the partial calcium channel Orai1, knockdown of 
either of these proteins suppresses SOCE through the phospholipase-C activated 
calcium response. This significantly reduces the ability of keratinocytes to initiate 
differentiated and express early epidermal differentiation markers (Numaga-Tomita & 
Putney 2013).  
 
As the calcium gradient continues to rise in the stratum spinosum, stimulation of 
calcium-dependent keratinocyte differentiation is coupled with the phosphorylation of 
the group of ErbB receptors, which encompass the epidermal growth factor receptor 
(EGFR). Activating EGFR induces the expression of activator protein-1 (AP-1) in 
keratinocytes, which helps to drive differentiation. Proteins involved in late epidermal 
differentiation such as TGM1, filaggrin, involucrin and loricrin all hold AP-1 binding 
sites in their promoter regions (Hanley et al. 2000; Schmuth et al. 2004). In calcium 
shift experiments the ErbB receptor activated changes with the amount of time spent 
under high calcium conditions, which also correlates to the localisation of ErbB 
receptors to specific stratified layers of the epidermis. There is a complex network that 
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leads to the timely expression of differentiation-related proteins in the epidermis, which 
is controlled by the calcium gradient through the activation of ErbB receptos, AP-1 
induction and further transcriptional promotion. As shown when either ErbB receptors 
or AP-1 proteins are aberrant terminal differentiation is inhibited (Saeki et al. 2012). 
 
As calcium levels continue to rise throughout the stratification of the epidermis a group 
of proteins that were expressed due to the initial suprabasal influx of calcium, 
envoplakin, periplakin and involucrin localise to the plasma membrane. Here they are 
accompanied by TGM1, the expression of which is also triggered in keratinocytes 
undergoing differentiation, this enzyme is activated by the further rise of intracellular 
calcium during late differentiation. TGM1 cross links involucrin to the plakins through 
the formation of isopeptide bonds as well as joining these proteins to other membrane 
bound proteins. This growing network of bound structural proteins at the plasma 
membrane develops into the scaffold that will hold the cornified envelope (Kalinin et al. 
2001). 
1.2.2. Desquamation  
Terminal differentiation in the epidermis concludes with keratinocytes undergoing 
cornification in the outermost layer, the stratum corneum. At this stage they have helped 
produce the intercellular structures of the interconnected cornified envelope and the 
complex lamellae of the lipid envelope. The squames accumulate at the periphery of the 
stratum corneum generating a thickness that varies for specific locations on the body. 
The growth of this tightly packed layer of retained squames is curtailed by the process 
of desquamation, through the action of proteases this process degrades structural 
proteins and allows a continuous shedding of the outermost squames (Egelrud et al. 
2000). This epidermal homeostasis is needed for the continuous turn over of the 
epidermis, with keratinocytes moving from proliferation, migrating to differentiation 
and becoming part of the stratum corneum in ~3 weeks (Baker & Kligman 1967). 
 
Proteases are crucial in the process of desquamation; they start to degrade the 
intercellular attachments to shed the outermost squames as differentiation finishes. In 
corneocytes the proteolytic degradation of corneodesmosomes is performed by the 
serine proteases kallikreins 5 and 7 (KLK5 and KLK7), which perform in tandem upon 
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the corneodesmosin, desmocollin-1 and desmoglein-1 structural proteins (de Veer et al. 
2014). Other kallikreins may also play roles in desquamation and have been shown to 
be present in the epidermis, such as the desmoglein-1 cleaving KLK14 and KLK8 
(Borgoño et al. 2007). The acidic environment of the stratum corneum is due to the 
lowering of the pH throughout epidermal differentiation. The low pH is an optimal 
working condition for the lysosomal aspartyl protease cathepsin D and the cysteine 
protease cathepsin V, both of which co-localise with corneodesmosomes (Igarashi et al. 
2004; Zeeuwen et al. 2007). 
 
The lympho epithelial kazal type related inhibitor (LEKTI) controls the degradation of 
corneodesmosomes by serine proteases in the stratum corneum. LEKTI is cleaved into 
its 15 functional protease inhibitor domains by the protease furin (Fortugno et al. 2011). 
The inhibition LEKTI exhibits on the kallikreins (KLK5, KLK7 and KLK14) of the 
epidermis ceases when the pH is at its lowest in the stratum corneum, this avoids any 
unspecific premature degradation in the lower levels of the epidermis (Deraison et al. 
2007). Proteolytic activity is further regulated by another group of kazal type protease 
inhibitors known as SPINK6 and SPINK9 (Meyer-Hoffert et al. 2009). The other main 
group of protease inhibitors in the epidermis regulating desquamation is the cystatins. 
Cystatin A (CSTA) for example has been shown to be present in the stratum corneum 
where it inhibits both cathepsin L and V and the exogenous proteases secreted from dust 
mites (Cheng et al. 2006). CSTA also localised to the lower levels of the epidermis 
where it was found to be important in maintaining cell-cell adhesion and thus epidermal 
stability under mechanical stress (Blaydon et al. 2011). The probable activity of cystatin 
M/E however is involved in the regulation of protease modulated TGMs (Zeeuwen et al. 
2010). The activation of the TGMs that cross link the pre-cursor proteins of the 
cornified envelope is regulated by a cascade of proteases including legumain and 
cathepsins L and D (CTSL and CTSD) (Egberts et al. 2004; Zeeuwen et al. 2010). 
1.3. Lamellar Granules 
The lamellar granule (LG) is a subcellular structure that can be detected by electron 
microscopy and can be roughly described as a storage vehicle or a secretary organelle. 
LGs are also known as lamellar bodies, Odland bodies or membrane coating granules; 
they are employed in several tissue types offering a host of cargos for different 
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extracellular roles. In the lungs LGs are synthesised in pneumocytes and transport 
phospholipid derivatives that are extruded as alveoli surfactants (Haller et al. 1998). 
They also help maintain the protective hydrophobic lining of the gastric mucosa and 
have a key role in synoviocytes and their role in the lubrication of joints (Dobbie et al. 
1995; Stremmel et al. 2012). LGs in the epidermis measure 200 – 300 nm and are a 
secretory vesicle crucial for correct late epidermal formation, they extrude a specific 
group of lipids and proteases involved in desquamation into the extracellular space of 
the upper stratum granulosum and the stratum corneum. This specific group of lipids 
forms the lipid envelope and in doing so the permeability barrier of the epidermis, a 
structure known to stop TEWL. The main constituent of this group of lipids are 
ceramides, though additionally LGs also carry cholesterol and fatty acids (Schmitz & 
Müller 1991).       
1.3.1. Ultrastructural organisation 
The presupposition with regard to the formation and structure of the LG leaned towards 
an ovoid shaped discrete organelle, made from a bilayer of membrane lipids. Formed 
from the folding and budding of the trans-Golgi network and then moving towards and 
fusing with the plasma membrane the LG would then extrude its contents into the 
extracellular matrix (Bouwstra et al. 2003). This concept was challenged due to the 
contents of LGs, the topology of the vesicles and the thermodynamic cost of the 
budding to fuse, when a continuous lamellae structure could be present (Norlén 2001a). 
A continuous trans-Golgi like structure was hypothesized in the ‘membrane-folding 
model’ conceived by Norlén. Norlén postulated that LGs do not become separate 
organelles from the Golgi, rather, produced by branching of a continuous trans-Golgi 
network. These bind with the plasma membrane and then unfold into the extracellular 
matrix of the stratum corneum, preserving membrane continuity (Norlén 2001a). 
Further investigation into the nature of LGs using a range of electron microscopy shows 
a LG predominately fitting the folding membrane model with some discrete ovoid 
shaped LGs. From which, it appears that morphology is cargo-dependent (Ishida-
Yamamoto et al. 2004; Fartasch 2004). 
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1.3.2. Molecular composition and cargo 
The LG can transport a diverse set of cargos from the precursors of the lipid envelope; 
glucosylceramides, cholesterol, phospholipids and sphingomyelin to their respective 
enzymes; β-glucocerebrosidase, steroid sulfatase, phospholipase A2 and 
sphingomyelinase (Hachem et al. 2006). Either as a continuous structure or a discrete 
organelle packing of the LG is crucial for lipid envelope formation. The delivery of 
lipids from either the Golgi or cytosol into the inchoate LGs allows for not only a high 
concentration of lipids to be transported, but also the coordinated packaging of 
enzymes. As without lipid transportation into the LGs there is no enzyme transportation 
into LGs and therefore they cannot act in envelope formation (Rassner et al. 1999). This 
briefly highlights the importance of the lipid transporter ABCA12. Mature ABCA12 
was shown to be present in the Golgi and retained in the developing or budding LGs. 
The co-localization of ABCA12 to the Golgi markers TGM46 (glycoprotein) and 
GM130 was present throughout the epidermis, whereas ABCA12, glucosylceramides 
and developed LGs co-localise exclusively in the stratum granulosum layer (Sakai et al. 
2007). This, and the action of ABCA12, are further discussed in 1.8.1. 
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Figure 1.2. Lamellar granule transportation model. LGs in keratinocytes are heterogeneous 
in form and the cargo they transport. LGs are derived from the trans-Golgi network and further 
their projection towards the membrane by an addition of lipids creating a continuous tubular 
structure. Cargos are predominately transported in these continuous lamellar structures until 
they fuse with the degrading apical membrane in keratinocytes of upper stratum granulosum 
early stratum corneum. Cathepsins are the caveat here; LGs that transport these proteases are 
discreet ovoid vesicles that are budded from inchoate LGs and possibly fuse later with the 
continuous form. Both forms extrude their contents into the extracellular space of the stratum 
corneum creating the lipid and cornified envelopes. 
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As shown in Figure 1.3. the secretion from LGs into the extracellular space occurs near 
the conclusion of terminal differentiation at the superficial cells of the stratum 
granulosum. Not only do LGs extrude a range of lipids and their respective enzymes, 
they also transport structural proteins involved in cornification like corneodesmosin and 
proteases such as KLK7, KLK8 and CTSD, that are involved in desquamation (Ishida-
Yamamoto et al. 2004). The deregulation of which can be seen when aberrant LGs do 
not transport their protease cargos, which leads to the retention and subsequent build up 
of squames in the stratum corneum. Disruption of the upper layers of the epidermis 
whether by means of tape stripping (mechanical stress) or detergents, results in a great 
and swift promotion of LG synthesis and secretion from the uppermost remaining 
keratinocytes. This is to repair barrier function and demonstrates the relationship 
between the concentration of lipids in the stratum corneum, barrier formation and LGs 
(Grubauer, et al. 1989).  
 
This rapid response to skin barrier disruption is produced by two interlinked properties 
of the epidermis, TEWL and the calcium gradient that runs throughout the epidermis. 
Disruption of the lipid envelope causes a transepidermal water flux and with it, an 
increase in calcium concentration in the area of perturbation. This increase up-regulates 
differentiation and lipid synthesis in the remaining stratum granulosum and enables the 
redistribution of lipids in the stratum corneum normalising barrier function (Grubauer, 
et al. 1989). 
1.4. Epidermal Lipids and the Permeability Barrier 
The epidermis of mammals protects them from the possible physical damage and 
dehydration inflicted upon them by the environment. The previously described cornified 
envelope consisting of corneocytes embedded into insoluble proteins and the lipid 
envelope achieves these properties. The lipid envelope or extracellular hydrophobic 
lipid matrix is a product of the differentiation of keratinocytes, made from skin-specific 
lipids it provides the permeability barrier against the movement of water and 
electrolytes (Ponec 1994). Alongside their pivotal function in the permeability barrier 
epidermal lipids also provide a defence against the invasion and colonisation of 
microorganisms whether they are commensal or pathogenic. When both barriers are 
non-functioning as described in patients with burns or very premature births, mortality 
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becomes a factor highlighting the importance of a functioning epidermis. The 
permeability barrier is located in the stratum corneum and accounts for 10% of the 
stratum corneum’s tissue mass and on average 50% of the lipid mass is ceramides, 25% 
cholesterol, and 15% free fatty acids with very few phospholipids (Gray et al. 1982; 
Feingold 2007). 
 
Lipids in the epidermis are key in the formation of the lipid envelope and thus in the 
formation of skins permeability barrier. The prevention of water loss through the skin is 
crucial and to this affect the barrier has to be kept as tight as possible (Blank 1952). 
Hydration is closely regulated in the stratum corneum, as apart from the minute amount 
of water needed in corneocytes to hydrate keratins present in IF, the over hydration of 
corneocytes causes them to swell uniformly and stratum corneum to expand 3-4 fold 
(Warner et al. 2003). Lipids expelled from the top of stratum granulosum form the 
complex lamellar membranes that reside in extracellular domains of stratum corneum. 
The majority of ceramide processing in the stratum corneum occurs extracellular, by the 
lamellar granules, though significant levels of glucosylceramides and ceramides are 
found within the cells and throughout the layers of the epidermis (Vielhaber et al. 
2001). 
 
Through LG exocytosis lipids and their respective catalytic enzymes are secreted 
together aiding the quick assembly of the lipid envelope, but also providing the 
extracellular matrix with bi-products like glycerol, formed from the catalysis of 
phospholipids, that aids water retention. Furthermore, the pH of the permeability barrier 
(5-5.5) is maintained by the production of free fatty acids, which is the optimal pH for 
the secreted enzymes β-glucocerebrosidase and sphingomyelinase and later the pH is 
further lowered for the proteases of desquamation (Fluhr et al. 2001). β-
glucocerebrosidase in turn reduces glucosylceramide into glucose and free ceramide, 
which itself can form sphingosine (Grubauer, et al. 1989). 
 
The entire epidermis produces a myriad of different lipids throughout the differentiation 
process; those meant for the lipid envelope have precursors that can be traced back to 
basal levels, existing as sphinganine, cholesterol sulfate and inchoate fatty acids. There 
is a pronounced change in lipids, their composition and cellular localisation through 
keratinocyte terminal differentiation (Elias 1983). In the lower levels of the skin both 
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polar and neutral lipids reside, which is the composition throughout many mammalian 
tissues, this balance is replaced with a bias towards a predominant neutral mixture of 
lipids. The neutral lipid cholesterol is one of these lipids found in the upper layers of the 
stratum granulosum. It exists as the metabolite cholesterol sulphate in the proliferating 
keratinocytes of the basale layer, where at a high concentration it acts as a protease 
inhibitor. The expression of the cholesterol sulfate catabolic enzyme steroid sulfatase in 
keratinocytes of the stratum granulosum reduces the level of cholesterol sulfate. The 
intracellular concentration of its’ enzymatic product cholesterol then subsequently 
increases to the amount found in the lipid envelope (Elias, et al. 1984). Later in 
differentiation the reduction of cholesterol sulfate reduces the inhibition of proteases 
involved in desquamation. In conditions with a dysfunctional cholesterol sulfatase 
enzyme the resulting cholesterol sulfate build up creates abnormalities in plasma 
membrane structure and extensive lamellar-phase separation in the lipid envelope 
(Zettersten et al. 1998). 
 
The neutral lipids at the greatest concentration in the stratum corneum belong to the 
group of ceramides, synthesized through the salvage pathway and hydrolysis of 
sphingomyelin or the de novo product of the addition of serine to palmitate (Mao-Qiang 
et al. 1993). Ceramides are lipid molecules comprising of a fatty acid and a sphingosine 
molecule, they are a common subunit of cell membranes. Ceramides are a precursor to 
the main component of the lipid envelope glucosylceramide, which is the structural crux 
of extracellular lamellar sheaths. Glucosylceramide is produced via the enzyme 
glucosylceramide synthase which forms a glycosidic between a carbohydrate head and a 
ceramide chain and is present at a high concentration in the stratum granulosum 
(Galadari et al. 1998).  
 
Though the importance of nonpolar ceramides cannot be overlooked in lipid envelope 
formation, the other lipids in the composition have pivotal roles too. As experiments 
have shown the removal of loosely bound nonpolar species alone histologically appears 
to cause only a modest level of barrier disruption, whereas the removal of sphingolipids 
and sterols leads to a more profound level of barrier perturbation (Grubauer, et al. 
1989). Ceramides are also part of the molecular relay activated as a cellular response to 
extracellular stress or signaling, like terminal differentiation, the suppression of cell 
growth and division and initiation of apoptosis (Galadari et al. 1998). 
  37 
The polar lipids glycoslyceramide and sphingomyelin are both products of ceramide 
processing in the lower stratum granulosum; they are then package into LGs through the 
lipid transporter ABCA12 (Sakai et al. 2007). They travel with catabolic enzymes and 
other lipids in LGs until they are extruded into the extracellular matrix where they are 
further processed into ceramides of different lengths establishing the extracellular 
lamellar membrane structures of the lipid envelope (Uchida & Holleran 2008). 
 
Alongside the array of processed ceramides of different lengths, free fatty acids and 
cholesterol, the other main component of the lipid envelope are the acyl ceramides. 
Acyl ceramides are a subgroup of the most dominant type of lipid in the lamellae, the 
ceramides. They are a key component in barrier formation as they aid the folding of the 
lipid lamellae (Holleran et al. 2006). The formation of acyl ceramides in the epidermis 
is a multi-step metabolic process, of which hydroxylation involving a cytochrome p450 
enzyme and elongation of the long chain fatty acid via ELOVL4 are crucial steps. In 
mouse models, mutant forms of either of these enzymes leads to high rates of neonatal 
mortality due to the inability to form a permeability barrier (Uchida & Holleran 2008). 
 
In the stratum corneum, free fatty acids bind covalently to the extracellular side of the 
membrane of coneocytes, forming a safe hold for other lipids to bind and aiding in the 
complementation of the lipid and cornified envelopes (Swartzendruber et al. 1987). 
Upon elongation free fatty acids become very long fatty acids (VLFA) in the stratum 
corneum, these are needed to covalently link the two envelopes together a process made 
viable by the exposure of the hydroxyl group on the VLFA. Two enzymes unique to the 
epidermis, ALOXE3 and ALOX12B, perform this manipulation of VLFA. They 
simultaneously oxygenate the separate double bonds of the free fatty acids and if either 
are mutated they cause barrier defects that are phenotypically similar (Fischer 2009). 
First of all the enzyme 12R-LOX encoded by the gene ALOX12B acts upon the fatty 
acid producing a hydroperoxide, then the enzyme eLOX3 encoded by the gene 
ALOXE3 converts the substrate into epoxyalcohol. This functional group is generated 
on the VLFA to help interlink the proteins of the cornified envelope with the lipids of 
the lipid envelope (Zheng et al. 2011). 
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1.4.1. Composition and Structure  
The lipid envelope, which is the crux of the epidermal barrier, can exist in different 
phases depending on its composition. When the components of the envelope are in their 
optimal arrangement the barrier can resist the ever-changing environmental conditions 
the skin is routinely subjected to, such as changes in humidity, temperature, pH, etc. To 
produce the most robust lipid envelope and thus stop phase transitions within that can 
cause lamellae separation and unwanted pore formation, a great homogeneity of 
physical arrangement is employed (Clerc & Thompson 1995). As interconnected 
lamellae are a mixture ceramides, sphingolipids and free sterols (Grubauer, et al. 1989). 
 
Predicted in the single gel phase model the next reducible level is actually highly 
heterogeneous in respect to lipid components and their orientation. Within the lipid 
lamella, lipids are orientated with alkyl hydrocarbon chains perpendicular to one other, 
either in a hexagonal state on a rotational axis or an orthorhombic system where 
hydrophobic chains are fixed, producing a rotational disorder (Norlén 2001b). This 
combined with the range of ceramide alkyl hydrocarbon chain lengths and the addition 
of cholesterol promotes lamellar structures and a gel phase envelope with greater 
pliability and plasticity where a single repeated phospholipid would not (Takahashi et 
al. 1996). A reduction of cholesterol in the stratum granulosum leads to a dysfunctional 
permeability barrier with slight deformities in membrane structure and widespread 
lamellar-phase separation (Zettersten et al. 1998). The repetitive nature of this 
continuous lamellar gel phase produces a robust lipid envelope functional in all 
environmental conditions.   
1.5. The Nuclear Hormone Receptors 
The intracellular lipids that undergo packaging and secretion to eventually become the 
building blocks of the lipid envelope also have a regulatory effect on gene expression 
by means of nuclear hormone receptor interaction. When these fundamental lipids reach 
a concentration threshold in the stratum granulosum they or their respective metabolites 
serve as signaling molecules, acting as ligands they bind to nuclear hormone receptors 
(Schmuth, et al. 2004).  
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1.5.1. Nuclear Hormone Receptors and their Ligands 
Lipids in the epidermis can be thought of as prompting their own packaging and in 
doing so the later stages stratum corneum formation. They do this through the activation 
of nuclear hormone receptors and the increased expression of the genes they regulate, 
genes coding the transport proteins that package lamellar granules. In keratinocytes the 
nuclear hormone receptors, liver X receptors (LXRs) are activated when bound to 
oxysterols, an oxidized form of cholesterol. LXRs have shown to be key protagonists in 
the initiation of keratinocyte differentiation and cholesterol transport (Schultz et al. 
2000). In comparison, fatty acids are the ligands of the peroxisome proliferator-
activated receptors (PPARs), which through an independent pathway also regulate 
terminal differentiation and lipid transport in keratinocytes. Together, LXR and PPAR 
stimulation facilitates the production of the lamellar membranes within the lipid 
envelope and epidermal development (Feingold & Jiang 2011). 
 
LXR and PPAR are two of the 36 nonsteroidal nuclear hormone receptors; other 
examples include the (VDR) vitamin D3 receptor and the farnesoid X-activated receptor 
(FXR). Crucially these nuclear hormone receptors; LXR, PPAR, VDR and FXR once 
liganded must dimerise with the retinoid X receptor (RXR) forming a functional 
heterodimer before transcriptional activation is attained (Edwards, Kennedy, et al. 
2002). To facilitate a precise change of epidermal formation activation of LXR or 
PPAR is preferred over the more ubiquitous RXR homodimer with it’s’ retinoid 
ligands. Retinoids have been known to suppress keratinocyte differentiation and 
epidermal stratification for some time; they act upon both keratin expression and the 
formation of the cornified envelope. RXR stimulation by retinoids activates a wide 
down stream regulatory pathway that ranges from the suppression of keratins involved 
in differentiation to the inhibition of cornified envelope formation. Though a 10 – 100 
fold increase in retinoid concentration is needed to reduce keratin expression compared 
to a reduction in cornified envelope formation (Gilfix & Green 1984; Eckert & Rorket 
1989). 
 
Nuclear hormone receptors bind to DNA at specific cis elements called hormone 
response elements (HREs), which are located in close proximity to the upstream 
promoter and distal enhancers of the target genes. Structurally, ligand binding occurs 
close to the C-terminal of the protein, whilst DNA binding is orientated via conserved 
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twin zinc fingers located centrally in all nuclear hormone receptor proteins (Edwards, et 
al. 2002). 
 
PPARβ/δ is expressed at the greatest concentration within the epidermis; the other two 
constitutively expressed PPAR isoforms are α and γ (Westergaard et al. 2003). Both 
LXR isoforms, α and β, are present in the epidermis and are activated by the same 
group of oxysterol, cholesterol derivatives (Chen et al. 2011). Generally in mammals 
LXRs play a crucial role in cholesterol homeostasis and form part of the reverse 
cholesterol response, regulating genes, such as ABCA1, which actively transports 
cholesterol. Once extracellular, cholesterol binds to the Apo-A1 protein producing a 
high-density lipoprotein (HDL), a transportation and storage molecule able to travel 
through the blood stream and reduce cholesterol concentration (Edwards et al. 2002). 
1.5.2. Nuclear Hormone Receptors and Terminal Differentiation 
The nuclear hormone receptors are important mediators of pathways involved in the 
terminal differentiation of keratinocytes. Upon topical treatment of mouse skin or 
cultured keratinocytes from mice, with agonists of PPARβ/δ, PPARγ and LXRs there is 
an increase in transcription and the subsequent translation of proteins involved in 
keratinocyte differentiation, TGM1, filaggrin, involucrin and loricrin (Mao-Qiang et al. 
2004; Schmuth, et al. 2004). In addition, enzymes involved in the processing of lipids 
for the lipid envelope like beta-glucocerebrosidase, a processor of ceramides in the 
upper layers of epidermis, showed increased expression and activity in murine 
epidermis treated with LXR/PPAR agonists. The overall effect of the LXR/PPAR 
agonists showed an improvement to a dysfunctional permeability barrier after treatment 
in mice via nascent lamellae formation (Man et al. 2006). Agonists of LXR/PPAR 
nuclear hormone receptors are the derivatives of or the lipid metabolites produced in the 
lower layers of the epidermis. Examples of which are oxysterols and fatty acids 
produced in the basale layer, which up-regulate the epidermal lipid processing, LG 
secretion and the successive extracellular lipid production (Man et al. 2006).  
 
Genes involved in epidermal differentiation such as TGM1, filaggrin, involucrin and 
loricrin all contain activator protein-1 (AP-1) binding sites within their promoter 
regions. When the recognition sequences of AP-1 are mutated up-regulation of these 
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genes through PPAR/LXR agonists is quiesced (Hanley et al. 2000). This suggest that 
AP-1 is a transcription enhancer through which the activation of LXR/PPAR nuclear 
hormone receptors increase the regulation of proteins involved in terminal 
differentiation in keratinocytes (Kömüves & Hanley 2000).   
 
In LG synthesis the lipid transporter protein ABCA12 packages glucosylceramides into 
developing LGs (Sakai et al. 2007; Akiyama 2013). Abnormalities in the ABCA12 
protein generate a reduction in LG formation or LGs with an irregular morphology and 
cargo (Expanded in section 1.8.1). PPARβ/δ, PPARγ and with a reduced effect LXR 
agonists all increase ABCA12 expression in cultured human keratinocytes which in turn 
increase the rate of LG formation, (Jiang et al. 2008) described in Figure 1.5. 
Furthermore, in the modeling of barrier dysfunction in mouse skin, activation of 
PPARβ/δ and RXRα/β heterodimers increase LG synthesis and secretion, which 
counteracts the perturbation of the lipid envelope. Lipid envelope restoration is not 
mirrored with the activation of either PPARα or PPARγ nuclear hormone receptors 
(Calléja et al. 2006).  
 
Topical application of retinoic acid to human skin, through the RXR nuclear hormone 
response, triggers the expression of many proteins that are crucial in the differentiation 
of keratinocytes, proteins like; TGMs, filaggrin, keratins 6 and 13, involucrin and 
loricrin (Gericke et al. 2013). Retinoid signaling in the skin does not specifically act in 
barrier formation and the proteins activated do not all work together in epidermal 
differentiation. However, retinoids have been trailed for use in combating Ichthyosis 
type skin disorders (Mihály et al. 2012).  
 
Keratinocytes are required to transport cholesterol to supply the lipid envelope with this 
pivotal constituent. ABCA1 is the membrane transport protein responsible for 
cholesterol efflux in keratinocytes, thereby regulating cellular and extracellular 
concentrations. This process does not involve the LG, but is integral to obtain the 
correct lipid envelope composition and in doing so permeability barrier plasticity 
(Feingold & Jiang 2011). LXRs when activated, by the binding of oxysterols, increase 
the mRNA and protein levels of ABCA1, with a greater up-regulation obtained from 
LXRβ over LXRα, in cultured human keratinocytes and mouse model epidermis (Jiang 
et al. 2006). Keratinocytes amass large quantities of the desquamation-regulating 
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compound cholesterol sulfate. Cholesterol sulfate stimulates differentiation through the 
increased expression of involucrin via the AP-1 protein. All the molecules mentioned 
free fatty acids, ceramides, cholesterol and cholesterol sulfate, have roles in 
keratinocyte differentiation and lipid envelope formation (Feingold & Jiang 2011). 
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Figure 1.3. The activation of nuclear hormone receptors in the epidermis. The effect 
PPAR/LXR activation has on the development of the epidermis is multifaceted with regard to 
the formation of the lipid envelope. Ranging from lipid synthesis, to the up-regulation of 
proteins involved in transport and envelope structure, PPAR/LXR activation is a key pathway in 
a correct epidermal differentiation.  
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1.6. The Ichthyoses 
Ichthyoses are a heterogeneous group of skin disorders, which through aberrant 
keratinocyte differentiation and desquamation, produces disorders of cornification 
characterized by tenacious scaling. In disorders with an inherited aetiology when 
causative genes have been segregated, their ensuing proteins are predominately 
involved in the synthesis, transport and formation of the lipid envelope or the 
desquamation of the upper cornified layer (Akiyama 2011). 
 
With rough divisions ichthyoses can be separated into three groups; the congenital 
forms, the acquired ichthyosis that are a systemic disease and the ichthyosiform 
disorders. The rare congenital ichthyoses present at birth with collodion membranes or 
an ichthyosiform erythroderma, the relatively more common inherited types like X-
linked recessive ichthyosis (XLRI) and ichthyosis vulgaris (IV) present immediately 
after birth (Oji & Traupe 2006). The acquired/systemic ichthyoses present with a variety 
of non-epidermal phenotypes, for instance acquired ichthyosis associated with systemic 
lupus erythematosus can trigger a range of hyperactive immune symptoms (Tlacuilo-
Parra et al. 2004). The different mechanisms by which ichthyoses cause perturbations in 
the epidermis provide a unique insight into the function of a myriad of lipids, proteins 
and enzymes involved in the terminal differentiation of keratinocytes. 
 
1.7. Harlequin Ichthyosis 
1.7.1 Clinical Features 
Harlequin Ichthyosis (HI; MIM242500) is the most severe disorder in the family of 
autosomal-recessive congenital ichthyosis (ARCI). The first recorded case was noted in 
1750 in the accounts of Reverend Oliver Hart (Waring 1932). In the past premature 
babies often died in the neonatal stage, at the early stage diagnosis of HI can be easily 
made due to a characteristic phenotype. HI is a chronic disorder that is infrequently 
fatal, due to the possible use of oral retinoids and modern neonatal care the mortality 
rates have declined to around 56%, in a study of 45 cases (Rajpopat et al. 2011). 
Sufferers from HI present with a dramatically thickened dehydrated skin over the 
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majority of the body, with large diamond shaped hyperkeratotic plates separated by 
deep fissures (Francisco et al. 2004). The abnormal skin restricts movement, breathing 
and can constrict limbs causing in utero autoamputation. Furthermore, neonates show 
anatomical disfiguration of the lips causing eclabium, eyelids causing ectropion and 
vestigial ears (Kelsell et al. 2005). With an extremely compromised skin barrier, HI 
neonates have a high probability of dehydrating through TEWL and sepsis due to 
secondary infection. Neonatal treatment is commonly supplemented with the 
application of retinoid drugs that stimulate the shedding of the retained squames to 
reduce the dramatically thickened epidermis (Brecher & Orlow 2003). HI infants that 
survive the early stages of childhood and further, produce a skin phenotype akin to a 
severe non-bullous congenital ichthyosiform erythroderma (NBCIE), an erythrodermic 
form of lamellar ichthyosis (Haftek et al. 1996).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. A typical presentation of HI at birth. The newborn exhibits the characteristic HI 
phenotype with hyperkeratotic plates, fissures, eclabium and flattened ears. HI past infancy 
presents as shown with hyperkeratosis, erythema and disrupted hair follicle growth similar to a 
severe NBCIE. 
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1.7.2. Ultrastructural Features of Harlequin Ichthyosis 
The histological study of HI has found a collection of abnormalities present in the 
epidermis of the majority of cases. The most striking feature is the hyperkeratosis, this 
thickening of the stratum corneum of retained, compressed squames is present in all 
cases of HI (Dale et al. 1990). There is increased stratification of the epidermis, not as 
dramatic as the enlarged stratum corneum, though each layer does show elongation and 
contain more keratinocytes in the relative phase of differentiation. Nuclei of 
keratinocytes are flattened in the HI epidermis at an earlier stage of differentiation 
relative to normal skin; however in some cases of HI parakeratosis occurs and these 
nuclei are retained in the uppers layers and not degraded (Hsu et al. 1989).  
 
Morphologically abnormal or absent LGs were detected with electron microscopy, 
though when present their location was confined to the lower levels and not in their 
normal transit between the stratum granulosum and corneum. This absence correlates to 
the lack of extracellular lipid lamellar and further disruption to the normal trafficking of 
lipids, structural proteins and proteases bound for the stratum corneum (Akiyama et al. 
1996). Electron microscopy indicates other types of disruption alongside the 
characteristic HI histology, such as the multitudes of vacuoles, autophagic in nature, 
neighbouring an accumulation of cholesterol and its’ derivatives in crystal form, both of 
which are retained in the cytoplasm of keratinocytes of the stratum corneum in the 
epidermis of HI patients (Buxman et al. 1979). 
1.7.3. Genetics of Harlequin Ichthyosis 
HI was shown to follow an autosomal recessive pattern of inheritance after a period of 
uncertainty due to cases of multiple family members affected and that the underlying 
cause could be through a dominant mutation. However, in 2005 Kelsell et al used a 
combination of single nucleotide polymorphism (SNP) chip array to map and 
microsatellite markers to confirm, a region of homozygosity, 2q35. Within this region 
causative mutations were found in the gene ABCA12 in 11 of the 12 individuals with HI 
screened.(Kelsell et al. 2005) The aetiology of HI coincides with defects in the gene 
ABCA12; the transcribed protein is a constituent of the superfamily adenosine 
triphosphate (ATP)-binding cassette (ABC) active transporters. All the mutations in this 
study were predicted to result in a truncated protein, they included nonsense mutations, 
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frameshift deletions and whole exon deletions (Kelsell et al. 2005). Around the same 
point in 2005 Akiyama et al corroborated this finding by showing HI segregating with 
recessive mutations in the gene ABCA12 (Akiyama et al 2005). 
 
In 2011 a clinical review of 45 HI cases added further confirmation that mutations in 
ABCA12 were causative and some of which were missense mutations. The review found 
that homozygous mutations produced a greater chance of early mortality than babies 
with compound heterozygous mutations, or the other prospective, compound 
heterozygotes have a survival advantage or benefit more from treatment. A possibility 
here is that another recessive disease may be lingering with no diagnosis. More 
plausible is the relationship of location of mutation in the protein and severity of disease 
phenotype (Rajpopat et al. 2011). 
1.8. ABCA12 
The gene ABCA12 can be found on the reverse strand of chromosome 2 between the 
coordinates 214,931,542-215,138,428. It holds three main transcripts, with the longest 
protein coding transcript holding 53 exons at a transcript length 9100bp and a translated 
length of 2595 amino acid residues. The second transcript starts in the 8 exon of the 
primary transcript and runs until completion, whereas the third is the first 3 exons of 
primary transcript only (Lefévre et al. 2003). The translation of the ABCA12 protein 
starts from the 221st residue in exon 1 and apart from the aforementioned alternative 
transcripts has no other splice variants. Membrane spanning ABC transporters such as 
ABCA12 mediate allocrites across membranes by conformational changes in their 
trans-membrane domains (TMD) via an ATP dependent translocation. The ABCA12 
protein holds two TMD, which house 6 membrane spanning α-helices and form the 
bridge that straddles the plasma membrane. Bound to the cytoplasmic end of each of 
these TMD are the ABC transporter domains (1 and 2) that hydrolyse ATP to ADP 
releasing the energy needed for transportation. ABC transporter domains contain the 
ATP binding domains or nucleotide binding domain (NBD), translated from 3 
conserved sequence motifs: Walker A and B domains and the signature C motif situated 
between the two Walker domains (Walker et al. 1982; Hyde et al. 1990). 
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The 3 motifs synonymous with ABC transporters; Walker A, B and signature C are 
crucial in the binding and hydrolysis of ATP, obtaining the energy required to alter the 
structural configuration of the TMD to transport allocrites across membranes. In the 
case of ABCA12 transporting lipids into LG transport vesicles against the electro-
chemical and concentration gradients (Vasiliou et al. 2009). The Walker A motif 
supplies a phosphate binding loop that holds the triphosphate in place for hydrolysis and 
remains bound to the ADP afterwards. While ATP is bound to the NBD the Walker B 
motif with its’ many hydrophobic residues and terminal aspartate creates a local 
environment that coordinates the positioning of a magnesium ion. This charged 
molecule induces a dipole across a bound phosphate that initiates ATP hydrolysis 
(Walker et al. 1982).  
 
The ABC transporter domains 1 and 2 of ABCA12 only share 36% sequence homology 
compared to that of NBD1 and 2, with their conserved structural motifs, share 87.5% 
homology. The dissimilarities in the two ABC transporter domains may infer slightly 
different roles and cause different severity of protein dysfunction when mutated. This is 
further explored in 1.8.3. The structure of the ABCA12 protein has not yet been 
resolved possibly as X-ray crystallography of such a large hydrophobic membrane 
spanning protein is extremely difficult to perform.  
 
1.8.1. The Role of ABCA12 in the Epidermis 
The ABCA12 protein is a member of the ABCA subfamily of ABC transport proteins; it 
actively transports allocrites against a concentration gradient into transport vesicles. In 
the epidermis ABCA12 is constitutively expressed in the suprabasal layers, but 
markedly up-regulated in keratinocytes of the stratum granulosum and still present in 
some retained corneocytes of the stratum corneum (Akiyama 2005). The mature 
ABCA12 protein localises to the Golgi apparatus, TGN and both forms of LGs. The co-
localization of ABCA12 to the cis-Golgi (GM130) and trans-Golgi (TGM-46) markers 
is continuous throughout suprabasal epidermis, though only in the upper stratum 
spinosum and stratum granulosum do LGs, ABCA12 and glucosylceramides co-localise 
(Sakai et al. 2007). At this point in epidermal differentiation ABCA12 packages lipids 
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from the cytoplasm and Golgi apparatus into the developing LGs (Sakai et al. 2007; 
Akiyama 2013). 
 
The lipids glycoslyceramide and sphingomyelin are products of ceramide processing in 
keratinocytes of the upper stratum spinosum and lower stratum granulosum. They are 
then package into LGs through the lipid transporter protein ABCA12 (Sakai et al. 
2007). When this trafficking is impaired through an aberrant ABCA12 there is an 
accumulation of glycoslyceramide and sphingomyelin in keratinocytes of the lower 
stratum granulosum and a reduction of these lipids in LGs (Mitsutake et al. 2010). In 
functional LGs they are accompanied by other lipids, which when extruded are further 
processed into ceramides with a range of properties that help manufacture the 
extracellular lamellar membrane structures of the lipid envelope (Uchida & Holleran 
2008). Suprabasal ceramides of the epidermis have been shown to up-regulate the 
transcription of the gene ABCA12 through the PPARβ/δ pathway. Showing that 
ceramide precursors of ABCA12 allocrites induce the expression of the protein that will 
transport their lipid derivatives (Jiang et al. 2009). 
 
Terminal differentiation of the epidermis concludes with the desquamation of 
keratinocytes from the stratum corneum. This shedding of the outermost layer of skin 
helps maintain the structural and functional integrity of the epidermis, which is 
prevented in HI. As extruded lamellar granule content, predominately complex lipids 
and enzymes, when released into the extracellular space is involved in the desquamation 
of the stratum corneum (Akiyama 2006). In HI hyperkeratosis and the retention of 
squames leads to a dramatically thickened stratum corneum and through histological 
study and in vitro modelling has been correlated to a reduction of proteases in the 
stratum corneum (Milner et al. 1992).  
 
Proteases are expressed late in epidermal differentiation, where they act in the 
desquamation of squames. They are transported to the point of desquamation by the LG 
system. In an organotypic co-culture (OTCC) with an ablated ABCA12 there was a 
reduction in protease activity in the stratum corneum due to a dysfunctional LG system. 
This OTCC mirrored HI epidermis and showed how the LG cargos and desquamation 
proteases CTSD and KLK5 are reduced in the upper layers of the epidermis (Thomas et 
al. 2009a). As previously described in 1.2.2. these proteases alongside others act in 
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cascades to degrade the structural proteins of the cornified envelope like desmoglein-1 
and corneodesmosin (Caubet et al. 2004; Descargues et al. 2006).  
 
While the distribution of CTSD and KLK5 are abnormal and their expression is reduced 
in ABCA12-ablated epidermis, this is not a constant theme with all proteins involved in 
desquamation. For example, KLK7 and its’ inhibitor LEKT1 are expressed normally in 
ABCA12-ablated OTCC (Thomas et al. 2009a). Taken into consideration that neither 
LEKT1 nor KLK7 co-localise with the ABCA12 protein, it can be postulated that there 
are parts of LG formation in absentia of ABCA12. This in turn corroborates with that to 
some extent LG formation is determined by cargo, as described in 1.3.1. This highlights 
the point that although ABCA12 is not directly or indirectly involved in the 
transportation of all proteases, when aberrant and unable to transport its’ lipid allocrites 
the fitness of these respective LGs is severely impaired.   
 
Through the study of patient material, mouse models and in vitro models many of the 
ways in which HI effects normal epidermal differentiation have been brought to light. 
Not only does the typical HI epidermis hold a dysfunctional lipid envelope and a 
reduction in the activity of desquamation proteases, it also exhibits premature terminal 
differentiation (Yanagi et al. 2008a). Immunohistochemistry demonstrates the change in 
differentiation marker localisation, where K2e, involucrin, loricrin, and TGM1 would 
normally be found in the stratum granulosum and corneum exclusively, in HI epidermis 
these markers can be found throughout the suprabasal layers.  Furthermore, levels of 
profilaggrin in skin from individuals with HI and a mouse model have found to be 
either elevated or normal, though levels of the processed, functional (27kDa) filaggrin 
monomer involved in cornified envelope formation and hydration are significantly 
deceased (Dale et al. 1990; Smyth et al. 2008). All of which suggests that either 
ABCA12 has a role in regulating keratinocyte differentiation or that the disruption 
caused in the upper layers of the epidermis by an aberrant ABCA12 has a negative 
effect on the biology of suprabasal keratinocytes. 
 
Oral retinoids are the most frequently used treatment for HI, as they stimulate the 
shedding of the retained squamous cells through the previously described RXR pathway 
(Brecher & Orlow 2003). Though the multitude of genes up-regulated by RXR 
stimulation in the epidermis seems slightly unspecific, retinoid treatment does aid 
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desquamation with relatively limited side effects (Eckert & Rorket 1989). In a clinical 
study of 45 HI cases, on only one single occasion did treatment with a RXR agonist 
have a related adverse effect, with a child contracting cataracts. A link between 
retinoids and cataracts was previously reported, but it was thought to be an association 
solely with adults and not with children (Rajpopat et al. 2011). 
1.8.2. The Role of ABCA1 in the Epidermis 
In HI there is an accumulation of glucosylceramides in the basal layers of the epidermis 
due to decreased transportation by LGs. Subsequently, there is a reduction in the 
concentration of ceramides, such as ω-hydroxyceramides in the stratum corneum (Zuo 
et al. 2008). Alongside these changes in ceramide transportation is the possible 
reduction in cholesterol regulation within the epidermis and the subsequent loss of 
cholesterol as a regulating molecule, as an aberrant ABCA12 has been shown to 
diminish ABCA1 cholesterol efflux (Fu et al. 2013).  
 
Keratinocytes are required to transport cholesterol to supply the lipid envelope with a 
pivotal constituent. ABCA1 is the membrane transport protein responsible for 
cholesterol efflux in keratinocytes, thereby regulating cellular and extracellular 
concentrations. This process does not involve the LG, but is integral to obtain the 
correct lipid envelope composition and in doing so permeability barrier plasticity 
(Feingold & Jiang 2011). When cholesterol combines with the range of ceramides in the 
lipid envelope they form gel phase lamellar structures that are predicted to have a 
greater pliability then those made from repeating phospholipids alone (Takahashi et al. 
1996). When the amount of cholesterol in the stratum corneum is reduced the 
permeability barrier becomes susceptible to TEWL through deformities in membrane 
formation (Zettersten et al. 1998).  
 
LXR and PPAR agonist have been implicated in the redistribution of terminal 
differentiation markers, which are premature in HI epidermis (Jiang et al. 2008). The 
activation of LXRs through the binding of oxysterols induces a significant increase in 
transcript and protein levels of ABCA1. The subtype LXRβ has a much greater affect 
then LXRα, as shown with studies utilizing mouse models and cultures human 
keratinocytes with LXR agonists (Jiang et al. 2006). With the ABCA1 protein known to 
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transport cholesterol and other phospholipids out of keratinocytes and its’ possible 
down-regulation under ABCA12 ablation there is an opportunity to re-establish this 
pathway through LXRβ (Schmitz & Langmann 2005; Fu et al. 2013). 
 
The metabolite and precursor to cholesterol in keratinocytes of the stratum basale is 
cholesterol sulfate, which in large quantities aids the regulation of differentiation and 
desquamation. Without the transportation of cholesterol via the ABCA1 protein, the 
intracellular build-up could limit the forward reaction of steroid sulfatase, resulting in 
an accumulation of cholesterol sulfate (Elias, et al. 1984; Zettersten et al. 1998). 
Cholesterol sulfate stimulates involucrin expression through the differentiation activator 
protein AP-1 and inhibits serine proteases involved in desquamation (Feingold & Jiang 
2011). 
1.8.3 ABCA12 and Disease 
A dysfunctional ABCA12 gene has been attributed to several autosomal recessive 
congenital ichthyosis (ARCIs); lamellar ichthyosis-2 (LI2) associated with missense 
mutations restricted to the first ATP binding domain (NBD1) and Nonbullous 
congenital ichthyosiform erythroderma (NBCIE) associated with missense mutations 
throughout the protein (Lefévre et al. 2003; Jobard et al. 2002). ABC transporter 
domains 1 and 2 have 36% homology and within these domains the NBD1 and 2 share 
87.5% homology. However, highly deleterious mutations in ABCA12, such as nonsense 
substitutions and frameshifts predominately underlie HI (Thomas et al. 2006; Scott, 
Rajpopat, et al. 2013). Missense mutations isolated to specific domains of the ABCA12 
protein also underlie some cases of HI, all of which infers there is a genotype to 
phenotype relationship for ABCA12, which is discussed further in chapter 3, (Thomas 
et al. 2006). 
 
1.9. ABC Transporters 
ABCA12 belongs to the ABC transporter superfamily, which is the largest transporter 
gene family. ABC transporters have lineages tracing from prokaryotic membrane 
transporters and have diverged into a diverse transporter family genetically present in 
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model organisms: Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila 
melanogaster and in all higher eukaryotes. They transport a large range of allocrites 
including lipids, sugars, proteins, peptides, metal ions and amino acids across both intra 
and extracellular membranes (Dean et al. 2001). The general organisation throughout 
the ABC family is a TMD and a NBD in half transporters or two of each TMD and 
NBD in full transporters. In full transporters the two halves share topological features 
and varying levels of homology depending on the transporter sub family. Within all the 
eukaryotic ABC transporters are the Walker A, B and signature C motifs, which are all 
highly conserved due to their participation in ATP binding and hydrolysis (Vasiliou et 
al. 2009). 
1.9.1. The ABCA Subfamily 
The ABCA subfamily consists of twelve full transporter proteins and a single non-
transcribed pseudo gene, ABCA11. The twelve functional transporters can be split 
roughly into two groups with the first group comprising of ABCA5, 6 and 8-10 forming 
a gene cluster on chromosome 17q24. This group of ABCA genes are still relatively 
unknown in terms of associated diseases, tissue location and function (Dean et al. 
2001). The second group are sparsely located on six different chromosomes and consist 
of the genes ABCA1-4, 7, 12 and 13. This group transport a range of lipids in different 
tissues at different points of differentiation.  
 
The cholesterol transporter protein ABCA1 plays a major role in regulating the levels of 
the intracellular high-density lipoprotein and cholesterol. Mutations in the gene ABCA1 
can cause familial hypoalphalipoproteinaemia or the more severe Tangier disease, the 
presentation on which form is determined by the location and type of mutation within 
the gene (Slatter et al. 2008). ABCA1 ablation causes a significant reduction in the 
amount of high-density lipoprotein in the blood and an accumulation of intracellular 
cholesterol in several tissues (Brooks-Wilson et al. 1999). 
 
The ABCA3 protein transports lipids into lamellar bodies found in the lungs. These 
lipid packed lamellar bodies extrude a surfactant on the alveolar type II cells, which 
maintains a low alveolar surface tension during respiration and is essential for normal 
lung function (Haller et al. 1998; Yamano et al. 2001). Mutations in the gene ABCA3 
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cause a deficiently in this lung surfactant and an increase in alveolar surface tension in 
new born babies (Shulenin et al. 2004). The lipid transporter that is expressed in the 
brain is ABCA13, mutations in which have been associated with a susceptibility to 
develop bipolar disorder and schizophrenia (Knight et al. 2009). 
 
In ABCA12, as with other ABC transporters there is a direct relationship between type 
and location of mutation with severity of disease. For example, ABCA4 ablation causes 
four forms of degenerative retinal dystrophy: Stargardt disease, cone rod dystrophy and 
retinitis pigmentosa, here severity of retinal perturbation and age of onset are dependent 
on the type of causative mutation in the gene ABCA4 (Heathfield et al. 2013; 
Kitiratschky et al. 2008). 
1.10. ARCI 
ARCI is a set of rare ichthyoses that can be genetically and clinically heterogeneous 
(Oji & Traupe 2006). With NBCIE the affected neonates present with a widespread 
collodion-like membrane, although the presentation and severity of the disease can be 
diverse (Sandler & Hashimoto 1998). At the most severe end of the spectrum is HI, 
which can be fatal. LI and NBCIE are less severe with better prognoses. 
 
NBCIE is phenotypically characterised by widespread erythema and overlying fine 
white scales. Affected individuals may develop palmoplantar keratoderma and nail 
dystrophy (Williams & Elias 1985). Biallelic mutations in the genes TGM1 (MIM 
190195), ALOXE3 (MIM607206) and ALOX12B (MIM 603741) have been found to be 
causative in patients with NBCIE (Huber et al. 1995; Krebsová et al. 2001; Jobard et al. 
2002). ALOXE3 and ALOX12B are a distinct subclass of mammalian lipoxygenases 
primarily confined to the epidermis. A mouse model of ARCI with a mutated ALOX12B 
gene produced pups with severe scaling and a deregulated epidermal formation with a 
thickened stratum corneum. This model and a subsequent in vitro study, utilising human 
epithelial cells found a dramatic reduction in the epidermal enzymatic products of 12R-
lipoxygenase (12RLOX), when ALOX12B contained nonsense or missense mutations 
(Eckl et al. 2005; Moran et al. 2007).  
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1.11. Hypothesis and Aims 
To further the understanding of the role of ABCA12 in HI, molecular diagnosis of HI 
patients and the genetic and functional characterisation of the patient derived HI cell 
line will be undertaken. The hypothesis underlying this study is that the aberrant 
ABCA12 in the patient derived cell line will induce in vitro aspects of HI, which 
represent the malformed HI epidermis and under the application of nuclear hormone 
receptor agonists these aspects will be modulated. 
 
• The identification of novel or known causative mutations in ABCA12 by a range 
of methods to further the understanding of the genotype to phenotype 
relationship in HI.  
 
• The development and utilisation of techniques to identify complex/regulatory 
mutations. 
 
• The complete genetic analysis of ABCA12 in the patient derived HI 
immortalised cell line and identification of the subsequent effects on the 
ABCA12 transcript and protein.  
 
• The use of calcium shift culture and the HI cell line to analyse the premature 
expression of terminal differentiation markers and the modulation of ABCA1.  
 
• Determine whether a recovery from the HI cellular phenotype can be achieved 
by renewed expression of ABCA1, through the application of LXR and PPAR 
agonists in monolayer and organic cultures. 
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2 Chapter 2: Materials and Methods 
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2.1.1. Nucleic Acid Methods 
2.1.2. DNA and RNA extraction 
DNA extraction from patient blood and keratinocytes was carried out with the QiaAmp 
DNA blood mini kit (Qiagen; Manchester, UK), using the blood sample and cultured 
cells protocols according to manufacturer’s instructions. Cells were plated in a well 
plate and grown until confluent, when they were detached by use of trypsin, washed and 
resuspended in 200 µl PBS. 20 µl protease and 200 µl lysis buffer AL was added and 
this mixture vortexed and incubated at 56°C for 10 minutes. After which the samples 
were briefly centrifuged and 200 µl of 70% ethanol was added. Following another few 
seconds of centrifuge the samples were pipetted into a QiaAmp spin column and spun at 
8,000 rpm for 1 minute. After the subsequent column washes with the AW1 and 2 
buffers the column was transferred to a new microcentrifuge tube, spun again to remove 
and remaining ethanol. 200 µl of buffer AE was used to elute DNA from the column. 
 
Isolation of total RNA was obtained from cells usually at high confluency at the 
termination of the experiment. RNA was also obtained from skin and hair using a 
handheld homogeniser to reduce the fibrous content. Obtained from hair by plucking of 
a few strands of hair with the hair follicle attached, the follicle was then detached and 
homogenised in 350 µl buffer RLT supplemented with 3 µl β-mercaptoethanol. The 
protocol was adapted from a Takeichi group publication (Takeichi et al. 2013). The 
cells were washed twice using PBS and then lysed directly in the well of the cell culture 
plate using 350 µl buffer RLT supplemented with 3 µl β-mercaptoethanol to inactivate 
the endogenous RNases. Cells were removed from the cell culture dish with a cell 
scraper (Fisher Scientific; Loughborough, UK), QIAshredder (Qiagen) was used to 
homogenise cell and tissue lysates and to degrade high molecular weight genomic DNA 
and cellular components. Following that the RNeasy mini kit (Qiagen) was used and the 
protocol followed to the manufacturer’s specifications. The RNA was eluted and 
resuspended from the column using 34 µl of RNase-free water. This was the same kit 
used for the extraction of RNA from cultured cells. All RNA obtained was stored at -80 
°C while not in use. 
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2.1.3. DNA and RNA quantification 
Both patient and control DNA was quantified by use of a NanoDrop (Qiagen; UK), 
ND1000 spectrophotometer. To operate, 1 µl of DNA is pipetted onto the measurement 
pedestal of the NanoDrop machine. The machine records the optical density of the 
sample at an absorbance of 260/280nm for DNA analysis, the ratio of absorbance at 260 
and 280nm gives a measurement of purity for the sample. A ratio in the range of 1.8-2.0 
is a satisfactory level. To measure the concentration of a sample of RNA, a similar 
protocol is utilised, exact the absorbance is measured between 263/230nm and a ratio 
between 2.0-2.2 is considered acceptable.  
2.1.4. Primer design 
All designed primers were purchased online from Sigma-Aldrich (Haverhill, UK). 
Specific primer pairs were designed for annealing to either genomic DNA or cDNA and 
for use in PCR amplification, Sanger sequencing, side directed mutagenesis or 
cloning/ligation. Predominately the online software Primer3 (v.0.4.0) was used to 
design primers for specific sequence and Ensembl to check location and primer regions 
for SNPs. The synthesised oligonucleotides varied in length from usually 18-26bp, 
depending on positioning, GC content of annealing sequence and regional SNPs. 
Gradient PCR reactions were used to optimise the annealing temperature for each set of 
primers, gradients would be in the region of 55-65°C and through band analysis the 
greatest optimisation would applied to future PCRs. Designed primers for the entirety of 
the ABCA12 transcript (cDNA), ABCA12 genomic and others associated primers for 
screening variants and allelic size variants can be found in Table A1.1, A1.2, A1.3 and 
A1.5 respectively. 
2.1.5. DNA amplification by polymerase chain reaction (PCR) 
To begin with a master mix was a produced for each set of PCR reactions, this would 
then be pipetted out into equal parts with the individual addition of primers and finally 
DNA added to the appropriate 200 µl (thin walled) PCR tubes (Thermo Scientific). 
BioTaq (Bioline) and AmpliTaq Gold (Life Technologies) were the two main Taq 
polymerase systems that were used. The BioTaq master mix contained: 10.4 µl of 
ddH2O, 2 µl of 10X buffer, 0.6 µl of MgCl2 (50 mM), 0.4 µl of dNTP, 0.2 µl of each 
forward and reverse primers (100 µm), and 0.2 µl of Taq polymerase and once in 
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individual tubes with 14 µl of master mix, 1 µl of DNA. AmpliTaq Gold was used more 
frequently and optimised for many different PCR reactions with different primers. The 
standard was a master mix of 7.8 µl of ddH2O, 1.5 µl of AmpliTaq Gold buffer II, 1.2 µl 
of MgCl2 (25 mM), 0.3 µl of dNTP, 1 µl of betaine, 1 µl of 10 µm forward and reverses 
primers; 0.2 µl of TaqGold polymerase and finally the appropriate addition 1µl of DNA 
after 14 µl were individually pipetted out. For the negative control, to check for 
contamination of any of the master mix components, 1 µl of ddH2O was added to a tube 
with 14 µl of complete reaction. The control and reaction tubes were spun by a bench 
centrifuge to reduce air bubbles and solution disruption and placed on a thermo cycler. 
Prior to this point all mixing, solutions and reagents were kept on ice whilst pipetting. 
 
All of the reaction tubes were placed into a DNA engine Tetrad 2 Peltier thermocycler 
(MJ Research) and the following programme was used to amplify the specific regions 
of DNA: 95 °C for 10 minutes to initiate the hot start Taq, followed by 37 cycles of: 95 
°C for 30 seconds for denaturation of the DNA, producing single stranded DNA, X °C 
for 30 seconds for the annealing stage, allowing primers to bind to the DNA – the 
annealing step would be optimised for every set of primers. An extension step of 1 
minute per 1Kb of amplicon at 72 °C was then carried out to extend complementary 
strands, after the 37 cycles was complete, the penultimate, an extension step of 72 °C 
for 10 minutes was carried out before samples were cooled to 4 °C. 
2.1.6. Agarose gel electrophoresis 
PCR products and any other DNA fragments were run on agarose gels to separate 
fragments by weight. A 1% w/v agarose gel can be prepared by heating 1gram of 
agarose in Tris-Borate-EDTA buffer (TBE) until dissolved in a microwave, ~2 minutes. 
The agarose-TBE solution was then cooled and then 0.5 µg/ml ethidium bromide was 
added and mixed until uniform. Whilst still liquid the solution was poured into a casting 
tray and combs were inserted to create wells. After 10 minutes the solution formed a gel 
that could be loaded with the PCR products that were mixed with orange G in a 2:1 
ratio and the 1Kb Plus DNA ladder 10% v/v (Invitrogen). Samples were 
electrophoresed at 75-120 volts and as the ethidium bromide interchelates with the 
DNA was visible and photographed by a transillumination (MultiImage Light Cabinet, 
Alpha Innotech Corporation and a Sony P-D890). 
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2.1.7. Gel purification 
DNA fragments were separated on electrophoresis gels before excision and purification 
for further sequencing or cloning. Agarose gels were synthesised following the protocol 
outlined in 2.1.6. with the exception of Tris-Acetic acid-EDTA buffer (TAE) preferred 
over TBE as excised fragments retain a higher concentration of DNA. DNA fragments 
were excised under UV light by use of a sterile scalpel and fragment containing cuboid 
segments of gel were retained in 1.5 microcentrifuge tubes. Purification was achieved 
through the application of the QIAquick Gel Extraction Kit, (Quiagen, UK) following 
the manufacturer’s instructions. Purified DNA was analysed on an agarose gel, by 
mixing the eluted DNA product 5:1 with loading dye, homogenising by pipetting up and 
down, before loading on to the gel. 
2.1.8. Sanger sequencing 
The preferred Sanger sequencing reaction was the BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems). The protocol was optimised to produce the 
following components and conditions: PCR product (1-3µl, depending on band 
brightness) was incubated with 6µl of ExoSAP (GenomeCentre) at 37 °C for 45 minutes 
followed by 80 °C for 15 minutes and 4 °C for 5 minutes. This degrades any remnants 
from the PCR reaction that could disrupt the sequencing reaction. Clean fragments were 
then added to a reaction of 1 µl of Big Dye Terminator Master mix v3.1, 3 µl of better 
buffer (Microzone), 1 µl of 10 µM of a forward or reverse primer that anneal within the 
amplified fragment and ddH2O making a final volume of 11.5 µl. The thermocycler 
program was 25 cycles at 96 °C for 30 seconds, 58 °C for 15 seconds, 60 °C for 1 
minute, finally the products were cooled at 4 °C for 10 minutes. 
 
Precipitation of the ExoSAP products was performed by the addition of; 2.5 µl of 125 
mM EDTA and 30 µl of cold absolute ethanol that were incubated on ice for 10 
minutes. Pellets were formed by centrifugation of the mixture at 4000 rpm, 4 °C for 20 
minutes; they were then washed with 125 µl 70% ethanol and incubated on ice for 
another 2 minutes, then centrifuged for 5 minutes at 4000 rpm. Precipitated BigDye 
products were then air dried at RT or on a hot block for 1 minute. They could be then be 
resuspended in 10 µl HiDi formamide, incubated at 95 °C for 3 minutes and on ice for a 
further 3 minutes. Products were then centrifuged for 2 minutes to remove any air 
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bubbles and placed on the ABI Prism 3130xl Genetic Analyser (Applied Biosystems, 
Life Technologies). Traces were analysed by using the chronograph software Chromas 
LITE v 2.01 (Technelysium Pty Ltd) and aligned using the Multalin multiple alignment 
tool (multalin.toulouse.inra.fr/multalin). The analysis of protein sequences and 
conservation between proteins or species was performed on ClustalW2 multiple 
sequence alignment tool and with reference to the NCBI protein database respectively 
(www.ebi.ac.uk/tools/msa/clustalw2) and (http://www.ncbi.nlm.nih.gov/protein). 
2.1.9. Reverse-Transcriptase PCR (RT-PCR) 
RT-PCR was performed using the Superscript II reverse transcriptase enzyme and kit 
(Invitrogen). Concentrations of reagents follow the manufacturer’s instructions, though 
are slightly optimised depending on RNA concentration. Per individual sample, making 
20 µl of cDNA, the following was pipetted into 200 µl RNase free thin-walled PCR 
tube: 8 µl of RNase free ddH2O, 1 µl of oligoDT, 0.5 µl of random primers (as 
hexamers), 1 µl of dNTP and finally 1.5 µl of RNA (diluted to 110 ng/µl). All the 
reactions were incubated at 65  ̊C for 5 minutes then removed for the thermo cycler and 
incubated on ice.  
Whilst samples were on ice 4 µl of 5x first strand buffer, 2 µl of 0.1M DTT and 1 µl of 
RNase OUT (Invitrogen) were added to the reaction. The individual reactions were 
incubated at 42 °C for 2 minutes before 1 µl (200 units) of superscript II reverse 
transcriptase (Invitrogen) was added to all apart from any negative controls. Negative 
controls were prepared with the RNA being used in the synthesis, but with RNase free 
water instead of the superscript enzyme. Samples were incubated at 42 °C for 50 
minutes followed by 70 °C for 15 minutes. PCR of the cDNA using primers 
complementary to the housekeeping gene HPRT was carried out to check for cDNA 
quality and genomic DNA contamination in the negative controls. 
 
2.1.10. Real Time PCR (qPCR) 
Primer design was carried out as explained in 2.1.4. with the extra provision of abiding 
to the GC content range of 55-62%. The annealing temperature (AT) for primer pairs 
was calculated by the equation:  
AT = 69.3 + (0.41 x GCcontent) – (650 / oligonucleotide length) 
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The lowest AT from the pair of primers is used as the AT for the initial optimisation 
reactions. Primers used for qPCR are listed in Table A1.4. The quantitative real time 
PCR was performed on a Rotorgene Q thermocycler (Quiagen, UK), by use of 
conventional methods. For every 20 µl reaction mixture held 2x Rotorgene Multiplex 
PCR Buffer, 1 µM of forward and reverse primers complimentary to genes under 
investigation and control, 1 ng of sample cDNA, 500 nM of labelled probe and ddH2O 
to complete the mixture. The reaction conditions for qPCR were 10 minutes at 95 °c, 
followed by 45 cycles of 95 °C for 15 seconds and 60 °C for a further 50 seconds. At 
every 60 °C stage, data collection was performed by the Rotorgene by means of 
fluorescence detection in the green and yellow channels, the emission of which was the 
result of the binding of 6-FAM and HEX labelled probes respectively. 
 
Relative expression of the gene of interest was calculated against the control gene by 
the delta CT method. Here the expression of the gene of interest is equal to 2deltaCT, 
where delta CT is calculated as the difference at which each fluorescence signal rises 
above background levels. A paired t-test was utilised for the statistical analysis of 
results. Significance was given at p<0.05 (*), highly significant at p<0.01 (**) and very 
high significance at p<0.001 (***).  
2.2. Molecular biology 
2.2.1. TOPO cloning  
TOPO TA cloning was used to sub clone PCR products, excised and purified from gels, 
to isolate possible transcript variants for sequencing. The TOPO TA kit (Invitrogen) 
was used as per the manufacturer’s instruction and utilises the transformation of 
competent cells described in 2.2.5. The 6 µl TOPO cloning consists of the following 
components; 0.5-4 µl (concentration dependent) of PCR product, 1 µl of salt solution, 1 
µl of TOPO vector and ddH2O to make up to 6 µl. The reaction mixtures were mixed 
gently before incubated at room temperature for 5 minutes. After the transformation of 
competent cells, clones can be analysed through PCR of TOPO vector M13 forward and 
reverse primer sequence sites.  
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2.2.2. Restriction enzyme digest 
Restriction enzyme digests were utilised to linearize plasmids, to increase transfection 
efficiency and to check DNA samples for variants. Restriction digests were performed 
as per manufacturer’s instruction, which for the majority of reactions gave the reaction 
mixture of: 1 µl of restriction endonuclease, 1 µl of the complementary 10x reaction 
buffer (New England Biolabs; MA, US), 5 µl of PCR product or 1-2 µg of plasmid 
DNA and ddH2O to make a final reaction volume of 10 µl. Reaction vessels were mixed 
gently and incubated at 37 °C for 1-2 hours followed by an inactivation step of 80 °c for 
20 minutes. Restriction digest products were analysed on a 2% agarose gel, as described 
in 2.1.6. and plasmids for transfections were aliquoted to reduce freeze-thaw cycle 
damage on the plasmid DNA.  
2.2.3. Transformation of competent cells 
The chemical transformation procedure of One Shot TOP10 chemically competent E. 
coli (Invitrogen) was used to amplify plasmid DNA, typically post-cloning, before 
undergoing mini/maxi preps (Qiagen). Following the manufacturer’s instructions; 1-5µl 
of plasmid DNA was added to a single vial of One Shot E. coli, gently mixed and 
incubated on ice for 30 minutes. The vial containing the plasmid DNA, E. coli and 
reaction mixture was heat shocked for 30 seconds at 42 °C, after which the vial was 
placed on ice while 250 µl of pre-warmed SOC medium was added. The vial was then 
incubated at 37 °C for 1 hour at 225 rpm on a shaking incubator, allowing the 
expression of antibiotic resistance genes. 20-200 µl from the vial was then spread 
evenly on pre-warmed, labelled LB agar plates made with a specific antibiotic 
complementary to the One Shot E. coli used. Plates were then inverted and incubated at 
37 °C overnight before individual colonies were selected in the morning.  
  
2.3. Cell Culture 
2.3.1. Cell lines and Conditions 
K17 and HI (harlequin ichthyosis patient derived) cell lines were immortalised from the 
patients using the HPV method and were cultured in EpiLife (Life technologies) with 
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the HGVS growth supplement provided, the addition 100 µg/ml streptomycin and 
cultured at 10% CO2 in a humidified incubator. The NEB1 and HaCaT immortalised 
human keratinocyte cell lines were used as controls and cultured in DMEM: 
(Invitrogen/PAA, Gillingham, UK) supplemented with 10% Foetal Calf Serum, 100 
µg/ml streptomycin, 1% L-glutamine, 1% RM+ and cultured at 10% CO2 in a 
humidified incubator. HEK293T and HeLa immortalised cell lines were also cultured in 
DMEM (Sigma-Aldrich, UK), supplemented with 10% Foetal Calf Serum, 1% L-
glutamine and 100 µg/ml streptomycin and cultured at 5% CO2 in a humidified 
incubator.  Medium was replenished every 2-3 days or when cells were split upon 
reaching 80-90% confluency. 
 
Maintenance of the cell culture was performed at high confluency; medium was 
aspirated, cells washed twice with PBS and dissociation of cells were obtained by 
incubation with 1x trypsin-EDTA. Serum-containing medium was used to quench the 
remaining active trypsin. Cells were then transferred to a conical bottomed falcon and 
centrifuged at 1000 rpm for 5 minutes, producing a trypsin-free pellet. The supernatant 
was removed, the pellet re-suspended in fresh medium and transferred to an appropriate 
flask.  
2.3.2. Cryopreservation 
To cryopreserve cell cultures, maintenance cultures were grown until 80% confluency 
in given volume and detached from the flask using the trypsin-EDTA method described 
in 2.3.1. Cells and trypsin-EDTA mixture was then pelleted by centrifugation, the 
supernatant was aspirated and the pellet was resuspended in a freezing serum (9:1 of 
FBS to DMSO). This mixture was then deposited into cryovials that were frozen slowly 
by use of an isopropanol enriched container, which is placed for 24 hours at -80 °C 
before transfer into vapour-phase nitrogen storage. When starting a new culture from a 
cryovial, the vial was defrosted quickly, to limit the amount of cell death and mixed 
with a standard complete culture medium. The mixture was then centrifuged at 1200 
rpm for 5 minutes and the pellet was resuspended and reseeded as a maintenance 
culture. 
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2.3.3. Fugene and PEI Transfections 
Aforementioned cell lines were seeded on 12-well plates at a seeding density of 5x104 
for Fugene transfections and 6x105 for PEI transfections due to the grater toxicity of 
PEI. Cells were seeded on coverslips for further experimentation using 
immunofluorescence. 24 hours after seeding transfection experiments were carried out 
using polystyrene tubes as to not reduce activity of transfection reagents, a possibility 
with polypropylene tubes. For the Fugene transfection from (Roche, UK), 50 µl (per 
well of transfection) of PBS was pipetted into two tubes. 500 ng of DNA was placed in 
the first and 1.5 µl of Fugene was added to the second. Both were incubated for 5 
minutes then DNA and Fugene were combined and mixed by agitating the tube. Once 
mixed the reaction tubes were incubate at room temperature (RT) for a minimum of 15 
minutes before their contents were pipetted drop-wise onto the appropriate cells. 
Transfection mixture and medium was left on the cells for 24 hours and changed after 
24 hours, the cells were used for experimentation after a further 24 hours. 
 
PEI transfections were performed on the same time scale and optimisations were carried 
out on the range of cell lines. A 3:1 ratio of PEI to total DNA, DNA was diluted to 0.5 
µg in high glucose medium and mixed. PEI (1 mg/µl) stock was diluted to 1.5 µl in 100 
µl of high glucose medium and mixed. Diluted PEI was added to the DNA, vortexed 
briefly and incubated for 20 minutes whilst cells were prepared for the transfection. 
PEI/DNA solution was added drop-wise and cells were incubated for 4-6 hours at 37 
°C. Transfection medium was removed at this point due to the toxicity of PEI and fresh 
medium was added to the cells.  
2.3.4. Transient siRNA-mediated ABCA12 knock down 
ABCA12 knockdown was performed using siRNA complementary for the two 
prominent transcripts of ABCA12 from Dharmacon (Thermo Scientific, UK) and the 
Dharmafect1 reagent (Fisher Thermo Scientific, UK). All work was carried out in 
RNase free and sterile conditions. All siRNA was re-suspended to a concentration of 
20µM in siRNA buffer (Thermo scientific) and the subsequent aliquots were stored at -
80 °C. Prior to knockdown experiments the transfection conditions were optimised 
using siGLO control siRNA from Fisher Thermo Scientific, UK.  
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Cells were seeded at a density of 2x105 cells per well, in a 6-well plate and incubated in 
standard medium at 37 °C, 5% CO2 for 24 hours prior to transfection. In individual 
polystyrene tubes, 10 µl of siRNA (100 nM final concentration) and 6 µl of 
Dharmafect1 were mixed in an antibiotic and serum free medium and incubated for 5 
minutes at RT in polystyrene transfection tubes. The siRNA-containing medium was 
added to the Dharmafect1, gently mixed-together and incubated for 20 minutes at RT. 
1.6 ml of standard (with FCS) antibiotic free medium was then added to the siRNA-
Dharmafect1 solution, mixed by inverting several times, and pipetted on to the cells at a 
final volume of 2 ml/well. The siRNA transfection was incubated for 24 hours at 37 °C 
before the medium was changed to standard medium containing antibiotics, to reduce 
the toxic effect of Dharmafect1 has on the cells. Controls were produced using a siRNA 
non-targeting pool from Fisher Thermo Scientific, (UK). The transfected cells were 
cultured for a further 2-5 days before harvested for protein or RNA.  
2.3.5. Calcium Shift in monolayer 
Cell lines were treated in accordance with 2.3.1. though were cultured in Epilife 
(Sigma-Aldrich) 0.06 mM Ca2+ for at least two passages, to around 60% confluency at 
37 ˚C in a humidifier incubator set to 5% CO2. At this point, 0 hour, medium was 
changed on both of the duplicates, one was replenished with 0.06 mM Ca2+ medium and 
the other was calcium shifted with the 1.2 mM Ca2+ medium. Lysates or RNA was taken 
every 24 hours from both sets for comparison. This was performed in multiple cell lines 
in the presence or absence of types of ligands. 
2.3.6. Agonist Application in monolayer 
Originally cell lines cultured in low and high calcium (2.3.5.), through optimisations 
cell cultures were calcium shifted for 24 hours prior to the application of agonist 
activators. Cell lines were seeded between 2x104 and 3.5x104 in a 24-well plate 
depending on growth of cell line. Cells were treated at 70% confluency with either the 
PPAR-β/δ agonist activator GW0742 suspended in 0.5% DMSO to give a final 
concentration of 8 µM in culture or the LXR-β agonist activator TO901317 suspended 
in 0.5% DMSO to give a final concentration of 10 µM in culture (GlaxoSmithKline). 
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Each time course set has control keratinocytes treated with only the vehicle, DMSO, at 
0.5%. 
 
TO901317 is a synonym of N-(2,2,2-tri-fluoroethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-
1-trifluoromethyl-ethyl)-phenyl]benzenesulfonamide, a small molecule nonsteroidal 
LXRβ agonist originally found in an investigation of intestinal cholesterol absorption 
and liver bile synthesis (Repa et al. 2000). GW0742 is a synonym of 4-[2-(3-Fluoro-4-
trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethylsulfanyl]-2-methyl-phenoxy}-
acetic acid, developed by GlaxoSmithKline for their small molecule portfolio, which 
contains this lipophilic carboxylic acid (Sznaidman et al. 2003). 
2.3.7. Testing for Mycoplasma 
Every different cell culture used was tested for mycoplasma using a combination of 
MycoAlert Assay Control Set and the MycoAlert Mycoplasma Detection Kits 
(Cambrex) following the manufacturer's instructions. 1.5 ml of medium that had been 
on cells cultured for 72 hours was centrifuged at 1500 rpm for 5 minutes to create a 
clear supernatant. 100 µl of the supernatant was then transferred to a well of a 96-well 
plate, in the same well 100 µl of MycoAlert reagent was added and both were allowed 
to incubate for 5 minutes at room temperature. The 96-well plate was then read using 
the luminescence program of a Bio-Tek, Synergy HT Multi-Detection Microplate 
Reader. After which, 100 µl of the MycoAlert substrate was added to the well and 
allowed to incubate for a further 10 minutes. This was then also read on the 
luminescence program and from this data a ratio of more than 1 between the first and 
second readings was symptomatic of an infected cell culture. 
2.3.8. Immortalisation of patient derived HI keratinocyte cell line  
The skin biopsy was taken from the patient and processed immediately. After 
dissection, dispase was used to separation the dermis from epidermis, following which 
trypsin was used for epidermal dissociation. The stable primary line of isolated 
keratinocytes were then transfected with a papillomavirus HPV16-derived E6-E7 
containing plasmid shown to disrupt senescence (Hawley-Nelson et al. 1989).  
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2.4. Antibody dilutions 
Protein Antibody Western Blot ICC IHC 
ABCA12 
AbCam Rb 
poly ab98976 
1/1000 
PBS-T 
1/200 1/200 
ABCA1 
AbCam Rb 
mono ab7360 
1/1000 5% 
Milk PBS-T 
1/250 1/250 
ABCA1 
AbCam Mo 
mono ab18180 
1/1000 
PBS-T 
1/400 1/400 
Vinculin 
AbCam Rb 
poly ab18058 
1/1220 5% 
Milk PBS-T 
- - 
Tubulin 
AbCam Rb 
poly ab15568 
- 1/750 - 
LXRβ 
AbCam Mo 
mono ab76983 
1/1000  
PBS-T 
- - 
Involucrin 
AbCam Mo 
mono 5Y5 
1/1000 
PBS-T 
1/200 1/300 
K14 
Mo mono 
LL001 
1/750 
(PBS-T) 
1/300 1/400 
K10 
AbCam Mo 
mono ab9026 
1/700 5% Milk 
PBS-T 
1/250 1/400 
GAPDH 
AbCam Rb 
poly ab37168 
1/1000 5% 
Milk PBS-T 
1/200 1/300 
TGM1 
AbCam Rb 
poly ab27000 
1/800  
PBS-T 
1/350 1/300 
Loricrin 
Covance Rb 
poly PRB145P 
1/1000 
PBS-T 
1/250 1/300 
 
Table 2.1.  Table of primary antibodies and their optimised dilutions for Western 
blotting, immunocytochemistry (ICC) and immunohistochemistry (IHC). 
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2.5. Immunostaining 
2.5.1. Embedding and Sectioning of frozen tissue 
Skin biopsies and mouse tissues were embedded from a flash frozen sample into OCT 
embedding medium (Thermo Scientific, UK) in custom-made tinfoil cages that were 
designed in accordance of size and shape of tissue and to allow for presentation of the 
epidermal cross section at the cutting edge. Sections were cut with a thickness of 0.5 µm 
on a OTF5000 cryostat (Bight Ltd, UK) and adhered to super frost plus slides (Thermo 
Fisher Scientific) before they were air dried for 10 minutes and then stored at -80 °C. 
The remaining sample was given a generous covering with the same OCT embedding 
medium before refreezing at -80 °C. 
2.5.2. Immunocytochemistry 
For experiments involving immunocytochemistry, cells were seeded onto coverslips 
placed at the bottom of 12-well dishes and staining normally proceeds at a point when 
cells have reached a confluency of 70-80%. Medium was aspirated off cells with 
consideration of coverslip position in well, and then the cells were washed twice in PBS 
and fixed using 4% paraformaldehyde (PFA) for 30 minutes at RT. After fixation the 
coverslips were washed 3x in PBS, then permeabilised with 0.1% Triton X100 for 5 
minutes. Blocking was performed using 3% BSA in PBS (blocking buffer) for 30 
minutes, all of which was at RT. 
 
The coverslips were inverted and placed upon a 50 µl drop of primary antibody, which 
was diluted in the blocking buffer at the correct dilution for the antibody and incubated 
for 1 hour at RT or 4 °C over night. The coverslips were washed in PBS to remove 
unspecific binding of the primary antibody and then incubated with the correct 
AlexaFluor secondary antibody for 1 hour at RT. DAPI was used as a nuclear stain at a 
concentration of 100 ng/ml. Coverslips were then mounted with Immu-mount (Thermo 
Fisher Scientific) and microscopic analysis was performed on the Leica epi-
fluorescence microscope (Leica Microsystems (UK) Ltd). 
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2.5.3. Immunohistochemistry  
Cut skin sections were air-dried on the lab bench for 45 minutes were washed twice in 
PBS and fixed using 4% PFA for 20 minutes at RT. After fixation the histology sections 
were washed 3x in PBS, then permeabilised with 0.1% Triton X100 for 5 minutes. 
Blocking was performed using 3% BSA in PBS (blocking buffer) for 30 minutes, all of 
which was at RT. Blocked sections were then incubated with 150 µl of primary 
antibody, that had been diluted in blocking solution, for 1 hour at RT or overnight at 4 
°C. Sections were washed 3x in PBS and incubated with the appropriate AlexaFluor 
secondary antibody for 1 hour at RT. After a further 2 washes with PBS the nuclear 
stain DAPI (100 ng/ml) was applied to the sections that were subsequently washed once 
more before mounting with Shandon Immu-Mount mounting medium (Thermo 
Scientific). Immunohistochemistry was analysed using the same microscope as the 
immunocytochemistry visualization. 
 
Haematoxylin and eosin (H&E) staining for assessing skin histology was carried out on 
paraffin slides. Slides were placed in a holder and transferred from glass bucket to glass 
bucket, which held different solutions. To start with the slides were deparaffinised by 
two separate xylene immersions for 5 minutes each. Then rehydrated by two separate 
100% EtOH immersions, each for the 3 minutes, followed by the same, but with 
solutions of 95% EtOH. Followed by a single was with 70% EtOH for 3 minutes, a 
rinse with ddH2O for 5 minutes before staining with haematoxylin for 6 minutes. The 
excess haematoxylin was rinsed off with running tap water for 10 minutes and dipped in 
acid alcohol for 1 second and rinsed well with tap water for a further 5 minutes. Slides 
were then counterstained in eosin for 15 seconds before they were dehydrated by two 
rounds of 95% EtOH for 3 minutes, followed by two rounds of 100% EtOH for 3 
minutes. Following a further two rounds in Xylene for 5 minutes, slides are allowed to 
dry at room temperature before mounting. 
2.5.4. FACS analysis 
FACS analysis was achieved by flow cytometry, using immunostaining of Annexin 
V/propidium iodide. 80% confluent cells were washed in PBS, detached from the plate 
using trypsin, pelleted, and re-suspended in 400 µl of Binding Buffer (Becton 
Dickinson). At room temperature the suspended cells were incubated in 2 µl of Annexin 
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V-FITC for 15 minutes, then Propidium iodide (5 µg/ml) was added to the cell before 
they were processed via cell sorting.  
2.6. Western Blotting 
2.6.1. Preparation of protein lysates from cells 
Whole cell protein lysates were produced at the termination of cell culture experiments, 
which, usually, coincides with a high confluency. The cells were washed twice in ice-
cold PBS before lysis and detached/lysed with boiling SDS sample buffer. Cells were 
lysed with around ~150 µl per well (for a 6-well plate) of 2X Laemmli buffer, which 
has the components of, 0.1 M Tris-HCL, 20% Glycerol, 4% SDS, 0.001% Bromophenol 
Blue and 1.44 M Beta-mercaptoethanol, (Laemmli 1970). The wells were scraped and 
the subsequent cell lysates were transferred to 1.5 ml microcentrifuge tubes and 
centrifuged at 13,000 rpm for 5 minutes. The supernatants were then transferred into 
new tubes that had been on ice. Sonication was performed on viscous samples and 
samples would be either loaded on SDS-PAGE or stored at -80 °C. 
2.6.2. Gel Electrophoresis (SDS-PAGE, pre-cast TRIS-Acetate or pre-cast Bis-
TRIS) 
To produce a separating polyacrylamide gel, of 6-12% depending on protein size and 
resolution, was prepared and pipetted in between two glass plates and that eventually 
held 0.75 mm spacers in a gel electrophoresis apparatus (Bio-Rad, Hemel Hempstead, 
UK). All of the Western blot equipment was cleaned with ddH2O and then 70% ethanol 
before the procedure was undertaken. The separating gel solution was overlaid with ~1 
ml of isopropanol to remove trapped air, and polymerised at RT taking around 15 
minutes. After polymerisation the isopropanol was poured away. For 10 ml of a 8% gel 
the components were as followed: 2.7 ml of ddH2O, 2.5 ml of 30% polyacrylamide mix 
(Protogel), 2.5 ml of Tris (1.5 M, pH8.8), 0.1 ml of SDS (10%), 0.1 ml of Ammonium 
Persulphate (APS, 10%) and 6 µl of N,N,NTetramethylethylenediamine (TEMED).  
 
Next a 5% stacking gel mixture was prepared and pipetted over the resolving gel, and 
allowed to polymerise at RT for approximately 25 minutes. The gel was run at 12 
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mA/gel in running buffer until the separation of correct protein weight was achieved. 
For 5 ml of a stacking gel the components were as followed: 3.4 ml of ddH2O, 0.8 ml of 
30% polyacrylamide mix (Protogel), 0.63 ml of Tris (1M, pH6.8), 50 µl of SDS (10%), 
50 µl of Ammonium Persulphate (APS, 10%) and 5 µl of 
N,N,NTetramethylethylenediamine (TEMED).  
 
The combs were inserted in the top of the gel whilst the separating gel was still in the 
liquid phase and to expel excess separating gel. Between 8-18 µl of protein sample per 
well and 5-12 µl of Rainbow Molecular Weight marker (GE Healthcare) or the HMW 
ladder HiMark (life technologies) were loaded on the set SDS-polyacrylamide gel. Once 
the separating gel had set the well combs were removed and the gel was situated in the 
gasket of the tank. Running buffer of; 1.44% Glycine, 0.1 SDS, 0.03% Tris in ddH2O 
was pour in the tank in both compartments, but the fluid was not meeting over the top of 
the gels. Protein samples would usually be heated to 95°C before running, though as 
predominately blotting was performed for large hydrophobic proteins samples were 
allowed to defrost and centrifuged at 13,000 rpm for 5 minutes prior to loading.  
2.6.3. Transfer to nitrocellulose membrane 
After the proteins were run through the gel to the required position, for antibody 
detection, transfer was performed, to move the proteins from the gel onto a 
nitrocellulose membrane. Hybond–C Extra (GE Healthcare) nitrocellulose membrane 
was used in a wet transfer electrophoretic cell system (Bio-Rad). The sponge pads, 
membrane, and blotting paper were all immersed in transfer buffer before transfer was 
undertaken. Transfer buffer is, 1.44% Glycine, 0.3% Tris, 20% methanol in ddH2O. The 
completed cassette was placed into the transfer tank and submerged in transfer buffer, 
the tank was ran it either 300 mA for 1.5 hours or 100 mA overnight.  
2.6.4. Protein visualisation by Ponceau Red 
The efficiency of loading and transfer was tested through the staining of the membrane 
with Ponceau Red solution. The membrane was immersed in the stain for 5-10 minutes 
and lanes of protein are resolved when the stain is removed by washing with ddH2O. 
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2.6.5. Blocking 
Upon completion of transfer and removal of the testing stain, the nitrocellulose 
membranes were blocked to prevent non-specific binding of the primary antibody to the 
membrane. Blocking was achieved through 10% (w/v) milk in TBS-Tween for 1.5 
hours or in PBS-Tween. TBS-Tween is, 2.423 g of Trizma HCl, 8.006 g of NaCl and 1 
ml of Tween20 in ddH2O. 
2.6.6. Primary antibody incubation 
Primary antibodies were diluted with either 5% milk TBS-T, 5% milk PBS-T or PBS-T. 
After blocking the membrane was cut into specific section depending on what size the 
test protein and control protein were. These sections were then incubated in their 
specific primary antibody solutions for 2 hours at RT. Any remnant primary antibody 
was washed off the membrane by 3x 5 minute washes in TBS-T to help ensure specific 
bind of the secondary antibody. After the washes membranes were incubated with 
secondary antibodies relative to whichever primaries were used. Secondary antibody 
dilutions were made with 5% milk TBS-T containing the appropriate horseradish 
peroxidase (HRP) conjugated anti-rabbit or anti-mouse immunoglobulins (Dako, Ely, 
Cambridgeshire, UK). Secondary antibodies were diluted 1/2000 for monoclonal 
primary antibodies and 1/3000 for polyclonal primary antibodies; the membranes were 
incubated for 1.5 hours at RT. 
2.6.7. Secondary antibody incubation and detection 
Following the incubation of secondary antibodies membranes were washed again for the 
same length of time and number of repeats as the washes following the primary 
incubation. Visualisation was achieved through incubated of the membranes in ECL or 
ECL Plus solution (Amersham, GE Healthcare, Buckinghamshire, UK) for 5 minutes on 
Clingfilm as to not let the membranes dry out. Excess development solution was 
allowed to run off the membranes were arranged to align the lanes of test protein with 
the correct control in a cassette. In a dark room photographic film (Amersham, GE 
Healthcare) was placed on the membranes for enough time to allow development of 
clear bands and fixed using an automated developer machine.  
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2.6.8. Stripping membranes for antibody re-probing 
To re-probe Western blot membranes they had to be stripped by immersion in a 
stripping buffer at 55°C for 45 minutes. The stripping buffer was made from 12.5 ml of 
Tris HCL pH 6.8 (0.5M), 20 ml of 10% SDS, 67.5 ml of ddH2O and 800 µl of ß-
mercaptoethanol. The striped membranes were then washed up to three times in PBS-T 
or TBS-T, depending on the proteins probed for, and developed to analyse the 
efficiency of the stripping method. If fit for use the membrane would be blocked again 
in the appropriate solution before continuing with the western blot method described in 
2.6.2.  
2.7. General methods  
2.7.1. Chemicals and consumables 
Chemicals used in these methods were procured from Sigma-Aldrich (MO, US) and 
laboratory consumables were from Thermo Fisher Scientific (UK), unless stated 
differently.    
2.7.2. Ethical procedure  
The patient samples and photographs obtained and processed in the following chapters 
were obtained with written consent and handled in accordance with the declaration of 
Helsinki 1964, the ethical guidelines most prominent in medical research for the use of 
human or animal samples. Patient information was collated where possible, though due 
to the nature of patient sample handing in some other countries well documented cases 
were not always possible. 
2.7.3. Next generation sequence data analysis 
The human reference genome hg19 was used to align raw pair ends of NGS data in the 
bioinformatic analysis. The preliminary and in-depth bioinformatic analysis was 
undertaken by Dr Vincent Plagnol (University College London, UK), which includes 
the quality calibration options, sequence soft clipping and adapter trimming. The 
resultant NGS data was filtered depending on the putative aetiology of the inherited 
disease clinical diagnosed or possible diagnosis. Subsequent calls were then further 
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checked against the 1000 Genomes Project (www.1000genomes.org), the Exome 
Aggregation Consortium (ExAC; exac.broadinstitute.org) and the dbSNP 
(www.ncbi.nlm.nih.gov/snp) databases. Possible variants were then securitised visually 
using the Integrative Genomics Viewer (IGV, Broad Institute, MA, US). 
2.7.4. Statistical analysis  
In the analysis of sample-control studies in chapters 4 and 5 the paired t-test statistical 
method was utilised in the comparison of two population means where samples are 
correlated. The paired t-test and subsequent p-value function was calculated on 
Microsoft Excel. Significance was given at p<0.05 (*), highly significant at p<0.01 (**) 
and very high significance at p<0.001 (***). 
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3 Chapter 3: Mutation Analysis of ABCA12 in 
Harlequin Ichthyosis 
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3.1. Introduction 
Mutations in the gene ABCA12 have been associated with several autosomal recessive 
congenital ichthyosis (ARCIs): lamellar ichthyosis-2 (LI2), largely associated with 
missense mutations restricted to the first ATP binding domain (NBD1) and non-bullous 
congenital ichthyosiform erythroderma (NBCIE), associated with missense mutations 
throughout the protein (Lefévre et al. 2003; Jobard et al. 2002). Homozygous or 
compound heterozygous nonsense substitutions and frameshifts are found in most 
harlequin ichthyosis (HI) cases (Thomas et al. 2006; Scott, Rajpopat, et al. 2013). 
However, missense mutations correlating to particular domains of the ABCA12 protein 
also underlie some cases of HI. The type and location of mutation in ABCA12 offers 
some indication as to the disease presented by the affected and in turn the severity of 
disease. This spectrum of disease phenotypes produced by an array of mutations to a 
single gene suggest there is a genotype to phenotype relationship for ABCA12 (Thomas 
et al. 2006). 
 
In 2005 it was demonstrated that HI was inherited in an autosomal recessive pattern and 
ABCA12 was found to be the causative gene. ABCA12 was identified by use of a chip 
array and microsatellite markers to define the region of homozygosity to 2q35 in which 
the ABCA12 maps (Kelsell et al. 2005). Causative ABCA12 mutations were predicted to 
be loss of function (LOF) including nonsense mutations, frameshift producing deletions 
or whole exon deletions (Kelsell et al. 2005). In parallel, a Japanese group also reported 
predicted LOF mutations in ABCA12 with HI (Akiyama et al. 2005). 
3.1.1. Genetic screening of ABCA12 in patients clinically diagnosed with HI 
This chapter describes the genetic screening of families with at least one case of 
clinically diagnosed HI towards the identification of mutations in the gene ABCA12. 
The typical HI phenotype in early life consists of: thick hyperkeratotic plates with 
intermittent fissures separating the skin; eclabium; ectropion; microcephaly and joint 
contractures with possible in utero autoamputation. The neonatal period is complicated 
by prematurity, respiratory difficulty and secondary infections (Waring 1932; Buxman 
et al. 1979; Kelsell et al. 2005). Infrequently neonates do not survive, with mortality 
depending on the treatment received and the severity of disease (Rajpopat et al. 2011). 
HI patients that survive this period and make it into childhood have a reduction in 
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phenotypic severity, as presentation resembles a non-bullous congenital ichthyosiform 
erythroderma (NBCIE) (Thomas et al. 2006). 
 
Here, ABCA12 mutation analysis was undertaken for 6 unrelated HI cases. A two phase 
screening strategy was used: first phase, a combination of PCR and Sanger Sequencing 
to target known recurrent mutations found in specific ethnic groups. If the first phase is 
unsuccessful the second phase is initiated. The second phase utilises next generation 
sequencing, to sequence specific larger sections of the genome. These regions can be 
selected and amplified by whole exome sequencing or by targeted capture of disease-
associated regions. Previously, the Kelsell group has also designed a custom microarray 
for sequence capture and next generation sequencing of the ABCA12 gene and other 
genes known to be causative in ichthyoses (Scott et al. 2013). Exome sequencing is now 
the preferred method due to cost reductions and ease. All of these methods were used 
for the identification of variants and when they failed in-depth analysis strategies were 
devised for patients with complex mutations.  
 
The genetic screening of HI aids in the diagnosis of the disease and can be performed 
prenatally and also preimplantation genetic diagnosis (PGD) can be used. Mutations in 
the ABCA12 gene also aids in understanding the genotype to phenotype relationship and 
how mutations in the same gene can lead to different cutaneous disorders.  
3.1.1. Results 
3.1.2. Case 1  
Case 1, the affected had died prior to confirmation of the initial diagnosis, which was 
achieved through photo evidence (Figure 3.1. C). With a DNA or tissue sample 
unattainable from the deceased affected the genetic analysis was performed on a 
paternal DNA sample. The clinical notes included the information that this family was 
consanguineous, which meant a possible causative mutation found in the paternal 
sample in a heterozygous state was likely to present in the maternal sample	(Aggarwal 
et al. 2014). 
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The paternal sample was screened for known ethnic specific mutations. The family was 
of Indian ethnicity, thus six mutations previously found in the gene ABCA12 of HI 
patients of Indian/Pakistani ancestry were screened; exon 15 p.W601X, exon 23 
p.V1089F, exon 27 p.W1294X, exon 39 p.W1928X, exon 42 c.6378delGC and exon 49 
c.7322delC (Thomas et al. 2006; Thomas et al. 2009a; Kelsell et al. 2005; Akiyama et 
al. 2006; Akiyama et al 2005; Rajpopat et al. 2011). The set of exons, complete with 
flanking intronic regions were amplified, the amplicons cleaned and underwent 
bidirectional Sanger sequencing as described in 2.1.8. by use of a ABI Prism 3130xl 
Genetic Analyser.  
 
The genetic screen of the paternal sample was negative for the ethnic specific 
mutations, but upon the analysis of exon 49 a heterozygous 5 bp insertion in exon 49 
was found. As shown in Figure 3.1. (A) the electropherogram of exon 49 of ABCA12 
for the paternal sample shows a double trace that initiates the thymine at c.7317 and 
indicates the presence of a heterozygous c.7317_7318insACAAA. The sequence 
alignment of exon 49 in Figure 3.1. (B) of control and paternal sequences illustrates the 
5 bp insertion due to the extra 5 nucleotides in the paternal sample and a frameshifted 
sequence. 
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Figure 3.1. Genetic screening of case 1. (A) Electropherograms of exon 49 of ABCA12, 
the double trace that originates from the outlined thymine indicates the presence of a 
heterozygous c.7317_7318insACAAA in the paternal DNA. (B) Sequence alignment of 
exon 49, comparing two control DNA sequences with the paternal DNA sequence shows 
an insertion of 5 bp and a frameshifted sequence in the paternal compared with 
consensus. (C) Clinical appearance shows the affected neonate of the paternal sample. 
Presenting at birth with a typical HI phenotype including, eclabium, ectropion, thick 
plagues with deep fissures and joint contractures. Photo used in accordance with 2.7.2. 
Ethical procedure.   
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The mutation c.7317_7318insACAAA p.Cys2439fs in exon 49 of ABCA12 does not 
produce a premature stop codon before the exon 49 intron 49/50 splice site. The 5 bp 
insertion does however alter the reading frame, substituting the 9 amino acids 
CSVILTSHS for the 11 amino acids INVPSSSHLTA at the end of exon 49. In silico 
analysis predicted the formation of a truncated protein or no ABCA12 protein 
translation due to non-sense mediated decay of the transcript. In the possibility that the 
mutated ABCA12 protein is translated, with 9 amino acids missing and 11 different 
amino acids inserted into the second ATP binding cassette domain. There is a very high 
probability that this considerable change to a conserved domain will have a detrimental 
effect on the functionality of the protein. This also corroborates with previous genotype-
phenotype reports where mutations in the second ATP binding cassette domain of 
ABCA12 lead to loss-of-function or reduced ABCA12 protein expression causing the 
severe HI phenotype (Rajpopat et al. 2011; Kelsell et al. 2005; Akiyama et al. 2006). 
 
The discovery of the mutation in ABCA12 confirmed the retrospective photographic 
diagnosis and aided in the prenatal diagnosis by molecular testing for the family’s then 
current pregnancy. As the parents were consanguineous, there is a strong likelihood that 
the maternal sample would also be heterozygous for the mutation 
c.7317_7318insACAAA p.Cys2439fs in exon 49 of ABCA12 and the affected child was 
likely to be homozygous (Aggarwal et al. 2014). 
3.1.3. Case 2   
DNA from case 2 was pooled together with other patient DNA samples for custom 
array targeted capture, which included 24 known disease genes associated with 
ichthyoses and other epidermal conditions (Scott, Plagnol, et al. 2013). Bioinformatic 
analysis revealed two likely disease-associated mutations in ABCA12, which were 
subsequently corroborated by PCR and Sanger sequencing of the affected child and 
parental samples. This analysis was performed in accordance with 2.7.3. Next 
generation sequence analysis, where filters were set for variants fitting an autosomal 
recessive inherited disease. Case 2 was found to be compound heterozygous for a 
missense change c.5936C>G, p.A1979G in exon 40 of ABCA12 and a 1 bp deletion of a 
thymine resulting in a predicted frameshift and a premature stop codon: c.6858delT, 
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p.F2286fsX5 of exon 46 of ABCA12 (Scott, et al. 2013). The missense change 
c.5936C>G, p.A1979G was found in the paternal sample and the 1 base pair deletion 
c.6858delT, p.F2286fsX5 was found in the maternal sample (Figure 3.2. and Figure 
3.3). 
 
The effect the deletion had on the transcript was evaluated by the in silico transcription 
analysis tool Expasy translation (http://web.expasy.org/translate/). This deletion causes 
a frameshift and a subsequent stop codon within 5 bp, which suggests a protein 
truncated of 7 exons. Proteins like the one translated from this allele are not always 
produced due to the increased degradation levels of an incomplete transcript by 
nonsense mediated RNA decay.  
 
The combination of next generation sequencing (NGS) with targeted gene capture when 
screening multiple implicated genes or a variety of diseases with known aetiologies is a 
useful asset in the molecular diagnosis of inherited diseases. This was undertaken as the 
alternative, screening many samples one gene at a time through PCR and Sanger 
sequencing is time consuming and expensive. The identification of mutations and which 
genes harbour them aids in the facilitation of prenatal diagnosis and genetic counselling. 
The analysis of the custom array targeted capture platform utilised in case 3 was 
undertaken along side Claire Scott and the follow up sequencing was done 
independently. 
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Figure 3.2. Sanger sequencing of the affected and parental samples to evaluate pulled 
variants in case 2. The missense change c.5936C>G, p.A1979G was found in the paternal 
sample and the affected, shown in the electropherograms of exon 40 of ABCA12. Neither 
parent carried both heterozygous mutations found in the affected. 
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Figure 3.3. Sanger sequencing of the affected and parental samples to evaluate pulled 
variants in case 2. The 1 base pair deletion c.6858delT, p.F2286fsX5 was found in the 
maternal sample and the affected, in the electropherograms of exon 46 of ABCA12. Neither 
parent carried both of the heterozygous mutations found in the affected. 
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3.1.4. Case 3 
In case 3 the affected presented at birth with a severe, though characteristic HI 
phenotype, shown in Figure 3.4. Even with modern neonatal healthcare the affected 
died 2 months after birth. A limited amount of DNA was retrieved from the affected; 
however it was enough for exome capture and NGS. Following data alignment the 
variants presented in Table 3.1. were selected as possible causative variants of an 
ichthyosis and of those, the variants identified in ABCA12 were isolated as the clinical 
diagnosis was HI.  
 
From the variants found in the gene ABCA12, all but one were common SNPs that 
caused synonymous changes (Table 3.1.). The variant in exon 17 of ABCA12 c.T2329A 
p.S777T had not been reported before and caused a non-synonymous change. However, 
it did not segregate within the family as both parents carried the variant at a 
homozygous state. No disease-causing variants were found in ABCA12 or in any ARCI-
associated genes as highlighted in Table 3.1.  
 
 
 
 
 
 
 
 
Figure 3.4. Clinical appearance of the affected in case 3. Shows the affected in the 
neonatal stage. Presenting at birth with a severe HI phenotype including; thick 
hyperkeratotic plates, fissures, eclabium, ectropion, and erythematous scales. Photo in 
accordance with 2.7.2. Ethical procedure.    
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Gene Zygosity Type SNP SIFT  db SNP 
ABCA12 HET synonymous SNV exon43:c.C6306T:p.Y2102Y - RS10498027 
ABCA12 HET synonymous SNV exon28:c.T4126C:p.L1376L - RS34351934 
ABCA12 HOM nonsynonymous 
SNV exon17:c.T2329A:p.S777T 0.44 RS7560008 
ABCA12 HOM synonymous SNV exon8:c.G888A:p.V296V - RS17501837 
ALOXE3 HET synonymous SNV exon16:c.C2124T:p.S708S - RS3809881 
NIPAL4 HOM nonsynonymous 
SNV exon4:c.A580G:p.R194G 0.54 RS6860507 
NIPAL4 HOM synonymous SNV exon5:c.T1245C:p.V415V - RS4704870 
PNPLA1 HET synonymous SNV  exon3:c.C174T:p.F58F - RS2239795 
PNPLA1 HET nonsynonymous 
SNV exon6:c.C1010A:p.P337H - RS12199580 
PNPLA1 HET nonsynonymous 
SNV exon8:c.T1306C:p.S436P - RS4713956 
SNAP29 HET synonymous SNV exon1:c.A18G:p.K6K - RS1061064 
 
 
 
 
 
 
 
Table 3.1. Selected variants from the exome data of affected in case 3. Variants found in 
the analysis of the exome data, shows genes associated with HI and other ARCIs. Variants 
resolved as either common SNPs with a MAF >0.1 or did not segregate in the family.  
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As no point mutations or small deletion/insertions were found in the exome of the 
affected, the next part in the genetic analysis was to check for complex mutations. 
These can be regulatory and lie outside the coding region, splice site mutations or large 
exon or multi-exon deletions/insertions that are difficult to detect in heterozygosity. A 
group of those complex mutations are the large intragenic deletions, which at the 
ABCA12 locus have been shown to be causative in HI, such as deletions of exons 8 
(Thomas et al. 2006), 12-16, 52-53 (Rajpopat et al. 2011), 23, 28-53 (Kelsell et al. 
2005). Full exon deletions in ABC transporters have been associated with other 
diseases, for example, the deletion of exons 23-29 in the gene ABCC6 with 
pseudoxanthoma elasticum and a double deletion of 13 and 17-30 exons in ABCA1 
causing Tangier disease (Miksch et al. 2005; Guo et al. 2002). The first step in 
screening for complex mutations was to screen areas of known deletions in ABCA12 in 
the patient and parental DNA samples. All the screened regions and original mutations 
are shown in Table 3.2.  
 
Mutation Exon 
c.529delT p.Ser177GInfsX26 6 
Exon Deletion - 8 
c.2021_2022del2 p.Lys674ArgfsX49 16 
c.2025delG p.Ile676PhefsX13 16 
c.3270delT p.Tyr1090X 23 
c.4158_4160del3* p.Thr1387del 28 
c.4262delG p.Gly1421GlufsX39 29 
5012delA Asn1671IlefsX4 33 
c.5125_5128del4 unknown 33 
c.6160_6161del2 p.Ala2054AspfsX10 42 
c.7322delC p.Val2442SerfsX28 49 
 Table 3.2. Previously described deletions within the gene ABCA12. Known deletions 
that have been previously found to be causative in cases of HI. All of which were 
screened for in the affected and parental samples. * Does not truncate protein. 
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Figure 3.5. An example of the deletion screening analysis undertaken in case 3. (A) 
Electropherograms of exon 16 of ABCA12, outlined position of the two known possible deletions in 
exon 16, c.2021_2022del2 (p.Lys674ArgfsX49) and c.2025delC (p.Ile676PhefsX13) for all 
samples. (B) Sequence alignment of exon 16, comparing paternal, maternal, affected samples with 
the known sequence for exon 16. (C) Photographic capture of an agarose gel, PCR fragments, 
amplified from all three samples were ran to check for multiple bands.  
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Figure 3.5 shows an example of the deletion screening analysis undertaken in case 3 for 
one of the nine sets of regions screened. Here the PCR fragments that include intronic 
flanking regions, were run on a high percentage agarose gel to check for multiple bands. 
Then fragments were sequenced and traces analysed and aligned. None of the deletions 
were present in any of the samples, as shown in the example for exon 16 in the Figure 
3.5. After screening for point mutations and insertion/deletions the next screening 
would be for discrepancies in allelic expression. 
 
Several SNPs at different locations in the gene ABCA12 were investigated and their 
inheritance from the paternal genomic sample to the patients was assessed. For example 
if the paternal sample was homozygous for a specific SNP and the patient sample was 
WT, then this could suggest a large deletion, removal through splicing or possibly a 
lack of expression or inheritance of the paternal allele.  
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Figure 3.6. Sanger sequencing of the paternal sample to identify allelic 
discrepancies in case 3. Electropherograms and sequence alignments of 4 exons 
of ABCA12 in case 3. Paternal sequencing trace is shown to check for all the SNPs 
in ABCA12 that were present in the affected, for the identification of allelic 
expression discrepancies by the presence of paternal variance. 
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The next part of analysis was to check the inheritance of SNPs from the paternal sample 
to the patient follows logical patterns of inheritance when taken into account the 
possible carrier status of the maternal sample. For example, in exon 8 the SNP 
c.G888A:p.V296V was found in the affected in a homozygous state and heterozygous 
in the paternal sample. In exon 17 the SNP c.T2329A:p.S777T was present in the affect 
in a homozygous state and the same in the paternal sample, suggesting it was inherited 
paternally and maternally. Also in exon 28 the SNP c.T4126C:p.L1376L was found to 
be heterozygous in the affected, though found not to be present in the paternal sample, 
suggesting a maternal mode of inheritance, all examples shown in Figure 3.6. All SNPs 
that were homozygous in the patient were either homozygous or heterozygous in the 
paternal sample, showing no allelic discrepancies. The next part of the analysis was to 
check the paternal cDNA for transcript discrepancies. Paternal RNA had to be used, as 
patient material was no longer available.  
 
ABCA12 cDNA was used to check for cDNA transcript discrepancies. Paternal RNA 
was isolated from hair as described in 2.1.2. an optimised protocol reduced the necessity 
for skin biopsies in this case. The total RNA was reverse transcribed to cDNA, which 
went through PCR and Sanger sequencing to check for SNP heterozygosity retention in 
the transcription process. PCR, run on an agarose gel, using paternal cDNA extracted 
from hair, showing there are sufficient amounts of ABCA12 in hair follicles. 
Amplification of the paternal cDNA with two sets of primers flanking exon 8 and 43 
was performed to assess for the retention of two heterozygous SNPs.  
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Figure 3.7. Expression discrepancy and aberrant splicing analysis of the paternal 
sample in case 3. (A) Electropherograms and sequence alignments, of two SNPs in 
ABCA12 in genomic and cDNA paternal samples. (B) Agarose gel photo capture, 
amplified ABCA12 exons of cDNA reverse transcribed from the RNA sample 
obtained from hair follicles. 
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Both SNPs in the paternal sample were present in a heterozygote state in the genomic 
DNA and the cDNA, showing that there is no evidence of lack of expression from one 
allele or aberrant splicing at these sites (Figure 3.7.). The next step was to continue the 
analysis of the transcript in the paternal sample. Using the primer pairs from table A1.1. 
the entire ABCA12 mRNA transcript was amplified and run on an agarose gel to check 
for small insertions or deletions and then sequenced. 
 
Primer sets were designed to have overlapping sequences and any sequence variants 
were analysed, an entire ABCA12 transcript was amplified from paternal cDNA. No 
multiple banding was seen for the paternal sample and all sizes corresponded to the WT 
for that amplicon. 
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Heterozygous  
Exon 8 SNP c.G888A 
(A)
(C) 
(B) 
    Cont. cDNA 
    Pat cDNA 
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1 
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Figure 3.8. PCR and Sanger sequencing in ABCA12 transcript analysis of case 3. 
(A) Electropherograms of an example of part of the ABCA12 transcript, showing 
paternal cDNA and control cDNA sequences, highlighting the presence of a SNP in the 
paternal transcript. (B) Sequence alignments, of 1 out of 16 parts of the complete 
ABCA12 mRNA transcript from the paternal and control samples. (C) Agarose gel 
photo capture, amplified ABCA12 exons of cDNA, sample 1 is paternal cDNA, sample 2 
is control cDNA and sample 3 is negative control. 
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Figure 3.8. shows an example of the sequencing analysis of the complete paternal 
transcript. From the alignment of the paternal, control and reference sequences there 
were no variants in ABCA12 apart from the SNPs already analysed and a variation in 
PCR fragment brightness, though this was not consistently present in either sample. 
From the analysis of ABCA12 in the patient and paternal genomic DNA, the exome 
capture of the patient and the multiple screening of the paternal transcript the data 
suggest that the causative mutation may well not be located within ABCA12, nor acting 
on the regulation of the ABCA12 gene. 
 
From exome data analysis, no other likely disease-associated homozygous or compound 
heterozygous changes in any genes were identified. However, a heterozygous mutation 
that was not present in the parents DNA, thus be of de novo origin, could be the 
underlying genetic cause of HI in this case. These variants are shown in Table 3.3.  
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Table 3.3. Filtered variants from exome data of the affected in case 3. Variants 
pulled from the exome data set with green denoting the four candidate variants and 
their respective genes. 
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Four heterozygous variants could be linked with a possible pathway associated with the 
HI phenotype. DSC1 desmocollin-1 isoform Dsc1b preproprotein and PCDHGA9 
protocadherin gamma-A9; mutations present in both genes could play a role in an 
ichthyosis-type disease as there is a desmocollin -1 and cadherin reduction in Netherton 
Syndrome. KSDR 3-ketodihydrosphingosine reductase precursor; although this has 
previously been linked with lymphoma, the enzyme is involved with sphingolipid 
biosynthesis. Sphingolipids are the third main component of the permeability barrier 
with ceramides and cholesterol. GOSR1 Golgi SNAP receptor complex member 1 is 
involved in general protein trafficking from the endoplasmic reticulum (ER) to Golgi in 
mammalian cells and is a component of the Golgi SNAP receptor (SNARE) complex. 
Deleterious mutations could possibly hinder LG development. Primers from table A1.3. 
were used to amplify the exons of interest in these genes and Sanger sequencing was 
utilised to sequence the fragments. However each variant was also present and 
heterozygous in either maternal or paternal DNA. 
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GOSR1 Splice Site variant: Exon 5 :c.440+6T>C 
Paternal WT Maternal (Het) c.440+6T>C Control WT 
   
DSC1 Exonic variant: Exon 2 :c.G139C:p.V47L 
Paternal WT Maternal (Het) 
c.G139C 
Control WT 
   
KDSR, Exonic variant: Exon 9 :c.G812A:p.G271E 
Paternal (Het) c.G812A Maternal WT Control WT 
   
PCDHGA9, Exonic variant: Exon 1 :c.T1354C:p.F452L 
Paternal (Het) c.T1354C Maternal WT Control WT 
   
Figure 3.9. Sanger sequencing of candidate variants in case 3. Electropherograms 
and sequence alignments of the 4 variants, which were selected from the exome data 
set of the affected and analysed in parental samples.  
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As one of the parents was heterozygous for the each of the four variants, they are not de 
novo in origin. It is highly unlikely that the HI phenotype of the affected was then 
caused by these variants. The next step in the analysis of case 3 is to sequence with 
whole genome capture both parental samples and filter for any variants in both coding 
and non-coding genetic regions. This method would also identify copy number changes.  
3.1.5. Case 4 
The DNA from case 4 was sequenced using the targeted sequence capture array 
approach described previously (3.1.3.) (Scott, Plagnol, et al. 2013). After filtering the 
data for rare mutations in ABCA12 a small homozygous deletion was identified 17 bp 
upstream of the start of exon 40, c.6286-17delTGT. The variant was not automatically 
flagged as a splice site mutation due to the distance away from the recognition site, but 
domains of the spliceosome need to bind further upstream for lariat production. Thus in 
silico splice site prediction was used to analyse the product of such a variant.  
 
 
Figure 3.10. Splice site analysis of case 4 of the variant c.6286-17delTGT, when the deletion 
of TGT was removed from the intronic sequence the acceptor site changed from the WT 
recognition site that obtained a score 0.48 to the alternative, which received a score of 0.60. 
www.fruitfly.org/seq_tools/splice. 
 
 
 
c.6286-17delTGT (deletion prior to exon 40) 
Possible Splice Site Mutation 
Loss of the first 30bp from the 55bp exon 40 
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The alternative acceptor site is predicted to have a high affinity for the spliceosome, it is 
located 30 bp within exon 40, which itself is only 55 bp long. To complete this case 
subsequent affected and parental DNA samples would be needed for the validation of 
variant (c.6286-17delTGT) and cDNA analysis should be performed to confirm the 
predicted effect on splicing. 
3.1.6. Case 5 
Parental DNA was analysed, as there was no DNA from the HI affected available. The 
two phase screening strategy was used: the clinical notes described the affected as 
middle-eastern, thus the six recurrent mutations listed in Table 3.4. were screened for. 
As none of the recurrent mutations were found the remaining 47 exons of ABCA12 were 
amplified by PCR then sequenced through the Big Dye and subsequent Sanger 
sequencing method in the laboratory. 
 
 
Ethnicity Mutation Exon Present 
Iranian 450insC 5 No 
Israeli Q354del 9 No 
Arab(other) Splice site 26(intronic) No 
Turkish Y1650X 32 No 
Egyptian R1880X 37 No 
Iranian Splice site 42(intronic) No 
Table 3.4. An example of the first screening in case 5. Showing the first 6 exons to be 
screened for known ethnic specific recurrent ABCA12 mutations.  
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Figure 3.11. Screening of case 5 using Sanger sequencing. Electropherograms and MultAlin 
sequence alignment of ABCA12 exon 15, from the sequencing of parental DNA. Arrows 
indicate the position of the two variants found in the maternal sample. MultAlin 
(multalin.toulouse.inra.fr/multalin/ ) SNP data from (www.ensembl.org/). 
 
In case 5, no mutation was found in the paternal sample, suggesting a possible deletion 
or regulatory mutation. The mother was heterozygous for a missense mutation in the 
second membrane-spanning domain of the ABCA12 protein. The variant labelled R is 
recorded as a SNP rs76979001, which produces the change c.1892G>A p.R631Q, at a 
MAF of 0.01, a SIFT of 0.16 (tolerated) and a PolyPhen of 0.118 (benign).  
 
There was no database information available for p.L634F, the greatest indicator as to 
the nature of this variant was the information available on the preceding amino acid. 
This residue is associated with two variants, the first p.Y633C, has no ‘rs’ number, 
though is listed on the COSM database, where it is cited as deleterious (SIFT of 0) and 
probably damaging (PolyPhen of 0.99). The second is p.Y633X, which is a known 
disease causing mutation in HI (Rajpopat et al. 2011). Both of which suggest this 
location on the first transmembrane domain of ABCA12 would yield a dysfunctional 
protein if mutated. In the fifth transmembrane domain the variant p.V1089F is an 
example that a missense mutation within these rich hydrophobic amino acid domains 
can be deleterious (Rajpopat et al. 2011). 
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This mutation (p.L634F) was the only variant found in the maternal DNA sample, 
which could possibly contribute to a compound heterozygote disruption of ABCA12. In 
efforts to complete this case a further paternal sample would be ideal to screen the 
ABCA12 transcript for complex mutations.  
3.1.7. Case 6  
In case 6 a provisional clinical diagnosis of HI and blood sampling was performed on 
the affected and both parents to screen for mutations in ABCA12 by exome sequencing. 
Exome sequencing using the DNA from Case 6 was performed using a combination of 
SureSelect system for target enrichment (Agilent Technologies) and sequencing on a 
HiSeq system (Illumina) (Blaydon et al. 2013; Brooke et al. 2014). Analysis following 
2.7.3. revealed no likely disease-causing ABCA12 variants. However, a likely disease 
causing change in the ALOX12B gene was identified: homozygosity for a missense 
mutation, c.1630T>C (p.Cys544Arg) in exon 12 of ALOX12B. Subsequent Sanger 
sequencing confirmed this finding in the affected and found both parents heterozygous 
for the mutation, which is in accordance with autosomal recessive inheritance (Figure 
3.13.A). The mutation (p.Cys544Arg) localises to the catalytic helix 21 domain, in a 
region of ALOX12B previously shown to carry mutations that remove the enzymatic 
activity of ALOX12B (Figure 3.13.B) (Eckl et al. 2005). Previously, ALOX12B 
mutations have been associated with NBCIE. 
 
The clinical progression was being assessed whilst these genetic studies were being 
performed. During the first year of life, the infant showed a steady yet marked 
improvement and almost complete resolution of skin features. The affected weighed 
8800 g (25 p), had a height of 69 cm (< 3 p) and OFC of 45.5 cm (10-25 p) at the age of 
13 months. Her neuromotor development was normal and the infant showed only subtle 
erythema affecting the distal lower limbs associated with overlying fine white scales 
(Figures 3.12.A&B).   
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Figure 3.12. Clinical and histopathological appearance of the affected female at the 
neonatal stage. (A) Showing ectropion, joint contractures, large thick yellow plagues 
with an uneven distribution and bisecting erythematous fissures. (B) Appearance of lower 
extremities at 13 months of age, showing fine white scaling over the entire body. (C) 
Haematoxylin and eosin staining shows a thickened stratum corneum in the affected 
compared to that of the control. (D) Immunostaining for ALOX12B shows a reduction of 
epidermal staining in the skin of the affected in comparison with control. Photos in 
accordance with 2.7.2. 
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A punch skin biopsy from the affected was obtained from a site on the forearm for 
histopathological work-up. Haematoxylin and eosin staining showed an epidermis with 
enlarged stratified layers and a thickened, compressed stratum corneum (hyperkeratosis) 
in contrast to the normal basket-weave corneum layers in a control skin (Figure. 
3.12.C). Immunohistochemical staining revealed that ALOX12B protein expression 
was reduced in the epidermis of the affected in comparison to control skin, where it 
appears to be expressed in the stratum granulosum (Figure. 3.12.D). These features 
were consistent with a disease causing mutation in the ALOX12B gene (Eckl et al. 
2005). 
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Figure 3.13. Genetic screening of case 6. (A) Electropherograms show the effected 
was homozygous for the mutation c.1630T>C in ALOX12B, which was found to be in 
the heterozygote state in both parents. (B) Partial ALOX12B gene schematic depicting 
the localisation of mutations in neighbouring exons that were previously shown to 
remove the enzymatic activity of 12RLOX (Eckl et al. 2005).      
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NGS and Sanger sequencing corroborate that the affected is homozygous for the 
missense mutation Cys544Arg in exon 12 of the ALOX12B gene. ALOX12B codes for 
arachidonate 12-lipoxygenase (12RLOX), an enzyme that produces 12-
Hydroxyeicosatetraenoic acid, an eicosanoid, which is a type of signalling molecule, 
that plays a role in keratinocytes and Langerhans’ cell interaction. Many LOX products 
hold pivotal roles in keratinocyte terminal differentiation and are crucial in barrier 
formation (Krieg et al. 2001).  
 
Recessive mutations in ALOX12B can cause NBCIE (Eckl et al. 2005). The cysteine to 
arginine substitution (Cys544Arg) within the catalytic helix 21 domain could reduce the 
enzymatic ability of the lipoxygenase domain it is situated in, as cysteine amino acids 
are often involved in the formation of disulphide bridges, a critical protein structure 
(Eckl et al. 2009). 
 
Cases can present with similar phenotypes to HI directly after birth, though skin 
development into early childhood is considerably different. The two siblings of the 
affected had died from secondary infections and septicaemia due to an irregular skin 
barrier formation after presenting with a similar phenotype as the affected at the 
neonatal/infantile stage. The mutation in the gene ALOX12B caused the affected to 
present with a HI-like phenotype at birth, that both phenotypically and histologically 
resolved to NBCIE over the first 13 months (Bland et al. 2015). 
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Case Sample Ethnic 
background 
History of 
consanguinity 
Clinical 
diagnosis 
Mutation Citation 
1 DNA  Indian Yes HI 
c.7317_7318ins
ACAAA 
p.Cys2439fs 
Aggarwal 
et al. 2014 
2 DNA from blood 
British 
caucasian No HI 
c.5936C>G 
c.6858delT 
Scott et 
al. 2013 
3 
DNA from 
blood, 
RNA from 
hair follicle  
British 
caucasian No HI 
Possible 
complex or 
regulatory 
- 
4 DNA from blood Pakistani Yes HI 
c.6286-
17delTGT 
Further analysis 
needed 
- 
5 DNA from blood Indian Yes HI 
Further 
analysis 
needed 
- 
6 DNA Turkish No NBCIE c.1630T>C p.C544R 
Bland et 
al. 2015 
 
Table 3.5. Summary of cases in chapter 3.  
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3.2. Discussion 
3.2.1. Genetic screening of ABCA12 in HI cases 
This chapter aimed to identify new ABCA12 mutations, utilise and develop new 
strategies when complex mutations were screened for. In this chapter mutations in 
ABCA12 were associated with HI for four out of the five cases that were diagnosed as 
HI. The other (case 6) was verified with a clinical diagnosis of NBCIE after an original 
diagnosis of HI. As expected with a recessive disease biallelic ABCA12 mutations 
account for around 98% of HI cases, with the remaining 2% identified with only one 
mutant allele, suggesting HI is a homogenous disease (Rajpopat et al. 2011). The 
majority of disease-causing mutations associated with HI are homozygous and are 
frequently attributed to parental consanguinity.  
 
Exome capture by definition sequences ~5% of the genome and captures the vast 
majority of the protein coding genes. A great advantage of this study is the sequencing 
of the entire genome will bring about the discovery of causative mutations in non-
coding regions such as mutations involved in regulation, stability of message and 
splicing.  
 
Genomics England is the governing body in control of the 100,000 genomes project, 
which has been set up to sequence, in its entirety, the genomes of 100,000 people within 
the population of England. Around 80% of rare diseases are inherited these include 
diseases like HI. Those suspected of having an inherited disease without a full 
molecular diagnosis are possible candidates for the 100,000 genomes project. They 
would be sequenced along side near family members, where possible parents to aid with 
the segregation of disease-causing variants. 
 
15,000 patients with rare diseases will have their genome analysed through the 100,000 
genomes project, with the overall theme to gain a molecular and clinical ‘big picture’ of 
many inherited diseases. The immediate benefits are a molecular diagnosis to enable the 
correct treatment of the affected as well as the option of participation in relative clinical 
trials where possible. The analysis of this large data set will also lead to the discovery of 
new pathways of disease and strengthening ones that already exist. As no molecular 
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diagnosis was concluded on for case 3 the affected would have been an ideal candidate 
for this project. 
 
A possible area of interest, which was not covered by the exome sequencing of the 
affected was the locus of the 3.7-kilobase large non-coding RNA (lncRNA) terminal 
differentiation-induced ncRNA (TINCR). The lncRNAs are multi-exonic RNA that are 
regulated by transcription factors and perform regularity roles from stem cell 
pluripotency to proliferation and differentiation (Guttman et al. 2009). TINCR regulates 
epidermal terminal differentiation through a posttranscriptional stabilisation, enabling a 
high concentration of epidermal differentiation gene mRNA (Kretz et al. 2013). Genes 
including ABCA12, ALOX12B, ALOXE3, LOR, and FLG. TINCR induces expression of 
ABCA12 in human keratinocytes via the TLR3-dependent pathway, which increases 
lipid and LG concentration of epidermis (Borkowski et al. 2013). As a TINCR-deficient 
epidermis has been shown to be lacking terminal differentiation ultrastructure like LG 
and reduced ABCA12 expression, it is viable that this locus would be of interest when 
furthering the investigation of case 3.  
3.2.2. The genotype-phenotype correlation of ABCA12 and HI 
Homozygous missense mutations have been found to be causative for disease in other 
members of the ABC transporter subfamily A. In Stargardt disease, missense mutations 
within conserved domains of ABCA4 account for 80% of case aetiology and in Tangier 
disease, 60% of causative mutations are missense and found within the conserved 
domains of ABCA1 (Lewis et al. 1999; Huang et al. 2001).  
 
Missense mutations in ABC1 domain of ABCA12 are predominately linked with 
causing LI2 in a sub group of the African population and infrequently linked with 
NBCIE (Lefévre et al. 2003; Sakai et al. 2009). No missense mutations of the ABC1 
domain have been found to be causative in HI, only whole exome deletions or deletions 
resulting in a frameshift in this region develop into HI (Akiyama 2005; Thomas et al. 
2006), though in the minority, missense mutations in other domains of the ABCA12 
protein are causative in HI. A single missense mutation in NBD1, conserved residues 
within the ABC1, domain of ABCA12 has been found to causative in HI; however, this 
de novo mutation was paired with a deletion in exon 28 in a compound heterozygote 
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state (Akiyama et al. 2006). As the missense mutation was found on a single allele and 
the other allele had a deletion in a conserved residue of NBD1, this still upholds that 
there are no missense mutations within ABC1 domain at a homozygous state causative 
for HI.  
 
Homozygous missense mutations in the ABC2 domain of ABCA12 have been found to 
be causative in HI (Kelsell et al. 2005). ABC transporter domains 1 and 2 have 36% 
homology and within these domains the NBD1 and 2 share 87.5% homology. All of 
which suggest both NBDs act in very similar ways to bind nucleotides, where as the 
ABC domains though form the cassettes that orientate ATP towards the NBDs, they 
may have slightly different roles in the function of ABCA12. The genotype-phenotype 
relationship in ABCA12 is such that type and location of mutation is not only an 
indicator of phenotype severity, but actually indicate which disease is present. The 
predominately missense mutation-associated NBCIE and LI2 are much milder 
phenotypically then HI, where the majority of causative mutations are homozygous 
deletions or truncations.  
 
The genotype-phenotype relationship may also play a distinct role in the probability of 
mortality. From previous clinical genetic screenings by the Kelsell group it was noted in 
2010 that although HI was still infrequently lethal when causation was linked with 
compound heterozygous mutations in ABCA12, the rate of mortality was reduced in 
these individuals. This was corroborated with a review of 45 cases of HI in which 
mortality, though still generally infrequent in HI, it was more common with 
homozygous mutations (Rajpopat et al. 2011); should probably be viewed as a greater 
benefit from treatment or survival advantage. Another possibility that may also skew the 
correlation is that the affected may harbour another mutation for a coexisting recessive 
disease, which would play a role in reducing the survival rate. More plausible is the 
relationship of the location and type of mutation in the protein and how it affects the 
severity of the HI disease phenotype (Rajpopat et al. 2011). 
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Figure 3.14. A schematic representation of the ABCA12 protein, denoting the location of 
known mutations and specific domains. Mutations have been grouped depending on the 
domain they localise to and coloured in accordance with the severity of disease they’ve been 
found to be causative in. LI2, CIE and HI causing mutations are coloured blue, orange and grey 
respectively with green resembling mutations that result in differing phenotypes. 1(Rajpopat et 
al. 2011), 2(Thomas et al. 2006), 3(Thomas et al. 2009a), 4(Castiglia et al. 2009), 5(Natsuga et 
al. 2007), 6(Akiyama et al. 2006), 7(Akiyama 2005), 8(Kelsell et al. 2005), 9(Yanagi et al. 
2008b), 10(Sakai et al. 2009), 11(Akiyama et al. 2007), 12(Rajpar et al. 2006), 13(Lefévre et al. 
2003). 
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3.3. Summary 
In this chapter, multiple molecular genetic techniques were used to ascertain and 
evaluate possible causative mutations for HI in the gene ABCA12. The mutations 
detected ranged from simple to complex and when a molecular diagnosis could not be 
defined an outline of future work was proposed. The majority of patients screened were 
clinically diagnosed with HI presenting with many of the characteristic phenotypes of 
the disease. The shift of ARCI clinical features as seen in the NBCIE case caused by a 
mutation in the ALOX12B underlies the importance of understanding skin development 
in early infancy for molecularly or histopathologically confirmed diagnosis and prompt 
treatment.    
 
Not only does the identification of mutations give molecular diagnostics a greater 
reservoir to help identify possible causative mutations in future cases. It also aids in the 
understanding of the functional mechanisms of the ABCA12 protein as described in 
chapter 4, where a patient derived HI cell line was isolated and characterised for further 
use in the analysis of ABCA12 and its role in the epidermis. 
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4 Chapter 4: Characterisation of a Patient 
Derived Harlequin Ichthyosis Cell Line 
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4.1. Introduction 
The ABCA12 protein is a member of the ABCA subfamily of ABC transport proteins; it 
actively transports lipids against a concentration gradient into LG transport vesicles 
(Sakai et al. 2007). ABCA12 ablation in HI results in absent LG or a reduction in their 
lipid cargos (Mitsutake et al. 2010). The contents of functional LGs are a myriad of 
lipids, which when extruded into the extracellular lipid lamellae membrane of the lipid 
envelope (Uchida & Holleran 2008). When this process is interrupted in HI a disrupted 
permeability barrier is formed leading to increased TEWL and the possibility of 
secondary infections. This epidermal defect (due to loss of ABCA12) leads to increased 
retention of squames through the dysregulated transportation of proteases and premature 
terminal differentiation (Thomas et al. 2009b).  
 
The precursors of the ceramides ABCA12 transports are present in the basal layers of 
the epidermis and have been shown to up-regulate the transcription of the gene ABCA12 
through the PPARβ/δ pathway (Jiang et al. 2009). Another nuclear hormone receptor, 
LXRβ, has been shown to up-regulate the transcription of ABCA1, which transports 
cholesterol in the epidermis, another constituent of the permeability barrier. This 
chapter aims to investigate this pathway and its role in epidermal differentiation and 
how it is modulated in HI, by utilizing a HI patient derived cell line and calcium shift. 
 
4.2. Results 
4.2.1. Genetic analysis of patient of patient derived HI cell line  
The affected individual was clinically diagnosed with HI at birth and is currently 26 
years of age. A DNA sample was sent for whole exome capture and next generation 
sequencing. Analysis revealed that the HI individual was a compound heterozygote for 
a nonsense mutation and a putative splice site mutation in ABCA12. The nonsense 
mutation is p.Glu2264X, producing a termination of the protein from exon 45 of 
ABCA12. The severity of this truncation indicates that this allele does not produce a 
functional protein and the transcripts produced will have an increased rate of 
degradation by nonsense-mediated RNA decay.  
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The other heterozygous mutation is a change to the putative acceptor site (AG) 
preceding exon 35 of ABCA12, c.5382-2a/g. To analyse this variant further and for 
other investigative studies into HI disease mechanisms, a skin biopsy was performed 
after informed consent (adult) and ethical approval from East London and City Health 
Authority Research Ethics Committee and following 2.7.2. The punch biopsy was 
halved, with one half flash frozen for IHC to check for markers of premature terminal 
differentiation, ABCA12 and ABCA1. Immunostaining of ABCA12 in the epidermis of 
the affect was drastically reduced compared to that of controls, as shown in Figure 4.6. 
The second half was used in the isolation and propagation of the HI patient derived 
keratinocyte cell line, with dispase and trypsin used for dermis separation and epidermal 
dissociation respectively. The keratinocytes were immortalised as described in 2.3.8. 
This was performed by Dr Andrew South, University of Dundee. 
 
The RNA transcribed to cDNA for the splice site analysis was isolated from the 
immortalised HI keratinocytes. To analyse this splice site in detail, primers were 
designed to amplify the region in cDNA and the amplicons were run on a high 
percentage agarose gel to differentiate between multiple bands produced by the 
spliceosome recognising different exon 35 acceptor sites in the allele with this mutation. 
An in silico splice site prediction model was utilised to predict the positions of 
alternative acceptor sites and give an idea of transcript composition with regard to exon 
35 and intron 34/35. 
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Figure 4.1. In silico splice-site prediction and agarose gel electrophoresis of 377bp 
cDNA fragment. (A) In silico splice site prediction modelling of the WT and HI cell 
line holding c.5382-2a/g. The WT fragment is highlighted in green and predicts the 
correct size of fragment amplified, red and blue are possible predicted fragments when 
the c.5382-2a/g mutation is taken into consideration. (B) Gel electrophoresis shows a 
triple band produced from the PCR of cDNA reverse transcribed from RNA extracted 
from the HI cell line. Both NEB1 and K17 controls produce an amplicon at 377 bp. (C) 
The set of fragments produced by the amplification of the splice site and their possible 
prediction models. 
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Figure 4.1. shows that the splice site mutation in the HI cell line does produce 
alternative transcripts to those on the Ensembl database, from the electrophoresis gel of 
PCR amplicons of the splice site region there are 3 distinct fragments are visible. The in 
silico splice site prediction model used www.fruitfly.org/seq_tools/splice for 
acceptor/donor sites analysed in this method can obtain a maximum score of 1 for level 
of affinity with the spliceosome. Primers for this section of transcript amplification can 
be found in A1.1. 
 
The middle fragment or the 2nd splice variant is at the same size as the WT fragment 
produced here from the amplification of cDNA synthesised from RNA extracted from 
NEB1 and K17 cell lines. The 1st and 3rd splice variants are larger and smaller 
fragments, respectively, as predicted by the in silico prediction, but to conclude on what 
had been retained and lost in the splicing process the bands were extracted from the gel, 
cleaned and sequenced.   
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Figure 4.2. Electropherograms of the Sanger sequencing of the 3 splice variants. 
Produced by PCR of cDNA from the HI and K17 cell lines, the amplified region 
straddled the possible exon 35 acceptor sites, shown in Figure 4.3. 
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As indicated at the top of Figure 4.2. and from Figure 4.1. the 2nd splice variant is of 
WT length and sequence for the HI cell line. This splice variant is probably a product of 
the alternative allele, as the exon 45 nonsense mutation would not affect the 
amplification of exon 35 and it’s splicing.  The 3rd splice variant aligns with the control 
sequence with a 20 bp deletion (TAATTATCACCCGAGCACGG) from the start of 
exon 35 producing a frameshift in the transcript. The 1st and largest splice variant is 
itself a composite of several transcripts that like the 3rd splice variant have a ~20 bp 
deletions from the start of exon 35, but also contain a retention of varying lengths of 
intron 34/35. These possible indels are due to the spliceosome selecting a multiple of 
low affinity alternative acceptor sites that subsequently changes which donor site can be 
utilised. 
 
Though the in silico splice site prediction did predict two alternative splice variants, it 
did not predict the utilisation of the donor site 20 bp into exon 35. Neither did it account 
for the range of acceptor sites within intron 34/35 that the spliceosome could recognise 
and thus produce many different lengths of intron retention. To further investigate if the 
splice site mutation c.5382-2a/g does lead to the transcription of any translatable mRNA 
in the HI cell line, the different transcripts within the largest fragment (1st splice variant) 
would have to be separated and sequenced.    
 
To do this, TA cloning was undertaken on the extracted amplified cDNA from the 
largest fragment, 1st splice variant. With the use of a topoisomerase I enzyme to unwind 
and reform supercoiled DNA and a TOPO vector to bind the individual PCR products, 
this permitted the individual cloning and then sequencing of all possible amplified 
transcripts, as shown in Figure 4.3.  
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Figure 4.3. TA cloning of aberrant splicing. Electrophoresis gel of HI cell line 
amplicons, TA cloning and subsequent PCR of exon 35, including exon 34 and 36 to 
ensure all alternative transcripts are captured. Single colonies were used from separate 
plates; plates were spread from individual TA cloning reactions, except for colonies 2 
and 4, which were taken from the same plate. The four smaller fragments are produced 
from the amplification of the M13 forward sequence to the reverse of the TOPO vector, 
when ligation of a PCR fragment does not occur. The four successful TA clones were 
then sequenced by Sanger sequencing.  
 
 
 
 
 
 
 
 
1 2 3 4 
bp 
200 
300 
400 
500 
650 
100 
TA Clone 
TA Cloning 
  121 
 
Figure 4.4. The MultAlin sequence alignment of the four TA cloning products. 
Showing the region covered by the amplicons of the TA cloning, aligned with exon 35 
of the ABCA12 gene. This disseminates the different transcripts within the 1st and 
largest splice variant and gives an indication as to the variety of splicing acceptor sites 
utilised. 
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Figure 4.4. shows the TA clone 1 is same length as 2nd splice variant (WT) with a 
point mutation; this fragment was extracted with the largest band on the original gel 
separation of splice variants. The point mutation could have occurred from the low 
proof reading fidelity of the DNA polymerase utilised in TA cloning.  
 
TA clones 2 and 4 have an acceptor site 20 bp within exon 35 and also hold the longest 
intronic retention. TA clones 2 and 4 are homologous, as expected when taking colonies 
for the same TA cloning plate, with the remainder of exon 35 frameshifted and the 
retained intron coding for a stop codon in 7 bp. TA clone 3 has an acceptor site 15 bp 
into exon 35, though a shorter intronic retention than TA clones 2 and 4 producing a 
slightly shorter fragment. This transcript has 42 bp of retained intron of which the last 
15 bp replaces the first 15 bp of exon 35, stays in frame and does not code for a stop 
codon, though will produce a protein with 14 additional amino acids to that found in the 
K17 cell line and on the Ensembl database. 
 
After freeze thawing and multiple passages, the HI cell line was re-checked for the 
presence of the causative mutations at the genomic level, to ascertain if they had been 
retained, as loss can occur during culturing or the immortalisation process. 
 
 
 
 
 
 
 
 
 
  123 
 
Figure 4.5. Electropherograms of Sanger sequencing for mutation analysis. From 
the PCR of exons 35 and 45 of ABCA12 from the genomic DNA of the K17 and HI cell 
lines. To screen for the found compound heterozygous mutations to check that the HI 
cell line has retained them. Frozen stocks were cultured through 15 passages to check 
for mutation retention. 
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4.2.2. Immunohistochemistry of ABCA12 and ABCA1 in the HI skin 
The skin biopsy was processed for histopathological work-up and frozen section were 
cut to immunostain for the expression and epidermal localisation of ABCA12 and 
ABCA1 proteins. The negative controls of the immunohistochemistry are in Figure 
A1.1. 
 
The general structure of the HI skin biopsy showed enlarged stratified layers of the 
epidermis and a thick stratum corneum of retained squames, in contrast to control 
(normal) skin (NS), which has a thinner, basket weave like stratum corneum (Figure 
4.6). The immunohistochemical staining revealed that ABCA12 protein expression was 
significantly reduced if not absent in the epidermis of the affected in comparison to NS, 
where ABCA12 protein expression localised to the upper stratum granulosum and 
stratum corneum. ABCA1 protein expression was also reduced in the epidermis of the 
HI skin where it localised to the stratum granulosum and corneum, in comparison to the 
NS where expression also localised to the basal layer as well as the upper stratum 
granulosum and corneum. The features described were all consistent with a disease 
causing mutation in the gene ABCA12 (Figure. 4.6). 
 
A consideration to make is that IHC of the HI epidermis will give a slight skewed 
appearance of protein expression when compared to NS due to the enlarged stratified 
layers.  
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Figure 4.6. Immunohistochemistry of HI patient skin and normal skin. 
Immunostaining against ABCA12 (upper panel) and ABCA1 (lower panel), showing a 
dramatic reduction in epidermal ABCA12 expression and to a lesser extent ABCA1 
expression in the HI skin compared to NS. IHC ABCA12 and ABCA1 antibodies 
(green), nuclei stained with DAPI (blue), captured at x20 magnification. 
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4.2.3. Analysis of transient siRNA mediated ABCA12 knockdown 
The compound heterozygous ABCA12 mutation indicated that transcription of ABCA12 
would be significantly reduced, which was supported by the near absence of ABCA12 
protein in the IHC. The IHC also showed a reduction in ABCA1 in the epidermis of the 
affected and to investigate if this was due to the ablated ABCA12, through the possible 
modulation of LXRβ, an ABCA12 siRNA knockdown (KD) was performed.  
 
K17 keratinocytes were seeded in low calcium media, then 24 hours later were calcium 
shifted to up-regulate ABCA12, as previous experiments found ABCA12 protein 
expression to be insufficient for immunoblotting detection at low calcium. This is 
consistent with the localisation of ABCA12 protein in the upper layers of the epidermis. 
After 24 hours of high calcium the keratinocytes were KD by transfection with 100 nM 
(final concentration) of either ABCA12 siRNA SMARTpool, complementary for the 
two prominent transcripts of ABCA12 or non-targeting pool siRNA (NTP) 
(Dharmacon).  
 
RNA isolates were taken at 24-hour intervals and qPCR of the RT-PCR cDNA was 
analysed on a Rotorgene Q thermocycler, shown in Figure 4.7(A). A 70-90 % knock 
down of ABCA12 was recorded for day 2 and 4 compared to the NTP. By day 6, which 
was day 8 of calcium shift the keratinocytes were in the final stage of terminal 
differentiation, outlined in Figure 4.9. This ABCA12 KD was achieved through much 
optimisation and though the experiment was duplicated, it could not be triplicated.  
 
From the qPCR ABCA12 KD data, day 4 was chosen to harvest protein lysate for 
immunoblotting, shown in Figure 4.7(B). The two major ABCA12 isoforms were 
present at similar quantities in the lysate of the calcium shifted K17 cell line, at 293 and 
257 kDa. Both of these isoforms achieved an approximately 75 % KD when transfected 
with the ABCA12 siRNA. ABCA1 and LXRβ protein expression were also reduced in 
the K17 cells transfected with ABCA12 siRNA suggesting a possible down-regulation 
by the reduction of ABCA12. A reproducible robust KD of ABCA12 for multiple days 
could not be achieved, possibly due to the calcium shift and the up-regulation of the 
ABCA12.  
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Figure 4.7. Analysis of ABCA12 knock down in culture. (A) qPCR analysis of total 
ABCA12 mRNA levels during ABCA12 KD after calcium shift, in the K17 cell line. 
The data is expressed as a percentage of the relative NTP control (100%) and is the 
average of experimental repeats. (B) Immunoblotting analysis of ABCA12 siRNA KD, 
reduction of ABCA12 at the protein level on D4 of KD after calcium shift in the K17 
cell line lysate. The immunoblotting of cell lysates for ABCA1 and LXRβ also showed 
a reduction in the expression of these proteins in comparison to their non-targeting pool 
(NTP) and vinculin loading controls. Immunoblotting quantification performed on 
ImageJ64 software.  
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4.2.4. Functional analysis of cell line under calcium shift 
Transcript analysis was performed to assess the difference in the level of ABCA12 
mRNA between the HI cell line and the K17 cell lines and how this was attenuated after 
24 hours of calcium shift. As suggested from the genetic analysis of the HI cell line 
there is a significantly reduced amount of the ABCA12 transcript in the HI cell line 
compared to that of control. In the HI cell line the ABCA12 transcript was up-regulated 
under calcium shift relative to low calcium culture, though to a level still significantly 
lower than the K17 cell line, shown in Figure 4.8(A). 
 
The presence of the ABCA12 transcript in the HI cell line Figure 4.8(A), could be from 
vestigial transcription from either allele. The mutation p.Glu2264X causes a truncation 
from exon 45 and the qPCR primers were complementary to sequence within exons 
40/41 (forward primer) and 43 (reverse primer). The present ABCA12 transcript could 
have been transcribed from this allele and may have not been completely removed 
through degradation by nonsense-mediated RNA decay. A vestigial amount of the 
ABCA12 protein is present in immunoblotting of HI cell line lysate, which is possibly 
due to the epitope of the ABCA12 antibody (abcam ab98976) corresponding to aa’s 
1979-2028 present before the p.Glu2264X mutation. 
 
The alternate allele, which holds the splice site mutation c.5382-2a/g could possibly be 
transcribed to produce this vestigial amount of ABCA12 transcript. Its splice variant TA 
clone 3 from splice variant 1 has 42 bp of retained intron of which the last 15 bp 
replaces the first 15 bp of exon 35, though it does stay in frame and does not code for a 
stop codon, as shown in (Figure 4.4.). If transcribed, this transcript may not translate a 
functional ABCA12 protein, however the transcript itself may be present. 
 
Figure 4.8(B & C) shows the ABCA12 transcript up-regulated through calcium influx 
in both K17 and HI cell lines, compared to low calcium controls. The significant 
relative increase is at the 48-hour time point in the K17 cell line. In the HI cell line the 
relative increase in the ABCA12 transcript occurs earlier at 24 hours and is still elevated 
at 48 hours. Many markers of terminal differentiation are expressed at relative high 
levels after calcium shift, though ~4 days (96 hours) after calcium shift all transcription 
and translation is reduced by half prior to the completion of terminal differentiation 
(Hennings et al. 1980). 
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Figure 4.8. qPCR data showing an increase of ABCA12 mRNA expression in culture 
under calcium shift. From 0.06 mM ca2+ (low Ca) to 1.2 mM ca2+ (high Ca) (A) Cell were 
either calcium shifted or low Ca2+ media was replenished and RNA was isolated after 24 
hours from HI and K17 cell lines. Data was normalised to high Ca2+ K17 control at 100% 
(B) Calcium shift in K17 cell line (C) Calcium shift in HI cell line (B & C) Average of 
triplicates, data was normalised to individual time point low Ca2+ controls at 100%. 
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4.2.5. FACS analysis of cell death and apoptosis during calcium shift 
To analyse terminal differentiation in the HI and control cell lines under calcium shift, 
the number of dead or apoptotic cells were counted using FACS. Premature terminal 
differentiation is a well-characterised phenotype of the HI epidermis, with keratinocytes 
expressing markers of terminal differentiation in earlier layers of the enlarged stratified 
epidermis. The keratinocytes of the HI epidermis that differentiate prematurely, enter 
programmed cell death earlier and are retained as squames in the enlarged stratum 
corneum.  
 
To assess if the HI cell line would mimic these cellular phenotypes in monolayer, HI 
and K17 cell lines were calcium shifted for 8 days, as observations indicated this was 
suitable to induce complete terminal differentiation in these cell lines. FACS in control 
versus HI cell line keratinocytes, are shown as two parameter scatter plots in Figure 
4.9(A) with cells labelled with AnnexinV/DAPI for the sorting of apoptotic and alive 
cells respectively. The method described in 2.5.4. From the scatter plot the migration 
from a live population subgroup in the K17 data to a subgroup moving towards 
apoptosis and enucleated ‘dead’ in HI data is visible. 
 
In Figure 4.9(B), the analysis of the FACS data for the average percentage of alive cells 
at day 8 of calcium shift. 34.4 % of the total K17 population assessed were alive in 
comparison to 13.03 % for the HI cell line (P value of 0.092 ns). In Figure 4.9(C), cells 
counted for apoptosis resulted in a more similar population size between the K17 (11.07 
%) and HI (8.57 %). No significant result was obtained; there is a probable relationship 
between calcium-induced differentiation and an increase cell mortality in the HI cell 
line, though other time points and control cell lines would be needed to verify this. 
FACS analysis at an earlier time point of calcium shift could possibly define an 
apoptotic population.  
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Figure 4.9. FACS analysis of cell death and apoptosis (A) Scatter plot of cells 
labelled with AnnexinV/DAPI and analysed by flow cytometry. (B) Analysis of 
average % alive cell population in K17 and HI cell lines at D8 of calcium shift. (C) 
Analysis of average % apoptotic cell population in K17 and HI cell lines at D8 of 
calcium shift. (B & C) averages of triplicates.  
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4.3. Discussion 
A patient derived immortalised cell line capable of reproducing the disease phenotype 
in vitro is a valuable tool in the study of any cutaneous disease. The mortal primary cell 
line is the most accurate representation of a disease in vitro, though they are limited by 
senescence-enforced limited life spans, which can alter between passages and are more 
complex to maintain. A supply of fresh biopsy samples is difficult to obtain and comes 
with logistical and ethical concerns.  
 
Mouse models of disease are another valuable tool in the analysis of HI, as they closely 
reproduce the HI human phenotype. Four HI mouse studies have been published to date, 
all of which found that ABCA12 deficiency in mice is embryonic lethal (Zuo et al. 2008; 
Smyth et al. 2008; Yanagi et al. 2008b; Yanagi et al. 2010). The most recent paper 
grafted ABCA12(-/-)  mouse skin on to healthy mice and found an improvement in HI 
skin differentiation (Yanagi et al. 2010). Hitherto this study, mouse models had been 
unsuccessful in questioning how HI skin has gradual self-improvement post-infancy. By 
studying the development of HI skin on mice embryos the earlier publications did lead 
to the verification of: the reduction of extracellular omega-hydroxy long chain 
ceramides and the increase of their intracellular glycosylated precursor in HI (Zuo et al. 
2008); the reduction of lipid efflux and the accumulation of neutral lipids in HI mouse 
skin (Smyth et al. 2008); the loss of processed ceramides in the stratum corneum and 
the reduction of the co-localisation between these ceramides and their transporter 
ABCA12 (Yanagi et al. 2008b). 
 
An immortalised patient derived HI cell line gives the opportunity to study these and 
other HI cellular phenotypes in a human in vitro model, needing less expenditure than a 
mouse model. The genetic analysis of the patient derived HI cell line 4.2.1. defined the 
causative mutations as a truncation-producing nonsense mutation p.Glu2264X and a 
putative splice site change of c.5382-2a/g. TA cloning of this allele showed how 
multiple low affinity acceptor sites can produce several different incorrect transcripts, 
which would possibly be degraded by nonsense-mediated RNA decay. The transcript of 
TA clone 1 may possibly be translated, however with the addition of 14 amino acids 
and the deletion of 2 from the WT ABCA12 protein.  
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This mutant ABCA12 protein would possibly be a target for endoplasmic reticulum-
associated protein degradation (ERAD), due to misfolding of the tertiary structure. In 
the ER proteins undergo post-translational modifications that aid in conformational 
changes. Incorrect peptides cause aberrant protein maturation and misfolded proteins 
are degraded by proteases in the ER before they enter the Golgi. The ABC transporter, 
cystic fibrosis conductance regulator (CFTR) undergoes this degradation. The ∆F508 
mutation in CFTR makes the protein a target for ERAD and due to this degradation 
CFTR is not present at the plasma membrane of epithelial cells, the core 
pathomechanism of cystic fibrosis (Cheng 1990). 
 
The HI cell line is an important tool in furthering the understanding of HI cellular 
phenotype and for the possible use in devising therapeutic strategies. Having a full 
genetic characterisation and studies into the cell line’s in vitro behaviour especially in 
terminal differentiation, furthered in chapter 5, allows for the utilisation of the cell line. 
Not only does HI cell line suggest genotype to phenotype correlation, it has also been 
shown to differentiate and stratify in organotypic cultures produced in the Kelsell group. 
However considerations should be taken into when using any immortalised keratinocyte 
cell line. Culture seeding densities and duplication rates should be carefully monitored 
as high confluency can initiate differentiation through cell-cell contact and bias 
differentiation studies (Poumay & Pittelkow 1995). Phenotypically, in monolayer or 
organotypic culture all of the physical and biological constraints of the epidermal 
environment are not present, which should be taken into account when making 
deductions from data. 
 
Keratinocyte apoptosis during calcium shift has previously been reported as a pivotal 
mechanism involved the dysregulation of differentiation in the HI epidermis. In 
accordance with the FACS data in 4.2.5. the protein kinase B (AKT) has been shown to 
down regulate apoptosis when ABCA12 is ablated (Yanagi et al. 2011). 
 
ABCA12 packages glycoslyceramide and sphingomyelin from the cytoplasm and Golgi 
apparatus into the developing LGs of keratinocytes in the upper stratum spinosum and 
lower stratum granulosum (Sakai et al. 2007; Akiyama 2013). When ABCA12 is ablated 
an accumulation of these lipids occurs in keratinocytes of the lower stratum granulosum 
and a reduction in LGs (Mitsutake et al. 2010). In functional LGs they are accompanied 
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by other lipids, which when extruded have a range of properties that help manufacture 
the extracellular lamellar membrane structures of the lipid envelope (Uchida & Holleran 
2008). Ceramides of the lower epidermis have been shown to up-regulate the 
transcription of the gene ABCA12 through the PPARβ/δ pathway. Showing that 
ceramide precursors of ABCA12 allocrites induce the expression of the protein that will 
transport their lipid derivatives (Jiang et al. 2009). 
 
Immunohistochemistry of ABCA12 and ABCA1 in HI skin (4.2.2.) and the siRNA 
mediated ABCA12 knockdown (4.2.3.) show a reduction in the ABCA1 protein when 
ABCA12 is significantly reduced (HI biopsy) or partially reduced (ABCA12 KD). An 
aberrant ABCA12 leads to a reduction in ceramide and sphingomyelin transportation 
and in turn glucosylceramide production causing disruption to LG and lipid 
bilayer/permeability barrier formation (Mitsutake et al. 2010). It is postulated that this 
reduces the amount of intracellular cholesterol as it is sequestered by these cellular 
ultrastructures or the permeability barrier (Hanley et al. 2000; Jiang et al. 2006). This 
low intracellular cholesterol and processed ceramide concentration leads to a reduction 
in formation of oxysterols and fatty acids respectively in keratinocytes (Yanagi et al. 
2008a), which in turn causes reduced binding of oxysterols to LXRβ and lesser so, fatty 
acids to PPARβ/δ leading to a reduction in ABCA1 transcription (Jiang et al. 2006). As 
the ABCA1 protein is known to transport cholesterol in the epidermis and is down 
regulated under ABCA12 ablation there is an opportunity to re-establish this pathway 
through the activation of LXRβ.  
 
Cholesterol transportation by the ABCA1 protein does not involve the LG, but is 
integral to obtain the correct lipid envelope composition and in doing so permeability 
barrier plasticity (Feingold & Jiang 2011). The addition of cholesterol to the myriad of 
ceramides in the lipid envelope assists in the formation of gel phase lamellar structures 
that are predicted to have a greater pliability than those made from repeating 
phospholipids alone (Takahashi et al. 1996). Also without this transportation of 
cholesterol the intracellular build-up could limit the forward reaction of steroid 
sulfatase, resulting in an accumulation of cholesterol sulfate (Elias et al. 1984; 
Zettersten et al. 1998). Cholesterol sulfate stimulates involucrin expression through the 
differentiation activator protein AP-1 and inhibits serine proteases involved in 
desquamation (Feingold & Jiang 2011). 
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A ligand-bound activated LXR/PPAR nuclear hormone receptor will up-regulate the 
expression of ABCA12, ABCA1 and AP-1 (among other proteins). AP-1 is a 
transcription enhancer regulating proteins involved in terminal differentiation in 
keratinocytes (Kömüves & Hanley 2000). The expression of the AP-1 protein is also 
induced by the calcium activated EGFR by the phosphorylation of ErbB, which helps to 
drive differentiation in keratinocytes. Proteins involved in late epidermal differentiation 
such as TGM1, loricrin, SPRR and involucrin all hold AP-1 binding sites in their 
promoter regions (Hanley et al. 2000; Schmuth et al. 2004). 
 
A different proposed mechanism for the regulation of ABCA1 by ABCA12, which may 
occur in macrophages, shows the physical binding of ABCA12, ABCA1 and LXRβ 
proteins. In this system when ABCA12 is ablated, LXRβ is unable to disassociate itself 
from ABCA1 even when attenuated by receptor-ligand binding, due to heterodimer 
formation. This reduces the up-regulation by LXRβ (Fu et al. 2013). 
 
ABCA12 is involved in the formation and regulation of a differentiated epidermis 
whether it is directly or by the lipids it transports. The down-regulation of ABCA1 
through NHRs when ABCA12 is ablated may also contribute to the HI phenotype by a 
reduction of cholesterol transported to the permeability barrier or by the build up of 
cholesterol slufate. Modulation of the AP-1 promoter by either calcium shift or NHR is 
a key regulatory pathway in epidermal differentiation, a process, which is dysregulated 
in HI skin. In HI the reduction of ceramide transportation into LG, which supply the 
constituents of the permeability barrier is the core pathomechanism of the disease. The 
premature terminal differentiation of the epidermis and the retention of squames in the 
enlarged stratum corneum due to a deficiency in protease transportation in HI are either 
a direct cause of the malformed permeability barrier, or a dysregulated/compensatory 
pathway from the aberrant ABCA12 or both. 
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4.4. Summary 
In this chapter the patient derived HI cell line was characterised by a range of molecular 
genetic and in vitro techniques. Analysis of the complex splice site mutation assessed 
the use of low affinity acceptor sites by the spliceosome. The in vitro studies gave an 
indication to the cellular pathways disrupted by this compound heterozygote mutation 
and to what extent the HI cellular phenotype was reproduced in monolayer.  
 
Chapter 5 will further the analysis of the pathway disrupted in the HI patient derived 
cell line. Calcium shift will be used to assess how the premature terminal differentiation 
phenotype manifests in HI cell line by the evaluation of markers of epidermal terminal 
differentiation. This will be done in combination with the application of NHR agonists 
as a potential strategy to recover a down-regulated ABCA1 and the possible modulated 
differentiation.   
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5 Chapter 5: A Possible therapeutic strategy for 
Harlequin Ichthyosis utilising Nuclear 
Hormone Receptor Agonists 
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5.1. Introduction 
The formation and regeneration of the epidermis complete with a functional 
permeability barrier and cornified enveloped is a multifaceted process, which involves 
the regulation of a magnitude of proteins. This extremely complex regulatory pathway 
is initiated by the calcium gradient, which triggers differentiation of keratinocytes by 
the phosphorylation of the ErbB receptors, which leads to the up-regulation of AP-1 and 
a full range of successive transcriptional activation (Hanley et al. 2000; Saeki et al. 
2012). AP-1 also contains a hormone response element located close to its promoter 
region, which nuclear hormone receptors can bind to and induce transcription (Edwards 
et al. 2002). PPARs and LXRs are nuclear hormone receptors, which are involved in the 
promotion of differentiation in keratinocytes. When activated by specific ligands PPAR 
and LXR promote the transcription of a range of proteins including AP-1, ABCA12 and 
ABCA1, leading to an increase in lipid synthesis and LG formation (Feingold 2007). 
The transcription enhancer protein AP-1, which can be induced through calcium shift or 
by nuclear hormone receptor agonists in keratinocytes, promotes the transcription of 
epidermal differentiation proteins including involucrin, SPRR, TGM1 and loricrin, 
which all contain AP-1 binding sites (Hanley et al. 2000; Schmuth et al. 2004; Kömüves 
& Hanley 2000). 
 
The loss of ABCA12 in HI skin appears to affect the process of keratinocyte 
differentiation. Proteins expressed specifically during normal terminal keratinocyte 
differentiation are dysregulated in HI (Figure 5.1.) (Thomas et al. 2009b). They are 
expressed early in HI epidermis and localise to the stratum spinosum and stratum 
basale, characteristic of a premature terminal differentiation phenotype (Thomas et al. 
2009a). 
 
ABCA1 is the membrane transport protein responsible for cholesterol efflux in 
keratinocytes (Huang et al. 2001). Cholesterol is a fundamental constituent of the cell 
membrane and is also present in the extracellular compartments of the upper layers of 
the epidermis where it is involved in the formation of the lipid envelope lamellae which 
make up the permeability barrier that limits TEWL (Schurer & Elias 1991). Loss of 
ABCA12 expression has been shown to down regulate the ABCA1 protein, shown in 
4.2.2. and 4.2.3. and other publications (Schmitz & Langmann 2005; Fu et al. 2013). 
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The activation of LXRs and PPARs through the binding of oxysterols and fatty acids 
induces a significant increase in transcript and protein levels of ABCA1. LXRβ has 
been shown to induce the greatest regulatory affect in human foreskin keratinocytes and 
in murine epidermis (Jiang et al. 2006). Coinciding with this investigation on the effect 
of LXR and PPAR agonists on keratinocytes, it was shown through IHC that PPARβ/δ 
activation stimulates general epidermal differentiation in mice and lipid accumulation in 
keratinocytes (Schmuth, Haqq, et al. 2004). Also cholesterol efflux was shown to be 
increased through the application of the LXRβ agonist TO901317 in ABCA12 knock-
out mouse skin-derived fibroblasts, which had a significant decrease of the ABCA1 
transcription compared to WT (Smyth et al. 2008).  
 
This chapter aims to explore the premature terminal differentiation phenotype in the 
immortalised HI keratinocytes. Then, the application of LXRβ and PPARβ/δ agonists 
was explored to assess their impact on the protein expression of ABCA1 in HI 
keratinocytes. 
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Figure 5.1. Schematic diagram of the epidermis and localisation of markers of 
epidermal differentiation. Differentiation modifies keratinocyte morphology, cellular 
content and function producing the permeability barrier and cornfield envelope. The 
change in protein content is highlighted on the right by arrows indicating the expression 
of: K14, a keratin marker of proliferation in the epidermis, K10, a keratin present in the 
supra basal layers of the epidermis, expressed at the initiation of differentiation and the 
terminal differentiation markers, TGM1, involucrin and loricrin present in the cornified 
envelope. BM, basement membrane; SB, stratum basale; SS, stratum spinosum; SG, 
stratum granulosum; SC, stratum corneum. 
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5.2. Results 
5.2.1. Immunohistochemistry of terminal differentiation markers in the HI skin 
IHC of normal and HI patient (from which the HI cell line was derived) skin biopsies 
with antibodies targeting markers of late epidermal differentiation revealed an abnormal 
expression profile of the terminal differentiation markers TGM1, involucrin and keratin 
2e (K2E) in the epidermis of the HI skin (Figure 5.2.). The uppermost panel shows the 
expression of the cornified envelope cross-linking protein TGM1. Coinciding with its 
function, TGM1 predominately localised to the stratum corneum in the epidermis of the 
normal skin. However in the epidermis of the HI skin TGM1 localised to the lower 
stratum granulosum and was continuously expressed from this layer onwards with a 
possibly membranous localisation. Involucrin was expressed in the stratum granulosum 
and stratum corneum in the epidermis of the normal skin, in contrast to the epidermis of 
the HI skin where it was present in all suprabasal layers. K2E is a marker of the upper 
stratum spinosum and stratum granulosum keratinocytes of the fully developed 
epidermis (Smith et al. 1999). K2E showed an expression consistent to this in the 
epidermis of the normal skin, but was present in all suprabasal layers in the HI 
epidermis, although at a possibly lower level of expression. The negative controls of the 
immunohistochemistry are in Figure A1.1. 
 
This analysis of the HI patient skin confirms the previously reported early expression of 
these late differentiation markers in HI skin (Thomas et al. 2009a). This may be due to 
early gene activation or a physical response due to the incorrect development of the 
epidermis. The premature expression of this range of differentiation markers is unique 
to HI, although other ichthyoses do present with a myriad of differentiation defects. For 
example, epidermolytic ichthyosis has an irregular staining pattern for K10 in 
suprabasal layers of the epidermis, which combined with defective profilaggrin 
processing generates corneocytes prematurely and hyperkeratosis (Ishida-Yamamoto et 
al. 1994). Both X-linked ichthyosis and NBCIE (chapter 3) display a disruption to 
epidermal formation and desquamation, which produce a dramatically thickened 
stratum corneum, but do not alter the expression of terminal differentiation markers 
(Zettersten et al. 1998; Epp et al. 2007). 
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Figure 5.2. Immunohistochemistry of HI patient and normal skin. Immunostaining 
against TGM1 (upper panel), involucrin (middle panel) and K2e (lower panel). Showing 
a dispersed expression with a premature localisation for these terminal differentiation 
markers in the enlarged stratification of the HI skin compared to NS. Immunostaining 
(green), nuclei stained with DAPI (blue), captured at x20 magnification. 
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5.2.2. Activation of PPARβ/δ and LXRβ increases ABCA1 mRNA and protein 
expression in the HI cell line 
In chapter 4, reduced ABCA1 protein expression was observed by IHC in HI skin 
compared to control  (4.2.2.) and also after ABCA12 siRNA knockdown in control 
keratinocytes by Western blotting (4.2.3.). To assess the efficacy of the PPAR and LXR 
activation in the renewal of ABCA1 protein expression in the HI cell line, small 
molecule agonists complementary to the PPARβ/δ and LXRβ nuclear hormone 
receptors were used. These subtypes were chosen as PPARβ/δ is expressed in the 
epidermis at a greater concentration than either of the α and γ PPAR isoforms 
(Westergaard et al. 2003). The LXR subtypes α and β are expressed equally in the 
epidermis, although as with PPARβ/δ, LXRβ appears to have the greatest regulatory 
effect in the epidermis (Chen et al. 2011). 
 
The PPARβ/δ agonist (lipophilic acetic acid GW0742) and the LXRβ agonist 
(benzensulfonamide TO901317) were optimised to have a final concentration of 8 and 
10 µM respectively. Similarly, these were the optimal concentrations used in a previous 
study to up-regulate cholesterol sulfotransferase in keratinocytes (Jiang et al. 2005). The 
immortalised HI keratinocytes were incubated with high or low calcium media for 24 
hours before both cultures were incubated with either the vehicle control, 8 µM of the 
PPARβ/δ agonist or 10 µM the LXRβ agonist for a further 48 hours. At the 48 hour 
time point, total RNA was isolated and qPCR of the RT-PCR cDNA was analysed on a 
Rotorgene Q thermocycler, shown in Figure 5.3(A). Data is expressed as fold increase 
of DMSO at 1 fold expression, PPARβ/δ agonist at low calcium increased ABCA1 
mRNA fold expression to 3.3 and 2.4 in high calcium. The LXRβ agonist increased the 
ABCA1 mRNA fold expression to 5.7 and 5.0 in low and high calcium respectively. All 
three ABCA1 transcripts are up-regulated at similar levels by the LXRβ agonist in 
keratinocytes (Jiang et al. 2006). 
 
The application of the PPARβ/δ and LXRβ agonists on the HI cell line was performed 
in keeping with the conditions of the calcium shift experiment (2.3.5. and 2.3.6.). After 
24 hours of calcium shift, the HI keratinocytes were incubated with either the vehicle 
control, 8 µM of the PPARβ/δ agonist or 10 µM the LXRβ agonist for 72 hours with 
whole cell lysates taken every 24 hours. The representative Western blot and subsequent 
densitometry to determine the protein expression of ABCA1 are shown in Figure 
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5.3(B). The densitometry values are mean averages of repeats (n=4) and statistical 
significance was deduced through t-test against vehicle control after loading control 
normalisation. * P < 0.05 ** P < 0.01 *** P < 0.001 
 
These results suggest that the level of ABCA1 transcript is not modulated by calcium 
shift, which corroborates with the IHC of normal skin (4.2.2.) that shows ABCA1 
protein present in the basal layers of the epidermis and with a previous study (Jiang et 
al. 2006). They show that activation of PPARβ/δ and LXRβ up-regulates mRNA and 
protein levels of ABCA1 in the patient derived HI cell line. After 48 hours of exposure 
to the agonists, LXRβ produces a greater up-regulation of both ABCA1 mRNA and 
protein compared to that of PPARβ/δ activation. The activation of PPARβ/δ showed a 
significant (**) increase compared to the vehicle control in ABCA1 protein consistently 
for each of the 3 days following the application of the GW0742 agonist. The activation 
of LXRβ showed a significant increase in ABCA1 protein over the vehicle control for 
the 3 days; D1*, D2*** and D3**, which was greater than PPARβ/δ activations on days 
2 and 3.  
 
In Figure 5.3(A & B) DMSO is the vehicle control that GW0742 (PPARβ/δ) and 
TO901317 (LXRβ) were suspended in at a concentration of 0.5 %. Multiple stocks of 
HI and K17 cells were used to for these experiments and their repeats. Supplementary 
data for the immunoblotting for ABCA1 after the NHR activation with agonist 
application shows an up-regulation in the levels of ABCA1 in a range of immortalised 
keratinocyte cell lines in A1.2.  
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Figure 5.3. PPAR and LXR activation increases ABCA1 mRNA and protein expression. (A) 
Increase of ABCA1 mRNA expression, HI cell line keratinocytes under went calcium shift, from 0.06 
mM ca2+ (low Ca) to 1.2 mM ca2+ (high Ca) then incubated with either vehicle control (DMSO), 
PPARβ/δ agonist (PPAR) or LXRβ agonist (LXR) for a further 48 hours. GAPDH was used as an internal 
control and qPCR data was normalised to the DMSO control for respective calcium concentrations and 
plotted as an average fold expression of the repeats. (B) Immunoblotting analysis of ABCA1 under 
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treatment, HI cells were calcium shifted for 24 hours, then incubated with either vehicle control (DMSO), 
PPARβ/δ agonist (PPAR agonist) or LXRβ agonist (LXR) agonist for 1-3 days. Western blot was 
performed on whole cell lysate and densitometry values are shown as a mean ± SD percentage of 4 
repeats. Data was normalised to DMSO controls at 100% for individual time points and to their respective 
vinculin loading control.  
 
5.2.3. The modulation of terminal differentiation markers under calcium shift and 
the application of agonists 
Markers of differentiation in the epidermis are expressed at discreet points along the 
path of a keratinocyte differentiation, as highlighted in Figure 5.1. The premature 
expression of markers of late differentiation in the HI epidermis indicates a disruption to 
this differentiation in the initial stages of the process, which occur in the lower 
epidermis under an increase to the calcium concentration.  
 
To continue the investigation of premature terminal differentiation from the IHC of 
Figure 5.2. markers of differentiation were to be assessed under calcium shift in the HI 
and control cell lines to evaluate if this HI characteristic is present in monolayer. A 
modulation in HI cell line differentiation marker protein levels would suggest the 
premature terminal differentiation phenotype is not a direct consequence of a physical 
malformation in the epidermis, for example a malformed permeability barrier. To assess 
this the terminal differentiation markers, involucrin, TGM1 and loricrin would be 
analysed alongside the suprabasal differentiation marker K10 and the marker of 
epidermal proliferation K14. The application of the PPARβ/δ and LXRβ agonists on the 
HI cell line would then investigate the activation of these regulatory pathways on the 
disrupted protein levels of differentiation markers. 
 
 
Involucrin  
Involucrin is a well-documented marker of late differentiation in the epidermis, where it 
is present in the stratum granulosum and stratum corneum. In HI skin, involucrin 
localises prematurely to the suprabasal layers. Involucrin mRNA has been shown to be 
up-regulated through AP-1 by both calcium shift and LXRβ activation in control 
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keratinocytes (Hanley et al. 2000). When activated in unison these factors have an 
accumulative on the level of involucrin mRNA.  
 
The HI and K17 keratinocytes were seeded for 24 for hours in low calcium conditions 
before calcium shifted for 5 days with 24 hours separating time points, as described in 
2.3.5. The low calcium control for each time point was used to distinguish between the 
modulation of differentiation markers by calcium shift and other in vitro factors. Whole 
cell lysates were taken at each time point for high and low calcium variables for both 
cell lines. The representative involucrin Western blots and densitometry to determine 
protein expression are shown in Figure 5.4(A). The densitometry values are mean 
averages of repeats (n=3) and a t-test was used to establish statistical significance 
against relative low calcium controls following loading control normalisation. * P < 
0.05 ** P < 0.01 *** P < 0.001 
 
Figure 5.4(A) shows an accumulation of the involucrin protein in the K17 cell line over 
the 5 days of calcium shift in the high calcium culture compared to that of the low 
calcium. The HI cell line has an overall greater up-regulation of involucrin than the K17 
cell line under calcium shift for each of the 5 days. Days 1-3 (D1*, D2** and D3*) 
show a significant up-regulation of involucrin from the calcium shift of HI 
keratinocytes compared to the calcium shift of K17 keratinocytes. Thus, involucrin 
expression was up regulated earlier and to a greater concentration under calcium shift in 
the HI cell line in comparison to the K17 cell lines, in keeping with a premature 
terminal differentiation phenotype. 
 
The application of the PPARβ/δ and LXRβ agonists on the HI cell line was performed 
as described previously (5.2.2.), immunoblotting and densitometry was performed on an 
average of 3 repeats for involucrin, as shown in Figure 5.4(B). In DMSO controls the 
level of involucrin protein increases over the 3 days when normalised to their respective 
loading control. These are equivalent to days 2, 3 and 4 of the calcium shift in the HI 
cell line and show the same pattern of involucrin protein expression up-regulation. This 
indicates that the DMSO is not having an obvious detrimental affect on the 
keratinocytes. A significant (D2*) down-regulation of involucrin protein expression was 
shown for both PPARβ/δ and LXRβ agonists 48 hours after their application. Only the 
LXRβ agonist showed a significant (D3*) down-regulation after 72 hours, although the 
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general trend for both agonists was a down-regulation of involucrin protein expression 
in the HI cell line for the 3 time points. This suggests that agonist application in the HI 
call line is reducing the level of the prematurely expressed involucrin. 
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Figure 5.4. Western blot analysis of the modulation of involucrin protein expression under calcium 
shift and treatment. (A) Immunoblotting of involucrin under calcium shift, HI and K17 cell line 
keratinocytes were either calcium shifted or low Ca2+ media was replenished, 0.06 mM ca2+ (low Ca) to 
1.2 mM ca2+ (high Ca). Whole cell lysates were taken every 24 hours for 5 days after calcium shift. 
Densitometry of involucrin western blot was normalised by the internal GAPDH loading control and to 
the individual time point low Ca control and plotted as a mean ± SD percentage expression of the 3 
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experimental repeats. (B) Immunoblotting analysis of involucrin under treatment, HI cells were calcium 
shifted for 24 hours, then incubated with either vehicle control (DMSO), PPARβ/δ agonist (PPAR 
agonist) or LXRβ agonist (LXR) agonist for 1-3 days. Western blot was performed on whole cell lysate 
and densitometry values are shown as a mean ± SD percentage of 3 repeats. Data was normalised to 
DMSO controls at 100% for individual time points and to their respective GAPDH loading control. 
 
 
TGM1 
TGM1 is a marker of late epidermal differentiation and an enzyme that cross links the 
structural proteins of the cornified envelope in the stratum corneum (Hennings et al. 
1981). In the HI epidermis TGM1 localises prematurely to the lower stratum 
granulosum. TGM1 has been shown to be up regulated in control keratinocytes, which 
have undergone calcium shift and been treated with PPARα and LXRβ agonists (Hanley 
et al. 1998; Hanley et al. 2000). The conditions and analysis of TGM1 protein 
expression under calcium shift and the application of PPARβ/δ and LXRβ agonists were 
performed as described for the analysis of involucrin.  
 
The analysis of TGM1 in the comparative calcium shift of the HI and K17 cell lines is 
shown in Figure 5.5(A). Compared to their low calcium controls, the HI cell line 
produced a greater up-regulation of TGM1 than that of the K17 cell line, for 3 days 
following the calcium shift. After statistical analysis of repeats TGM1 protein 
expression at D1* and D3* was shown to be significantly greater in the HI cell line, 
which is possibly an in vitro consequence of the premature terminal differentiation 
phenotype. The application of either PPARβ/δ or LXRβ agonists yielded no significant 
modulation of TGM1 protein expression over the 4 days following treatment of the HI 
cell line keratinocytes, as shown in Figure 5.5(B). * P < 0.05 
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Figure 5.5. Western blot analysis of the modulation of TGM1 protein expression under calcium 
shift and treatment. (A) Immunoblotting of TGM1 under calcium shift, HI and K17 cell line 
keratinocytes were either calcium shifted or low Ca2+ media was replenished, 0.06 mM ca2+ (low Ca) to 
1.2 mM ca2+ (high Ca). Whole cell lysates were taken every 24 hours for 5 days after calcium shift. 
Densitometry of TGM1 western blot was normalised by the internal GAPDH loading control and to the 
individual time point low Ca control and plotted as a mean ± SD percentage expression of the 3 
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experimental repeats. (B) Immunoblotting analysis of TGM1 under treatment, HI cells were calcium 
shifted for 24 hours, then incubated with either vehicle control (DMSO), PPARβ/δ agonist (PPAR 
agonist) or LXRβ agonist (LXR) agonist for 1-4 days. Western blot was performed on whole cell lysate 
and densitometry values are shown as a mean ± SD percentage of 3 repeats. Data was normalised to 
DMSO controls at 100% for individual time points and to their respective GAPDH loading control. 
 
  
Loricrin 
Loricrin is a component of the cornified envelope in the stratum corneum and is 
expressed in differentiated keratinocytes. Select PPARγ agonists, when applied to 
control keratinocytes under calcium shift have been shown to up regulate both the 
mRNA and protein levels of loricrin (Yan et al. 2015). In a ABCA12 KO HI mouse 
model the level of the loricrin protein in the epidermis had no significant modulation in 
comparison to WT mice at the same developmental stage (Smyth et al. 2008). The 
analysis of loricrin protein expression under calcium shift and the application of 
PPARβ/δ and LXRβ agonists were performed as described for the analysis of 
involucrin. 
 
In Figure 5.6(A & B) the immunoblotting of loricrin exhibits a double band, only the 
smaller of the two bands, which was present in both cell lines, was used for the 
densitometry quantification. A cDNA was reverse transcribed from RNA isolated from 
the HI and K17 cell lines to evaluate the genetic origins of this double band, Figure 5.7. 
Under calcium shift both HI and K17 keratinocytes showed a similar up-regulation of 
loricrin protein levels relative to low calcium controls. This up-regulation of loricrin 
was plotted as HI against K17 and showed only minor discrepancies in loricrin protein 
levels between the two cell lines for each time point, as shown in Figure 5.6(A). 
Loricrin protein expression exhibited no significant modulation for the 4 days following 
the application of either PPARβ/δ or LXRβ agonists on HI cell line keratinocytes, as 
shown in Figure 5.6(B). 
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Figure 5.6. Western blot analysis of the modulation of loricrin protein expression under calcium 
shift and treatment. (A) Immunoblotting of loricrin under calcium shift, HI and K17 cell line 
keratinocytes were either calcium shifted or low Ca2+ media was replenished, 0.06 mM ca2+ (low Ca) to 
1.2 mM ca2+ (high Ca). Whole cell lysates were taken every 24 hours for 5 days after calcium shift. 
Densitometry of loricrin western blot was normalised by the internal vinculin loading control and to the 
individual time point low Ca control and plotted as a mean ± SD percentage expression of the 3 
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experimental repeats. (B) Immunoblotting analysis of loricrin under treatment, HI cells were calcium 
shifted for 24 hours, then incubated with either vehicle control (DMSO), PPARβ/δ agonist (PPAR 
agonist) or LXRβ agonist (LXR) agonist for 1-4 days. Western blot was performed on whole cell lysate 
and densitometry values are shown as mean ± SD percentage of 3 repeats. Data was normalised to 
DMSO controls at 100% for individual time points and to their respective vinculin loading control. 
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Figure 5.7. Electrophoresis gel of loricrin size variants analysis in HI and K17 
cell lines. PCR of 583 bp section of exon 2 of the loricrin gene. Amplification of the 
highly repetitive glycine loop domains, producing 3 distinct bands from the PCR of 
cDNA of both cell lines. Table A1.5. Primers used for screening loricrin variants. 
Loricrin allelic size variants 
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The amplification of the 583 bp of exon 2 (1196 bp), as shown in Figure 5.7. produces 
three distinct fragments in the HI and K17 cell lines and a single band in the genomic 
control. The middle fragment was produced by the amplification of an allele containing 
a sequence of WT length for this part of exon 2. The smallest fragment is possibly due 
to the amplification of an allele with deletions within this highly repetitive region. Exon 
2 is the only coding exon in the loricrin gene and is known to contain polymorphic 
deletions within the glycine rich loop domains (Yoneda et al. 1992). The glycine loops 
are known to be flexible structures within the loricrin protein, which aids to the 
plasticity of the cornified envelope, as loricrin makes up 50% of the protein content in 
the cornified envelope (Hohl et al. 1991).  
 
K10 
 
K10 is part of the type 1 cytokeratin family and forms heterodimer intermediate 
filaments with K1 in the suprabasal keratinocytes of the epidermis. In a HI KO mouse 
model, K10 was up regulated in basal layer keratinocytes compared to control mice 
(Smyth et al. 2008). The analysis of the protein expression of K10 under calcium shift 
and during the application of PPARβ/δ and LXRβ agonists was performed as described 
in the analysis of involucrin. 
 
The first two days following calcium shift indicated a significant up-regulation (D1** 
and D2**) in the HI cell line of the protein expression of K10 in comparison to the K17 
cell line, after normalisation with low calcium controls, shown in Figure 5.8(A). 
Showing a premature expression of a marker of suprabasal keratinocyte differentiation 
marker in the HI cell line. It should be noted that variations in the number and size of 
the glycine loop repeats present in the V2 subdomain can lead to broad size 
polymorphism of K10 (Korge et al. 1992). As with loricrin this can lead to double 
banding in the immunoblotting of the K10 protein as seen in the K17 cell line, though 
this may also be caused by heterodimer formation of keratins. 
 
24 hours after treatment a significant (D1* and D1**) down-regulation of K10 protein 
expression was shown for PPARβ/δ and LXRβ agonists respectively in the HI cell line. 
The down-regulation continued for until 48 hours post treatment, though only the 
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PPARβ/δ agonist was a significant change at D2*, as shown in Figure 5.8(B). This 
suggest, in corroboration with the involucrin results that the application of these specific 
nuclear hormone receptor agonists down-regulates the K10 protein level, which is 
prematurely expressed under calcium shift in the HI cell line. * P < 0.05 ** P < 0.01  
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Figure 5.8. Western blot analysis of the modulation of K10 protein expression under calcium shift 
and treatment. (A) Immunoblotting of K10 under calcium shift, HI and K17 cell line keratinocytes were 
either calcium shifted or low Ca2+ media was replenished, 0.06 mM ca2+ (low Ca) to 1.2 mM ca2+ (high 
Ca). Whole cell lysates were taken every 24 hours for 5 days after calcium shift. Densitometry of K10 
western blot was normalised by the internal GAPDH loading control and to the individual time point low 
Ca control and plotted as a mean ± SD percentage expression of the 3 experimental repeats. (B) 
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Immunoblotting analysis of K10 under treatment, HI cells were calcium shifted for 24 hours, then 
incubated with either vehicle control (DMSO), PPARβ/δ agonist (PPAR agonist) or LXRβ agonist (LXR) 
agonist for 1-3 days. Western blot was performed on whole cell lysate and densitometry values are shown 
as a mean ± SD percentage of 3 repeats. Data was normalised to DMSO controls at 100% for 
individual time points and to their respective GAPDH loading control. 
 
 
K14 
 
K14 is one of the main structural proteins expressed by the proliferating keratinocytes 
of the stratum basal. K14 expression is not modulated in control keratinocytes under 
either PPAR or LXR agonists. The analysis of K14 in HI and K17 keratinocytes under 
calcium shift and the application of PPARβ/δ and LXRβ agonists on the HI cell line 
were undertaken as described for the analysis of involucrin. 
 
Both the HI and K17 cell lines showed no modulation of K14 under calcium shift. They 
did however show an increase in K14 protein expression in the low calcium controls 
over the 5 days, in keeping with the role of K14 in proliferation of undifferentiated 
keratinocytes. In comparison between the two cells there was no significant of K14 
expression, as shown in Figure 5.9(A). Shown in Figure 5.9(B), K14 protein 
expression exhibited no significant modulation for the 3 days following the application 
of either PPARβ/δ or LXRβ agonists on HI cell line keratinocytes.  
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Figure 5.9. Western blot analysis of the modulation of K14 protein expression under calcium shift 
and treatment. (A) Immunoblotting of K14 under calcium shift, HI and K17 cell line keratinocytes were 
either calcium shifted or low Ca2+ media was replenished, 0.06 mM ca2+ (low Ca) to 1.2 mM ca2+ (high 
Ca). Whole cell lysates were taken every 24 hours for 5 days after calcium shift. Densitometry of K14 
western blot was normalised by the internal GAPDH loading control and to the individual time point low 
Ca control and plotted as a mean ± SD percentage expression of the 3 experimental repeats. (B) 
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Immunoblotting analysis of K14 under treatment, HI cells were calcium shifted for 24 hours, then 
incubated with either vehicle control (DMSO), PPARβ/δ agonist (PPAR agonist) or LXRβ agonist (LXR) 
agonist for 1-3 days. Western blot was performed on whole cell lysate and densitometry values are shown 
as a mean ± SD percentage of 3 repeats. Data was normalised to DMSO controls at 100% for 
individual time points and to their respective GAPDH loading control. 
 
 
 
5.3. Discussion 
The up-regulation of AP-1 by the binding of specific agonists to nuclear hormone 
receptors has been shown to increase the mRNA and proteins levels of many of the 
markers of epidermal terminal differentiation. This up-regulation of multiple genes 
occurs at high calcium conditions either in vivo within the upper layers of the epidermis 
or in vitro when media calcium concentrations are changed from low to high calcium. 
The calcium gradient in the epidermis induces the activity of protein kinase C, which 
through the AP-1 transcriptional complex increases the expression of involucrin, TGM1 
and K10 among others proteins of epidermal differentiation (Denning et al. 1995; Rossi 
et al. 1998). Calcium shift and the activation of nuclear hormone receptors can up 
regulate the transcription of AP-1 independently or simultaneously, when coinciding 
with one another, an accumulative affect has been observed (Hanley et al. 1998; Hanley 
et al. 2000). 
 
The calcium shift investigation of HI and K17 cell lines describes an in vitro model of 
premature terminal differentiation from the expression of differentiation markers and 
the positive control, shown in 5.2.3. Both HI and K17 cell lines showed an up-
regulation of involucrin, TGM1 and K10 for the 5 days of calcium shift and 
comparatively the HI cell line produced a significant up-regulation. There was no 
comparative modulation for loricrin as both cell lines showed an equal up-regulation of 
loricrin under calcium shift, which corroborates with the non-modulated loricrin 
expression of HI KO murine epidermis (Smyth et al. 2008). A combination of up-
regulation and earlier expression is present in the HI cell line as the first 3 days is when 
the differentiation markers profile expression has the most apparent and significant 
difference between the HI and K17 cell lines.  
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This suggests, in confirmation with the IHC of HI skin (5.2.1.) that an aberrant 
ABCA12 leads to an early or premature activation of these late differentiation markers. 
This product of the dysregulation in the HI epidermis is possibly a consequence of 
atypical promotion of transcriptional regulators in keratinocytes.  
 
The calcium shift of the HI patient derived cell line produces a premature and 
exaggerated response in the markers epidermal differentiation. From studies on the 
activation of nuclear hormone receptors and calcium shifting in control keratinocytes 
the activation of the PPARβ/δ and LXRβ nuclear hormone receptors in combination 
with high calcium should produce a putative accumulation of AP-1 induction and thus 
up-regulation of markers with AP-1 binding domains. However the application of the 
agonists GW0742 (PPARβ/δ) and TO901317 (LXRβ) on the HI cell line significantly 
reduced the protein expression of involucrin and K10. There was no modulation of 
TGM1 over the time course following the application of agonists, though it was up 
regulated by calcium shift. Loricrin showed no modulation through either calcium shift 
or agonist application, though there was discrepancies between isoform expression 
levels.  
The electrophoresis gel of loricrin size variants indicates the presence of polymorphisms 
within the glycine loop structures of the loricrin proteins in both cell lines, shown in 
Figure 5.7. (Hohl et al. 1991).  Due to the high percentage homology of the smaller two 
fragments amplified from different alleles there is a predisposition for heteroduplex 
formation during amplification (Yoneda et al. 1992). Heteroduplexes take more time to 
migrate through the matrix of an electrophoresis gel due to the uncomplimentary base 
pairs forming a kink in the backbone of the DNA molecule. This heteroduplex 
formation is the possible mechanism for the largest fragment present in both cell lines. 
To assess this possible heteroduplex formation, cloning the largest fragment should 
produce clones containing only the two smaller fragments if a heteroduplex is present. 
 
ABCA1 expression was up-regulated through the LXRβ agonist TO901317 in human 
foreskin keratinocytes and through topical application, mouse epidermis (Jiang et al. 
2006). This agonist was also shown to up regulate cholesterol transportation in 
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fibroblasts derived from a HI mouse model, which exhibited a decrease in ABCA1 
transcription compared to WT mice (Smyth et al. 2008). In the HI cell line the 
activation of PPARβ/δ or LXRβ induced an increase of ABCA1 mRNA in low or high 
calcium and a significant increase in the level of the ABCA1 protein over 72 hours. 
This suggests that PPARβ/δ and more so LXRβ activation could be used to re-establish 
ABCA1 expression in HI keratinocytes. 
 
The ABCA12 protein packages glycoslyceramide from the cytoplasm and Golgi 
apparatus into the developing LGs of keratinocytes in the lower stratum granulosum and 
when ABCA12 is ablated these ceramides accumulate in the cytoplasm (Sakai et al. 
2007; Akiyama 2013). Ceramides like oxysterols have a regulatory, alongside their 
structural, function in keratinocytes (Galadari et al. 1998). Ceramides activate PPARβ/δ 
in the epidermis, which has been shown to stimulate differentiation (Schmuth, Haqq, et 
al. 2004).  
 
The efflux of cholesterol in keratinocytes is maintained by ABCA1, an increase in free 
cholesterol was shown in fibroblasts derived from ABCA12 aberrant mice (Smyth et al. 
2008). The concentration of free cholesterol reduces between the stratum basale and the 
stratum granulosum and is then re-established in the stratum corneum in the epidermis 
of normal skin (Lampe et al. 1983). A metabolic pathway that reduces the concentration 
of free cholesterol in the lower layers of the epidermis is the formation of cholesterol 
sulfate. This reaction is catalysed in the epidermis by cholesterol sulfotransferase type 
2B isoform 1b (SULT2B1b) and the product, cholesterol sulfate, is a key regulator of 
differentiation as well as desquamation and lipid envelope formation (Hanley et al. 
2001). 
 
The ablation of ABCA12 and down-regulation of ABCA1 leads to an accumulation of 
free cholesterol and ceramides in the cytosol of HI keratinocytes. The cholesterol 
derivative, cholesterol sulfate, induces AP-1 independently of nuclear hormone 
receptors and increases the expression of epidermal differentiation proteins, which hold 
AP-1 regulatory sites (Hanley et al. 2001). This dysregulated activation would coincide 
with the initiation of calcium-induced differentiation, which cumulatively may produce 
the premature terminal differentiation phenotype in the HI epidermis and the early up-
regulation of these proteins in the HI cell line under calcium shift. The formation of 
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cholesterol from cholesterol sulfate in the epidermis is catalyzed by the enzyme steroid 
sulfatase. Steroid sulfatase is aberrant in patients with X-linked ichthyosis, which have a 
build up of cholesterol sulfate in the suprabasal layers of the epidermis (Williams & 
Elias 1981). In X-linked ichthyosis the dysregulation of cholesterol sulfate causes a 
disruption to epidermal formation, desquamation and the permeability barrier, showing 
the importance of cholesterol sulfate regulation in the epidermis (Zettersten et al. 1998).  
Upon treatment of the HI cell line with the PPARβ/δ and LXRβ agonists, up-regulate 
ABCA1 and re-establish cholesterol efflux, reducing the amount of free cholesterol for 
cholesterol sulfate synthesis. From the results obtained in this chapter, AP-1 induction 
from the accumulation of calcium shift and cholesterol sulfate is greater than that of 
calcium shift and PPARβ/δ and LXRβ activation, which occurs under the application of 
agonists to differentiating HI keratinocytes. This would account for the significant 
increase in ABCA1 and the significant decrease of involucrin and K10 protein levels 
exhibited during premature terminal differentiation by the application of PPARβ/δ and 
LXRβ agonists.  
 
 
5.4. Summary 
This chapter shows how the patient derived HI cell line under, calcium shift, shows 
similar behaviour to the HI skin, shown by IHC and previous investigations into the 
premature terminal differentiation phenotype of the HI epidermis. The application of 
PPARβ/δ and LXRβ agonists on the HI cell line exhibited an up-regulation on the 
transcript and protein levels of the possibly reduced ABCA1. This application also 
reduced specific markers of differentiation, which were activated prematurely in the HI 
cell line under calcium shift. 
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6 Chapter 6: Final Discussion and Future Work 
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6.1. Background 
The ABC transporter, ABCA12, transports ceramides into LGs in keratinocytes under 
calcium efflux in the upper layers of the epidermis. The extent to which this mechanism 
enables the correction function of the epidermis is apparent in HI epidermis where no 
functional ABCA12 is present. However, the HI epidermis not only presents with a 
defective transportation of ceramides but rather a range of functional impairments 
including premature terminal differentiation and deregulation of desquamation due to 
the impaired transportation of proteases and TEWL.  
 
This thesis focused firstly on expanding the genetic role of ABCA12 in HI through the 
molecular diagnostics of HI patients and the genetic characterisation of the patient 
derived HI cell line. Secondly on the functional role of ABCA12 in HI through the 
analysis of the functional representation of the HI cell line and the application of 
nuclear hormone receptor agonists.  
 
6.2. Mutation analysis of ABCA12 and the genotype – phenotype 
relationship 
Utilising a range of molecular techniques, causative mutations were located in the gene 
ABCA12 for four out of the five cases clinically diagnosed as HI at birth. The other 
clinical diagnosis was reassessed to be NBCIE, a less severe ARCI after a homozygous 
mutation in the gene ALOX12B was identified (Bland et al. 2014).  
 
HI is the most severe disorder in the family of ARCI, which also contains NBCIE and 
LI. Mutations in ABCA12 have found to be causative for each of these distinct diseases, 
which indicate a complex genotype to phenotype relationship. An example of this 
complexity is that missense mutations within one specific domain of ABCA12, the 
ABC1 domain, are associated with NBCIE and LI (Lefévre et al. 2003; Sakai et al. 
2009). However, HI-associated ABCA12 mutations are often deletions and truncations 
of ABCA12 (Akiyama 2005; Thomas et al. 2006). The ABCA12 genotype to phenotype 
relationship not only dictates which ARCI is present, but also has a possible role in the 
survival rate of HI, with homozygous mutations in ABCA12 correlating with a higher 
chance of mortality (Rajpopat et al. 2011). 
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Mutations in other ABCA genes lead to inherited disorders and show a mutation 
location bias to conserved ABC domains. In Stargardt disease, which is a macular 
degeneration of the retina mutations in the ABC transporter domains of ABCA4 
represent 80% of the causative mutations molecularly diagnosed. The missense 
mutations of a conserved domain are also found to be causative in the majority of 
Tangier disease cases, which is a deficiency of HDL due to an aberrant ABCA1 (Lewis 
et al. 1999; Huang et al. 2001).  
 
Another skin disease that has a spectrum of genotype-phenotypes is dystrophic 
epidermolysis bullosa (DEB). A well established aetiology between DEB and the gene 
COL7A1 has been established for both recessive (RDEB) and dominant (DDEB) modes 
of inheritance (Bruckner-Tuderman 2010; Dang & Murrell 2008). The most severe 
DEB phenotype is produced by recessive nonsense mutations resulting in a truncated 
transcript and a loss of the collagen VII protein, which presents as extreme scarring and 
large blistering of the feet and hands or of areas with bony protrusions. Premature stop 
codons and missenses mutations in the gene COL7A1 present as a milder RDEB, 
whereas DDEB is the least severe form of DEB in which the blistering phenotype 
lessens with age (Chung & Uitto 2010; Bruckner-Tuderman 2010). 
 
In summary, mutations in ABCA12 have been found to be causative in three distinct 
diseases within ARCI group: HI, NBCIE and LI2. After the early months/years of skin 
development, there is a reduction in the severity of the presentation of HI, which 
develops to resemble NBCIE, showing the importance of understanding skin 
development and molecular diagnosis in the clinical management of HI. 
6.3. Treatment of HI 
HI is the most severe type of ARCI and with modern neonatal care it is infrequently 
fatal. With no well-established treatment, management of HI currently has more of a 
supportive role; however, it was observed that the prescription of an oral retinoid drug 
possibly increases the survival rate (Rajpopat et al. 2011). Genetic counselling and 
preventative preimplantation of known carriers are two preventative measures currently 
possible due to the identification of causative mutations in ABCA12.  
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Modern management of the HI patient at the neonatal stage is undertaken with the use 
of temperature and humidity controlled incubators, antibiotics, pain control, fluids, 
electrolytes and topical emollient oil (Sharpe & Hyman 2014). After the neonatal period 
and into childhood, the HI skin develops and changes to resemble a severe NBCIE. At 
this stage patients can present with further complications including; a loss of 
thermoregulation, alopecia, contractures, diminished stature and scarring (Dyer et al. 
2013). With a greater number of HI patients surviving past infancy further later life 
repercussions may become apparent as clinical data is accrued, e.g; patients with the 
skin disease RDEB have a high probability of developing squamous cell carcinoma 
(SCC) in later life, due to skin malformations associated with the disease (Reed et al. 
1974). Around 90% of patients diagnosed with severe RDEB are likely to present SCC 
in middle age, with SCC formation in areas which were previously blistered or scared 
(Fine et al. 2009; Mallipeddi 2002). 
 
Topical and oral retinoids are currently used in the clinical treatment of HI and other 
ichthyoses. The application of retinoids on the skin induces a range of immune response 
and differentiation proteins in keratinocytes, though the ubiquitous expression of the 
RXR nuclear hormone receptor throughout the skin and that RXR can form active 
dimers with RAR, PPAR and LXR accumulates in an unspecific response when 
activated (Gericke et al. 2013). For example, retinoic acid induces epidermal proteins, 
which are not usually expressed at the same point of differentiation and do not 
contribute in the formation of the permeability barrier (Mihály et al. 2012).  
 
Isotretinoin (13-cis-retinoic acid) is an oral retinoid treatment most commonly 
prescribed for the treatment of severe acne. Recently, isotretinoin was prescribed on day 
7 of life for a HI patient in combination with the defined management and was reported 
to help reduce scales, fissures and improve the ectropion and eclabium after 3 and half 
months (Sharpe & Hyman 2014). Isotretinoin alongside other oral retinoids, acitretin 
and etretinate were administered from the first week of life to many of the HI patients 
analysed in a study of 45 patients. This study showed a higher survival rate for HI 
patients treated with the oral retinoids of 83% than those treated without of 24%. As 
previously discussed mutation type may affect the probability of survival, as highlighted 
in this study where all the patients that did not survive were homozygous for mutations 
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in ABCA12. Less than half of those that did survive regardless of treatment had 
homozygous ABCA12 mutations (Rajpopat et al. 2011). One of these cases did however 
develop cataracts, a known side effect of retinoid treatment in adults (Brecher & Orlow 
2003). 
 
Part of this thesis looked to develop possible alternative therapeutic strategies to 
retinoids and in particular the use of the nuclear hormone receptors PPARβ/δ and LXRβ 
to induce ABCA1 expression. To accomplish this a keratinocyte cell line was derived 
from a HI patient who had a compound heterozygote mutation in the gene ABCA12. The 
nonsense p.Glu2264X and c.5382-2a/g, a complex splice site mutation of the putative 
acceptor site, which lead to the use of multiple low affinity acceptor sites. Functional 
analysis of the HI cell line and IHC of the patient biopsy revealed a characteristic HI 
epidermal phenotype and a reduction in the protein expression of the cholesterol 
transporter ABCA1. ABCA1 cholesterol transportation in the epidermis functions to 
add cholesterol to the range of ceramides in the lipid envelope, which has been shown 
to aid in permeability barrier plasticity (Takahashi et al. 1996; Feingold & Jiang 2011). 
 
The patient derived HI cell line was shown to initiate a premature terminal 
differentiation under calcium shift by the significant increase of the expression levels of 
K10, involucrin and TGM1 proteins compared to controls. The addition of PPARβ/δ 
and LXRβ agonists on the HI cell line increased the transcript and protein levels of the 
reduced ABCA1. The application of these agonists on the HI cell line reduced the 
expression of the proteins expressed prematurely under calcium shift. In the HI cell line 
the PPARβ/δ and LXRβ agonists up regulate ABCA1 and possibly increase cholesterol 
transportation, reducing cholesterol sulfate synthesis. Thus, topical application of the 
nuclear hormone agonists may offer a therapeutic option for HI. 
 
Gene and protein replacement therapy are alternative possible therapeutic strategies for 
treating HI, which are currently in development for the treatment of other inherited skin 
disorders. In the treatment of Netherton syndrome the first attempt at gene therapy was 
undertaken using a recombinant adeno-associated retrovirus vector, which was cloned 
with the WT sequence of SPINK5. Transfection of Netherton syndrome-derived patient 
keratinocytes with the recombinant viral particles lead to a 75% recovery of SPINK5 
mRNA expression and translated into a functional LEKTI protein (Roedl et al. 2011).  
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This strategy was furthered by the use of a SPINK5 lentiviral vector, with an involucrin 
promoter sequence transfected organotypic culture and in vivo mouse-human skin graft 
models. Results corroborated with the earlier study as LEKTI expression was restored; 
furthermore, epidermal formation was improved in both models and due to the secretory 
nature of LEKTI corrective satellite populations formed (Di et al. 2011). A phase one 
clinical trail has been proposed utilising this system and vector, which aims to graft 
SPINK5-corrected keratinocyte stem cells on patients with a Netherton syndrome 
molecular diagnosis (Di et al. 2013). 
 
A similar strategy was employed in the initial studies into the treatment of 
epidermolysis bullosa (EB); an ex vivo system of expanding corrected keratinocytes into 
sheets for skin grafting by use of a WT retroviral vector and epidermal stem cells. These 
skin grafts were applied to patients with EB and developed an adherent epidermis, 
which after the first year follow up showed a significant reduction of blisters, 
inflammation and infections (Mavilio et al. 2006). Corrective gene transfer as a 
therapeutic strategy however, does have disadvantages such as the random integration 
of the exogenous gene into the patient’s genome, a process known to induce 
carcinogenesis due to atypical oncogene promotion. In HI, corrective gene transfer of 
ABCA12 has reportedly been achieved in HI keratinocytes in vitro where it recovered 
glucosylceramide cellular distribution (Akiyama 2005).  
 
A possible therapeutic strategy, which has not yet been explored in the treatment of HI, 
is protein replacement therapy. In theory, recombinant WT ABCA12 protein could be 
injected or topically applied to the skin, without the drawbacks of gene therapy to re-
establish glucosylceramide transportation. The intradermal application of recombinant 
collagen VII was investigation as a treatment to RDEB. The addition of collagen VII to 
collagen VII KO mice reduced mortality, eased blistering and increased the number of 
dermal epidermal junction anchoring fibrils (Remington et al. 2009). In patients with 
RDEB autologous fibroblasts were injected to the intradermal region at sites of 
blistering to increase the transcript level of COL7A1. The translated protein was 
mutated, however, the number of vestigial anchoring fibrils increased, which help to 
reduce blistering and aid wound healing (Wong et al. 2008). 
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In the treatment of Netherton syndrome, small particle inhibitors are being investigated 
to perform the inhibition of the serine protease inhibitors KLK5 and KLK7 when 
LEKTI is aberrant. 1,2,4-Triazole derivatives were found to inhibit KLK5 and KLK7 
and did not produce a cytotoxic response in keratinocytes. These inhibitors may re-
establish desquamation through the cessation of the deregulated proteolytic cascades in 
Netherton syndrome and relieve symptoms of the disease (Tan et al. 2013). 
 
Three apparent complications to the utilisation of ABCA12 protein therapy in HI is the 
administration of the treatment through the HI epidermis, especially the hyperkeratotic 
plates. Also, as ABCA12 is known to function within keratinocytes the large transporter 
must be modified to enter the cell and then to access the Golgi apparatus where LG are 
formed and ABCA12 is known to function at the correct stage of differentiation. A 
summary of the possible therapeutic strategies for HI is shown in Figure 6.1. 
 
6.4. Future Work 
Organotypic cultures would ensure that the in vivo epidermis was more closely 
represented in an in vitro culture and would further the investigations that were 
undertaken in monolayer. This work would give a truer representation of the nuances of 
complex cellular behaviours, such as cell migration, differentiation and proliferation 
(Oh et al. 2013). In this study the HI patient derived cell line would be used to simulate 
the HI epidermis and enable the analysis of the premature terminal differentiation 
phenotype and further the understanding of the application on nuclear hormone receptor 
agonists in HI as a potential future therapeutic strategy. IHC and Nile red lipid staining 
could be used to evaluate these organotypic cultures and the changes in their 
composition under the application of agonists. This could also yield results on the 
recovery of ABCA1 expression, barrier perturbation, the possible increased level of 
cholesterol sulfate and if there is any modulation in the markers of terminal 
differentiation, which are premature in HI. 
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Figure 6.1. Possible therapeutic strategies for HI. (A) Prenatal testing gives the opportunity for an 
early diagnosis and even preimplantation in special cases to ensure a functional ABCA12. (B) The topical 
application of NHR agonists, specifically PPARβ/δ and LXRβ activation. (C) The addition of a 
recombinant functional ABCA12 protein a specific epidermal layer. (D) Gene therapy and the possibility 
of ABCA12 gene correction by retroviral vector transfection of epidermal stem cells. 
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8.1. Appendix 1 
 
Primer sequences used in genotyping studies, all the oligonucleotides shown are 
arranged 5’-3’.  
 
Forward primer Reverse primer Exons Product (bp) 
CAGCCCTCAAGGAAGCTATG CTTGGGTGCTCTGGAATGAT 5’UTR-4 514 
TCTTTCCATTCCTGCAGACC AGACAGAAGCTGCCACACAG 3-7 602 
TGCCTTTCTAACATGACCCTTT GTGAACCTCTGGCCAAACTG 6-10 547 
GCAGATTTCTGCATTTTCTCCT GTGAACCTCTGGCCAAACTG *5’UTR-10 305 
TGTGGAATGAGGATGATGGA TTCATTTGCAGTGCCTGTTC 9-13 562 
TGACTGGAGATCCAAGCAAA CCTTGTGGTGTGTTCATTCG 12-17 654 
CTGCCCAGAAGTGTTCCATT GCTGATCGATGATGTCAATGTT 16-21 637 
TTGAAACAGATAGATGAACTCG
AT 
TAAGCCAGGCAAAGAAATGG 20-24 685 
GACCTCCGGCTTCATGAGTA CCAAATCGCTCCTTCCAATA 23-27 620 
TGCTTGGTATGTCAGGAATGTC 
  
CTTCCTCTTCATGCCTCCTG 26-30 658 
GCACCTTCTCCTATATGGTTCC TTGTGACTCTTTGGTCAAGTTCA 29-33 697 
ACCGTGGAGGAGGTCTTTCT TCGTTGCCCAGTGAGGTTA 32-37 678 
TGTTTGCTCCTGCTCAGAAA AAACGCTACAGGCACCAAGT 36-42 610 
ATTGGCGTGACATGCTACTG TCTCCCTTACATGTGAAGAATT
AAA 
41-45 616 
TCTCAGGGCACCATGTTTTT TGAAGGGCATCAGGTGAAGT 44-48 565 
CTGGGTCACGTTGATTCTCA GCTGCATGAACTTTGTGAGG 47-51 550 
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Table A1.1. ABCA12 cDNA primers. Primers designed to negate SNPs and produce 
amplicons with overlapping flanking regions to ensure full coverage of transcript and a 
continuous sequence. Exons *5’UTR-10 checks for presence of the secondary ABCA12 
transcript. 
	
	
Exon Forward primer Reverse primer Size 
(bp) 
1 CAGCCCTCAAGGAAGCTATG TTGGGGGCATGTTAAGACTC 389 
2 CAGTTGGTCAAATATTCAGCTTG CTTTCTGACTAACTTGAAAATCTAGGG 392 
3 CATAACACCCTCCAAGACTGC CTAAGCTTGCATGGCTTCCT 425 
4 CATTGGTGTGTGGTTAGGTGA CCATACTCAGGCAACCATGA 407 
5 GGAATTTGCCACTTTTCCAG GGTGCTCCAAACATCTTGCT 362 
6 CACATTCATGCATTCGCTCT CCAGTCAGCATTTCCCAGTC 465 
7 TGGAGTTACAGGGAAAAGATCC TCCATAACCTTGATGACCACAG 594 
8 TTTGTTGAGATTTTGTGCATGA TCCCTTTCTCCACACTTTGATT 459 
9 CAAATATTTCCAACAAAAGAGCA TGCAAGCTCAGAACTGAAAAAG 487 
10 CCGGCCAACTGCATAGTATT CAAATCACCAGACTGAAACTGA 395 
11 CTGGTTTCCTAAATGACCTTGC GTCGTAAGTAGGGCCATTATAAATCT 349 
12/13 CCAAATGCCAACTAACCACATA GAGTTTGGTTGGGAACTTCAAA 696 
14 AGACATCTGCCCCTGAGAAG TGAGGCCTCCAGGTTTATCA 395 
15 GTTTGATTCTTGAGGACCTTTTG TAAATGGATCTCATCCCTCATAGT  410 
16 TCTTAGGTAAACGCCCAGGAAT TGGCAAAAAGTGTTGCTAGGTA 493 
17 AAAAGGAATTATGGAAACTGTAAGGA TCTTGACATGTGGTAAGTGCTG 483 
18 CTGTCAATTTGCCATGTGGA GCACATATCCAGGGCAGAAG 386 
19 GCTGTCATTTGAAACTTTTGACC CCCTGTCTCAGACCTTCTCTCT 439 
20 CCAACCCCCAATCTTCTCTT CCAGGGTCTCATTTTTCTTTG 404 
21 CGACCCATTTTCTTTGGTGT TGGTTGCCTACATGAAAGGTT 502 
22 TCTGAGGTTGACACCTCCAAT TGGTGAATGTTGTTCCTTTCA 594 
23 TGGGGTAATACCGATTATTTTCA TCAGCTGCTTTTGTGATTTG 412 
24 GGCATATTTCACATAGCAAGCA GGCATATTTCACATAGCAAGCA 584 
25 GCATGGTTGGTAAGGGACTG CTGTGACACACAGCACAGTTG 288 
26 CAACAGCATTCAGCTATGCAAG GAAGTCAACCATAAAAAGCATGTATCTG 326 
CACTGGCCTTGATAGGGAAA CAAAATGAAGCCATTGGTCA 48-3’UTR 635 
  195 
27 TGGAAACTGAGACCACCTTTT GAGTCCAAAGACGCATGTGTAG 443 
28 GAACCCTGGTTCTCCACTCTTA CTTCCTCCATCTGGGAAATGTA 517 
29 GTTTGCCCTTGACTGAGAAGA CTGGCCGGTAAGGATAATGA 519 
30 TGAATCCTCAAGAGTTTATTGTACC CTCAAACTCCCAGGCTCAAG 495 
31 CTGGCCCTGAATTTTTCTTG CCAGGATTTCGATGCTCACT 492 
32 GCTCATCACCTCACCCTCTG CTGTCTAGCTGGGGCAACAT 504 
33 CCCAGCTAGACAGCACGTATC GGAGGCTTAAATTTCCTTAGTGTT 461 
34 CAATGGAAGGTCCAAGGCTA CTCATGGCCTTCATTCAGGT 506 
35 CACGGCAAGACTCTGTCTCA CAGCTTTCTTCCAGGCAAAT 326 
36 TGAAAAATCAGTAAATTGTTCTGTGA TGAGCTGCCCAGATCCATA  370 
37 TCTTGGTGTAGGTGAGATGACTTC AAGGCTGTTTAAATAAAACTGAGAA 441 
38 CAGAAACAAAAAGTTGAGCTCCT CAGAATTGGAACCACTGTGC 330 
39 GAGAACAGTGCATAATCTTCCAA CTGCCACCTGTGAAGAAACA 349 
40 AAAAAGGTCCCCCAAATAAAAT CCAGCCCTTCTAGATTGACATT 302 
41 CCTTATTTGTGTCACAGCCAAC CACTGGATGAAGATAAGCCTGA 462 
42 GAATGTTAGAAGCAATGGGAACA CATGTCAAATGAAACCCCAAG 387 
43 TGCCTCAGCCTCCTAAAGTG GATGAGGCCCAAAAAGAATTT 409 
44 CAAATTCAGCCTATATGGGAAA GCCAAACATTTCCATATTACCAA 510 
45 GTGACATGAAAACCCATCAAAA CCAGGCTGGTCTCAAACTCT 458 
46 CCAGGGAGAAGAGGGAGAGA CATTTCCACCCACCTTAATAGC 335 
47 GTCACTGACCACCATGACCA CCACTGCCAGAAGGAAAATG 395 
48 GCTTTAAGGGTTTTGGCACA GCTTTGCACAATAGCTAGCACA 326 
49 TTGAACTTTTTGACAGCAGCA CTTTTCCCACCTGTCATCCT 334 
50 TAGCCTGGGCAACAGAGTG GCTTCCAAAGATTAGCTTGTCC 390 
51 CCAGTTTGCAACATGTCCTG GTAGAGACGGGGTTTCACCA 400 
52 CTGTAGCATCATTTTCAGTGGA TGCTAAGTTTTTCAGGTGCAAG 398 
53 CGCTTGCACTAGGAGAGAGG GCAACAACACTCACTGACCTT 406 
	
Table A1.2. ABCA12 genomic primer pairs. Primers designed to capture the entirety 
of the 53 exons and around 100bp of flanking intronic sequence of ABCA12, utilised in 
the genotyping of ABCA12.    
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Table A1.3. Genomic primer pairs. Primer sequences for four different candidate 
genes used in screening variants found in a patient’s exome data in 3.1.4. 
 
 
 
 
 
 
 
 
Table A1.4. Primers used for qPCR (Rotorgene) with at least one primer of each 
primer pair bridging neighbouring exons. 
 
 
Primer Sequence  Product (bp) 
GOSR1ex5F TGAATTCCATAAAACCAAAGCA 193 
GOSR1ex5R AATCTCAACCACGGTTCTGC 193 
DSC1ex2F GTGATCAAATTTAATTCCTGATATTTT 238 
DSC1ex2R CCGGCCTACTATGTGGTTTT 238 
KDSRex9F CGAGCACACTCCACTGTTTC 209 
KDSRex9R GCAGAGCTTACCTGCTGGAG 209 
PCDHGA9ex1F ACGGTGACTGCAACAGACAG 274 
PCDHGA9ex1R GGATGGTATCCTCTGCCAAG 274 
Primer Sequence  Product (bp) 
GAPDHF TGGCCCCTCCGGGAAACTGT 92 
GAPDHR CCTTGCCCACAGCCTTGGCA 92 
ABCA1F TTAAACGCCCTCACCAAAGAC 281 
ABCA1R AAAAGCCGCCATACCTAAACTCAT 281 
ABCA12F GTGGGAGCGTCAAGTACTCC 583 
ABCA12R CCTCCAGAGGAACCACCTC 583 
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Table A1.5. Primer sequences used for the screening of loricrin allelic size variants 
in 5.2.3. 
 
8.2. Appendix 2 
Appendix data from the functional studies of chapters 4 and 5 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.1. Negative controls from the immunohistochemistry of HI and NS. For 
the terminal differentiation markers and ABCA12 and ABCA1 analysis in the epidermis 
of HI skin 5.2.1. & 4.2.2.  
Primer Sequence  Product (bp) 
LORICRIN-2F GTGGGAGCGTCAAGTACTCC 583 
LORICRIN-2R CTCCAGAGGAACCACCTC 583 
NS HI RB 
MOGT 
  198 
 
 
 
Figure A1.2. A preliminary study of the modulation of the protein expression of 
ABCA1 in keratinocytes under PPARβ/δ and LXRβ activation. This experiment 
was preformed using the same protocol and conditions, with the exception of a different 
ABCA1 antibody, which furthers the accuracy of the results in 5.2.2.  
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ABCA1 protein expression with NHR agonists 
